{"meta":{"query_hash":"a330434edc0c","filters":{"venue":"The Lancet Haematology"},"cohort_total":173,"direct_labels_cover":1,"predictions_cover":173,"exported":173,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a330434edc0c","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Lancet+Haematology"},"results":[{"id":"W1822814480","doi":"10.1016/s2352-3026(15)00090-3","title":"Integration of red cell genotyping into the blood supply chain: a population-based study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"NIH Clinical Center; National Institutes of Health; Australian Government; Canadian Blood Services; U.S. Department of Health and Human Services","keywords":"ABO blood group system; Genotyping; Medicine; Red blood cell; Antigen; Immunology; Blood type (non-human); Red Cell; Serology; Genotype; Typing; Population; Red blood cell distribution width; Database; Antibody; Internal medicine; Biology; Genetics; Gene","score_opus":0.03801000566112186,"score_gpt":0.2897165603883023,"score_spread":0.25170655472718045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1822814480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988674,0.0001630487,0.0003342273,0.000059325466,0.000008310214,0.000016390311,0.00014522791,0.0000032178916,0.0004028657],"genre_scores_gemma":[0.9993481,0.00009562153,0.00018346145,0.00006186597,0.000009603795,0.000014897845,0.000100036814,0.0000049403816,0.00018141471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954782,0.002102331,0.00027209678,0.0012269734,0.00046186804,0.00045858088],"domain_scores_gemma":[0.9949851,0.001170084,0.0017440867,0.0009369277,0.00064920774,0.0005146933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002559528,0.00080014,0.0006154352,0.00091732125,0.0011431093,0.0017908538,0.0013318158,0.0023169562,0.0021429372],"category_scores_gemma":[0.007297439,0.0015549428,0.0012949711,0.0025863573,0.0012106542,0.0018240372,0.0012748684,0.0022566135,0.0004445208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038883826,0.00028511242,0.99481636,0.000021739923,0.00041474713,0.00020310242,0.0011237375,0.00007451653,0.00070676696,0.00009917035,0.00017537232,0.0016904199],"study_design_scores_gemma":[0.00003088613,0.00077101163,0.9961708,0.00002247273,0.00036523747,0.00046016907,0.0012599583,0.00041938908,0.0000870189,0.000091082635,0.00029877896,0.000023235674],"about_ca_topic_score_codex":0.013683904,"about_ca_topic_score_gemma":0.011824046,"teacher_disagreement_score":0.013683904,"about_ca_system_score_codex":0.00084927113,"about_ca_system_score_gemma":0.0005897715,"threshold_uncertainty_score":0.027208507},"labels":[],"label_agreement":null},{"id":"W1851987558","doi":"10.1016/s2352-3026(15)00113-1","title":"The merits and limits of pooling data from nuclear power worker studies","year":2015,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pooling; Nuclear power; Nuclear engineering; Nuclear physics; Artificial intelligence; Engineering; Computer science","score_opus":0.18244402527363593,"score_gpt":0.37687541712973466,"score_spread":0.19443139185609873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1851987558","genre_codex":"review","genre_gemma":"commentary","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077401854,0.4987557,0.17276537,0.12121806,0.03585588,0.022490107,0.030369792,0.0010793364,0.04006389],"genre_scores_gemma":[0.541419,0.08423665,0.20469198,0.06636064,0.028448464,0.04499444,0.02578475,0.0013182453,0.0027458456],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.12135202,0.6844652,0.12698749,0.016830873,0.048020497,0.002343998],"domain_scores_gemma":[0.06538338,0.7676646,0.040759664,0.08952705,0.034377888,0.0022874807],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.73536783,0.0033044147,0.0124657275,0.027504522,0.0047874954,0.02026134,0.011910313,0.006657891,0.0045006075],"category_scores_gemma":[0.8776648,0.0030312482,0.01192888,0.037037235,0.008173885,0.018477011,0.021572387,0.0054031294,0.0013533932],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008170873,0.00038422705,0.11450892,0.118303604,0.097238705,0.0013070479,0.020229325,0.0031093748,0.0010306512,0.036228217,0.056826305,0.54266286],"study_design_scores_gemma":[0.00449673,0.004056311,0.14932013,0.15511702,0.06089295,0.0027784486,0.015535705,0.0045618317,0.0025156313,0.2509862,0.34845638,0.0012826782],"about_ca_topic_score_codex":0.0051821927,"about_ca_topic_score_gemma":0.005870863,"teacher_disagreement_score":0.73536783,"about_ca_system_score_codex":0.0046960204,"about_ca_system_score_gemma":0.010276491,"threshold_uncertainty_score":0.32633865},"labels":[],"label_agreement":null},{"id":"W1915793285","doi":"10.1016/s2352-3026(15)00190-8","title":"Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Pre- and post-test probability; Deep vein; Prospective cohort study; Venous thrombosis; Thrombosis; Cohort; Surgery; D-dimer; Radiology; Vein; Pulmonary embolism; Cohort study; Algorithm; Internal medicine","score_opus":0.02107327035383646,"score_gpt":0.29525428826330535,"score_spread":0.2741810179094689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1915793285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969482,0.00037865742,0.0017366706,0.000096305885,0.000045648085,0.00015440413,0.0004247821,0.000019067083,0.00019630125],"genre_scores_gemma":[0.9930132,0.00012725708,0.0053599183,0.00006315696,0.000032248376,0.00016310147,0.001107257,0.000016283842,0.00011766236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99576306,0.00188239,0.0004255804,0.0012475803,0.00044492178,0.0002364559],"domain_scores_gemma":[0.9920433,0.0040326864,0.0015194437,0.001049514,0.00081842823,0.000536603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008167416,0.0012463648,0.002200959,0.0011623384,0.00069988257,0.0025816641,0.001748077,0.0016856702,0.0014543633],"category_scores_gemma":[0.017641688,0.0008086105,0.0022110224,0.0013220557,0.0005050053,0.0016285798,0.0012250888,0.0014145257,0.00023341588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021801418,0.00088690786,0.9587408,0.0001542197,0.0028675683,0.00013122539,0.00015179298,0.0014814716,0.0007539813,0.00018318617,0.00063273625,0.012214777],"study_design_scores_gemma":[0.009047936,0.011331392,0.90250003,0.00018972032,0.008706045,0.0015583178,0.00053581095,0.0631097,0.00083441765,0.0009891985,0.0010511385,0.00014635305],"about_ca_topic_score_codex":0.00297754,"about_ca_topic_score_gemma":0.003914554,"teacher_disagreement_score":0.008167416,"about_ca_system_score_codex":0.0010052884,"about_ca_system_score_gemma":0.0012328107,"threshold_uncertainty_score":0.043193936},"labels":[],"label_agreement":null},{"id":"W1965842006","doi":"10.1016/s2352-3026(14)70020-1","title":"Treating clots in cancer: moving closer to an answer?","year":2014,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Hamilton Health Sciences; Ontario Clinical Oncology Group; McMaster University","funders":"","keywords":"Rivaroxaban; Medicine; Vitamin K antagonist; Pulmonary embolism; Low molecular weight heparin; Antithrombotic; Venous thrombosis; Thrombosis; Warfarin; Deep vein; Internal medicine; Atrial fibrillation","score_opus":0.041572187774547784,"score_gpt":0.350342778595155,"score_spread":0.3087705908206072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965842006","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018510304,0.30623507,0.0003638839,0.6763996,0.015031956,0.0000092640785,0.000064404754,0.0000262588,0.0016844535],"genre_scores_gemma":[0.009258251,0.5765789,0.0019903695,0.26916197,0.14022061,0.00006859389,0.00015035758,0.000081288075,0.0024896222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98726475,0.004705664,0.0022637849,0.0011881317,0.003660939,0.0009167302],"domain_scores_gemma":[0.9208086,0.044826023,0.006296864,0.001761676,0.019804591,0.0065021063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01955632,0.001675065,0.0078965295,0.0035712689,0.0037619972,0.014660396,0.0038914904,0.0267941,0.019603662],"category_scores_gemma":[0.0827513,0.0013574881,0.0029032766,0.0029826448,0.010408982,0.026769662,0.00630911,0.043692973,0.0078114085],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071868184,0.0003700959,0.0019147896,0.009476416,0.0006412461,0.00043743532,0.0007651796,0.00060112064,0.00032375404,0.03583246,0.6321372,0.31678173],"study_design_scores_gemma":[0.0012670734,0.0005629164,0.0033829398,0.023905141,0.0007897304,0.0011051196,0.0038479122,0.0007214663,0.00026539894,0.12142213,0.842317,0.00041311036],"about_ca_topic_score_codex":0.008868697,"about_ca_topic_score_gemma":0.014552507,"teacher_disagreement_score":0.0267941,"about_ca_system_score_codex":0.006598071,"about_ca_system_score_gemma":0.015542882,"threshold_uncertainty_score":0.10342491},"labels":[],"label_agreement":null},{"id":"W2026016649","doi":"10.1016/s2352-3026(15)00003-4","title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","year":2015,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; McMaster University","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Splenectomy; Meta-analysis; Immune thrombocytopenia; Relative risk; Randomized controlled trial; Confidence interval; Gastroenterology; Platelet; Lymphoma","score_opus":0.15312143755456406,"score_gpt":0.40161448540477473,"score_spread":0.24849304785021067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026016649","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061052646,0.99273187,0.000315658,0.00011871906,0.00018206531,0.00015463312,0.0001735711,0.000018064475,0.00020006625],"genre_scores_gemma":[0.26090074,0.73386294,0.0023386222,0.0013052721,0.00030959825,0.00043963332,0.00046332105,0.000025925692,0.00035403404],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99583167,0.0017475903,0.0012462166,0.0005036743,0.00046829667,0.00020251224],"domain_scores_gemma":[0.9941136,0.0040389528,0.0012014374,0.00019405597,0.0003231684,0.0001287895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005591081,0.0019499849,0.016723856,0.002839111,0.00042179198,0.0022989276,0.0020135744,0.0021376284,0.004447696],"category_scores_gemma":[0.014560119,0.0012128784,0.024880279,0.003318863,0.000672341,0.0016962399,0.0013153796,0.002305974,0.00031527574],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009614174,0.00008910162,0.0022828088,0.3501694,0.61179644,0.00012805927,0.000091382644,0.0005417143,0.00033258172,0.00015650771,0.00071915874,0.024078688],"study_design_scores_gemma":[0.004251011,0.0006070558,0.0027876259,0.014811592,0.9755853,0.000103850696,0.000056658442,0.00017897868,0.00009902539,0.00018350649,0.0013054709,0.000029919724],"about_ca_topic_score_codex":0.005735022,"about_ca_topic_score_gemma":0.015808752,"teacher_disagreement_score":0.016723856,"about_ca_system_score_codex":0.00212583,"about_ca_system_score_gemma":0.0019696061,"threshold_uncertainty_score":0.029568791},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["metaepi_broad"],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2104054161","doi":"10.1016/s2352-3026(15)00068-x","title":"Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Amyloidosis; AL amyloidosis; Immunoglobulin light chain; Biopsy; Pathology; Internal medicine; Antibody; Immunology","score_opus":0.06521785889323627,"score_gpt":0.3157278044658536,"score_spread":0.2505099455726173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2104054161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783933,0.00089183374,0.00008735321,0.000112042944,0.000016250053,0.00000958711,0.00084468734,0.0000042125375,0.00019474573],"genre_scores_gemma":[0.9982332,0.000262265,0.000047454178,0.000076068696,0.00003699381,0.00001674383,0.0011786128,0.0000037203488,0.00014499748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99870944,0.00040410328,0.0001459165,0.00033848916,0.00012875958,0.00027314585],"domain_scores_gemma":[0.9930393,0.0011179524,0.0025809987,0.0009394112,0.000731795,0.0015904651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019612117,0.0005527968,0.001283421,0.00063693314,0.00084347295,0.0015247217,0.0010425667,0.0014205999,0.0012151673],"category_scores_gemma":[0.0046715993,0.0006987156,0.0017595431,0.0018587171,0.0009029597,0.0015719457,0.0011696701,0.0022651819,0.00035101522],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017265117,0.00015594855,0.9952963,0.00004928558,0.00087170076,0.00027078518,0.00014534518,0.00009435126,0.0002252731,0.00003374506,0.00032607312,0.00080468936],"study_design_scores_gemma":[0.00010693933,0.00032052305,0.99823135,0.000021361571,0.00035230932,0.0002627176,0.0002605449,0.00014567263,0.000028284267,0.0000683395,0.00018439314,0.000017633274],"about_ca_topic_score_codex":0.011971357,"about_ca_topic_score_gemma":0.009826506,"teacher_disagreement_score":0.011971357,"about_ca_system_score_codex":0.0011060644,"about_ca_system_score_gemma":0.0007447883,"threshold_uncertainty_score":0.023803353},"labels":[],"label_agreement":null},{"id":"W2127175732","doi":"10.1016/s2352-3026(15)00114-3","title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Hospital for Sick Children","funders":"Novartis Pharmaceuticals Corporation; Novartis; GlaxoSmithKline","keywords":"Eltrombopag; Medicine; Placebo; Immune thrombocytopenia; Internal medicine; Thrombopoietin receptor; Thrombopoietin; Romiplostim; Pediatrics; Surgery; Platelet","score_opus":0.03145599271383102,"score_gpt":0.2921678993521696,"score_spread":0.26071190663833854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127175732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97875756,0.014564443,0.0004785901,0.000586281,0.0006451638,0.0026208437,0.0009786682,0.00006516672,0.0013032313],"genre_scores_gemma":[0.9806629,0.0103569,0.0011457938,0.0010120524,0.00064360705,0.003007595,0.0008734535,0.000020536367,0.00227722],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99901915,0.000537043,0.0000804632,0.00012001061,0.00007986513,0.00016335178],"domain_scores_gemma":[0.9989373,0.00040321465,0.0002650139,0.0000989552,0.00005775012,0.0002377634],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002014551,0.0015282438,0.0043826154,0.00052735675,0.00038892162,0.0011962872,0.0010724192,0.0026477494,0.005300356],"category_scores_gemma":[0.0023287858,0.00078886177,0.0026010976,0.0006929586,0.0016417564,0.0012170915,0.0005751416,0.0028441618,0.00055345555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9860555,0.0020417352,0.00044439803,0.0010797709,0.0012759445,0.00006162414,0.000037529015,0.00011165034,0.001150745,0.00007417187,0.00026936244,0.00739757],"study_design_scores_gemma":[0.96479034,0.031750225,0.0019814852,0.00005976361,0.0007626083,0.00003648179,0.000021818974,0.00006926409,0.00010265104,0.00003958358,0.00037458527,0.000011148803],"about_ca_topic_score_codex":0.0019288467,"about_ca_topic_score_gemma":0.0029960035,"teacher_disagreement_score":0.005300356,"about_ca_system_score_codex":0.00078988296,"about_ca_system_score_gemma":0.00085721345,"threshold_uncertainty_score":0.017731428},"labels":[],"label_agreement":null},{"id":"W2135936995","doi":"10.1016/s2352-3026(14)70018-3","title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","year":2014,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":284,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; London Health Sciences Centre","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Pulmonary embolism; Regimen; Population; Internal medicine; Venous thrombosis; Randomized controlled trial; Warfarin; Cancer; Low molecular weight heparin; Surgery; Thrombosis; Atrial fibrillation","score_opus":0.02850244584894512,"score_gpt":0.31415890950065106,"score_spread":0.28565646365170594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135936995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5416268,0.43250328,0.0047955248,0.0015585279,0.004511288,0.006595568,0.00448254,0.00040457095,0.0035218385],"genre_scores_gemma":[0.9191869,0.06625088,0.0029627925,0.001674627,0.0012460755,0.004150518,0.0016268403,0.00007765911,0.002823627],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961855,0.0018507941,0.0008464519,0.00053561316,0.00028432964,0.00029731722],"domain_scores_gemma":[0.99699867,0.0016534646,0.0007915688,0.00020730322,0.00016341973,0.0001856389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042530643,0.003503166,0.014803666,0.001595701,0.00054756436,0.0024812496,0.0013839812,0.0027732856,0.004849978],"category_scores_gemma":[0.008822444,0.0014804925,0.019246344,0.0013771744,0.0010034575,0.0016260992,0.0011123535,0.0035148053,0.0005073971],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77708447,0.00024062837,0.0012593438,0.02761409,0.17915288,0.000106643354,0.000107668544,0.0006437603,0.0011294091,0.00014178296,0.0006297286,0.0118895555],"study_design_scores_gemma":[0.7725913,0.0077140727,0.0041411207,0.0014487404,0.21114098,0.00010487397,0.000108824875,0.00061853963,0.00043049367,0.0005196297,0.0011040499,0.00007740905],"about_ca_topic_score_codex":0.003539724,"about_ca_topic_score_gemma":0.0067631816,"teacher_disagreement_score":0.014803666,"about_ca_system_score_codex":0.0015988757,"about_ca_system_score_gemma":0.0012395964,"threshold_uncertainty_score":0.022492588},"labels":[],"label_agreement":null},{"id":"W2155403628","doi":"10.1016/s2352-3026(15)00028-9","title":"One million haemopoietic stem-cell transplants: a retrospective observational study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Princess Margaret Cancer Centre","funders":"World Health Organization","keywords":"Medicine; Observational study; Retrospective cohort study; Stem cell; Oncology; Internal medicine; Intensive care medicine; Genetics","score_opus":0.18156565499117197,"score_gpt":0.3366682449817053,"score_spread":0.1551025899905333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155403628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439174,0.0025894246,0.00023415552,0.00022525991,0.000038531398,0.000020971205,0.0021605121,0.000006163348,0.00033332492],"genre_scores_gemma":[0.9951806,0.0010254584,0.000217514,0.0003630312,0.000066697,0.00004173983,0.0028643666,0.000012126403,0.00022846131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967871,0.0006881415,0.00062604476,0.0010179246,0.0003922189,0.0004884787],"domain_scores_gemma":[0.9873427,0.0027830517,0.006447582,0.0015936588,0.00067500776,0.0011579683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002036672,0.00053186517,0.0013806309,0.0011575039,0.0010558144,0.002024047,0.0011890862,0.0015347193,0.0026722257],"category_scores_gemma":[0.0075707673,0.0014745375,0.0015241527,0.0040087034,0.0006917433,0.0018606042,0.0014819899,0.0022430152,0.0006752065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004989389,0.000078981204,0.9967693,0.00008270176,0.00059421884,0.0003148093,0.00015761952,0.000038167324,0.00013972295,0.000090120695,0.0004870027,0.00074843573],"study_design_scores_gemma":[0.0001042947,0.00034812593,0.9940546,0.000104839986,0.00060879684,0.0021752506,0.0009884321,0.00019362132,0.00007983019,0.0001661814,0.001138329,0.00003777599],"about_ca_topic_score_codex":0.007651853,"about_ca_topic_score_gemma":0.008560078,"teacher_disagreement_score":0.007651853,"about_ca_system_score_codex":0.0010426403,"about_ca_system_score_gemma":0.0012321267,"threshold_uncertainty_score":0.015214682},"labels":[],"label_agreement":null},{"id":"W2162020809","doi":"10.1016/s2352-3026(15)00020-4","title":"90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Université de Nantes; Université de Bretagne Occidentale","keywords":"Radioimmunotherapy; Medicine; Tolerability; CD22; Refractory (planetary science); Internal medicine; Oncology; Nuclear medicine; Gastroenterology; Lymphoma; CD20; Adverse effect; Immunology; Antibody","score_opus":0.04679705980917849,"score_gpt":0.3532113727698215,"score_spread":0.30641431296064303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162020809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971073,0.0011569106,0.00024671908,0.00019437974,0.000046777477,0.00029498487,0.00020058156,0.000048977236,0.00070327945],"genre_scores_gemma":[0.99433726,0.0018887575,0.0006382212,0.000491092,0.000061151404,0.00046809117,0.0005474905,0.000039741994,0.0015281197],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996625,0.000142477,0.000013564344,0.000063667416,0.000027124925,0.000090613226],"domain_scores_gemma":[0.99973124,0.000049132865,0.00005300268,0.000039298084,0.000014237956,0.00011310042],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009791804,0.0012926635,0.0019191324,0.00032238272,0.0002800494,0.001048788,0.0007021078,0.0010213276,0.0017938236],"category_scores_gemma":[0.0005725891,0.0006246027,0.0010354789,0.00039331848,0.00089025946,0.00083045405,0.00036403193,0.002937934,0.0008674424],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6227437,0.056333177,0.013326444,0.0009961389,0.0028473225,0.0009647859,0.0011765481,0.007257425,0.080576874,0.00064860436,0.0053980025,0.20773089],"study_design_scores_gemma":[0.4763495,0.4801664,0.027103176,0.000051452902,0.0012796719,0.0008169108,0.00018591323,0.0020706856,0.005730595,0.0003136816,0.0058702393,0.00006172864],"about_ca_topic_score_codex":0.0013006348,"about_ca_topic_score_gemma":0.0017268758,"teacher_disagreement_score":0.0019191324,"about_ca_system_score_codex":0.00087710674,"about_ca_system_score_gemma":0.0007453418,"threshold_uncertainty_score":0.0063639283},"labels":[],"label_agreement":null},{"id":"W2187343014","doi":"10.1016/s2352-3026(15)00197-0","title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"AbbVie Biotherapeutics; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Oncology; Phases of clinical research; Thalidomide; Clinical trial","score_opus":0.11369672653323207,"score_gpt":0.37215393679621306,"score_spread":0.25845721026298096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2187343014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352795,0.0030572792,0.0003219079,0.0006671734,0.00016331229,0.00055259693,0.00063351524,0.00007434271,0.0010018455],"genre_scores_gemma":[0.99007446,0.0019552975,0.0013279535,0.0015129222,0.00026153756,0.0007728054,0.0016592488,0.000045978315,0.0023896496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991091,0.00044598134,0.00004770909,0.0001346804,0.00007798094,0.00018442982],"domain_scores_gemma":[0.999054,0.00025645117,0.00020323168,0.000093588926,0.000053616743,0.00033917572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002358057,0.0018093607,0.0031536825,0.0004925996,0.00031040388,0.0014010179,0.0011394591,0.0016284923,0.0036172038],"category_scores_gemma":[0.0015270676,0.0007600004,0.0021163446,0.00052089745,0.001201005,0.0018347069,0.00065286254,0.003639708,0.0010399311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9275394,0.012642342,0.002298682,0.00041858514,0.0017485048,0.00007089993,0.00015314312,0.0013829952,0.0053147417,0.00011213532,0.0014701613,0.046848435],"study_design_scores_gemma":[0.9102726,0.080416225,0.0061914255,0.000027646598,0.00052239955,0.00006639257,0.000043180597,0.0004960695,0.0006858014,0.00017062026,0.001081399,0.000026212345],"about_ca_topic_score_codex":0.0011627953,"about_ca_topic_score_gemma":0.0021375124,"teacher_disagreement_score":0.0036172038,"about_ca_system_score_codex":0.0013177043,"about_ca_system_score_gemma":0.0010939972,"threshold_uncertainty_score":0.012470782},"labels":[],"label_agreement":null},{"id":"W2199894139","doi":"10.1016/s2352-3026(15)00200-8","title":"Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism","year":2015,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Eltrombopag; Myelodysplastic syndromes; Internal medicine; International Prognostic Scoring System; Placebo; Tolerability; Oncology; Adverse effect; Platelet; Bone marrow; Pathology; Immune thrombocytopenia; Alternative medicine","score_opus":0.02247899036029892,"score_gpt":0.2737507969408261,"score_spread":0.25127180658052717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2199894139","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044314796,0.0033425787,0.000054837416,0.98787886,0.0070129093,0.0000026391886,0.000025439338,0.000010144395,0.0012294706],"genre_scores_gemma":[0.010066111,0.004911827,0.0003710206,0.90174323,0.0812354,0.000016444152,0.000062031,0.000022242508,0.001571733],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969035,0.0011968551,0.0005605704,0.0002885246,0.00072034256,0.00033027277],"domain_scores_gemma":[0.99020725,0.0054476974,0.00076487975,0.0002876794,0.0013380818,0.001954363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029696657,0.00053787744,0.0018874239,0.0007304048,0.0021885233,0.0038320122,0.0015336425,0.0344041,0.004234858],"category_scores_gemma":[0.029993305,0.00061251485,0.0015916327,0.00074355333,0.0027299374,0.0043030516,0.0014349794,0.040543225,0.0040187566],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030464327,0.00009549099,0.0038906694,0.00016258149,0.00008698644,0.0049076634,0.0001803465,0.00023151141,0.00030562453,0.0042425673,0.9331661,0.052425824],"study_design_scores_gemma":[0.0012143753,0.00040471047,0.0062420634,0.0023169012,0.0002518257,0.017445311,0.0009772261,0.0015220213,0.0005303538,0.04767039,0.9212373,0.00018766442],"about_ca_topic_score_codex":0.0038251122,"about_ca_topic_score_gemma":0.008628668,"teacher_disagreement_score":0.0344041,"about_ca_system_score_codex":0.004734908,"about_ca_system_score_gemma":0.0038920988,"threshold_uncertainty_score":0.03435427},"labels":[],"label_agreement":null},{"id":"W2225295868","doi":"10.1016/s2352-3026(15)00257-4","title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","year":2015,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":244,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Pulmonary embolism; Deep vein; Fondaparinux; Thrombosis; Low molecular weight heparin; Vitamin K antagonist; Surgery; Anticoagulant; Population; Warfarin; Internal medicine; Atrial fibrillation; Venous thromboembolism","score_opus":0.07625267285548144,"score_gpt":0.3885107301357913,"score_spread":0.31225805728030986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2225295868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004924,0.0072842385,0.00022304419,0.000248384,0.00016342867,0.00019147026,0.00044627304,0.000018843735,0.001375074],"genre_scores_gemma":[0.9967114,0.001550511,0.0002744928,0.0002858496,0.00032825273,0.000108530105,0.00045878193,0.00000763003,0.00027455355],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99745756,0.0012353134,0.0002833682,0.0004925947,0.00034496182,0.00018628845],"domain_scores_gemma":[0.9937528,0.003082196,0.001654024,0.0005830599,0.00022634027,0.00070157246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00334254,0.0008411806,0.0019860524,0.00054655795,0.00036692398,0.0018185134,0.0008685908,0.0014937837,0.0024399443],"category_scores_gemma":[0.006997047,0.000618893,0.0026535783,0.0006825257,0.0013204468,0.0015593056,0.00043737591,0.002699801,0.00048760953],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9392153,0.0059879418,0.021108633,0.00064703973,0.0052129477,0.00007853845,0.00012832078,0.00036524973,0.0016614266,0.0001709969,0.0005102308,0.024913447],"study_design_scores_gemma":[0.47710168,0.3286283,0.17492731,0.0002815772,0.011356147,0.0005514978,0.00028170733,0.0023189716,0.0014386612,0.0010212747,0.0019264455,0.00016636607],"about_ca_topic_score_codex":0.00051661074,"about_ca_topic_score_gemma":0.00052029104,"teacher_disagreement_score":0.00334254,"about_ca_system_score_codex":0.0008070259,"about_ca_system_score_gemma":0.00072139024,"threshold_uncertainty_score":0.017677248},"labels":[],"label_agreement":null},{"id":"W2286860957","doi":"10.1016/s2352-3026(16)00002-8","title":"Caesarean delivery and risk of childhood leukaemia: a pooled analysis from the Childhood Leukemia International Consortium (CLIC)","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute; World Health Organization","keywords":"Medicine; Caesarean delivery; Caesarean section; Pediatrics; Odds ratio; Obstetrics; Logistic regression; Pregnancy; Internal medicine","score_opus":0.014018937127553659,"score_gpt":0.2662453954563988,"score_spread":0.25222645832884516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286860957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70546496,0.26993534,0.0031963615,0.00088437746,0.00089780503,0.00021167769,0.016726654,0.00020157515,0.0024813316],"genre_scores_gemma":[0.9719667,0.018654803,0.0011344854,0.0006465187,0.00045482657,0.0001923877,0.0059508714,0.00008401487,0.00091533],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9919974,0.0047110477,0.0007969869,0.0014242306,0.00046917793,0.000600982],"domain_scores_gemma":[0.9903538,0.004351541,0.0020573698,0.0019694865,0.0007824527,0.00048519095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073993118,0.001775771,0.0056426334,0.0018049412,0.00047763434,0.0021172483,0.00142935,0.001999243,0.0026872377],"category_scores_gemma":[0.012542469,0.0015031119,0.01784929,0.0033008298,0.00048021183,0.0008177777,0.0016862169,0.0016982195,0.00041613117],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07767308,0.00011483965,0.26187834,0.008257722,0.63069814,0.0005967751,0.0001921475,0.0022771235,0.0017147461,0.00039852236,0.0059371623,0.010261421],"study_design_scores_gemma":[0.0090271635,0.0018663779,0.32208613,0.0010758173,0.6601144,0.00039059206,0.00034331693,0.0012369137,0.0003414575,0.00041934676,0.0029613809,0.00013701321],"about_ca_topic_score_codex":0.021657666,"about_ca_topic_score_gemma":0.023982821,"teacher_disagreement_score":0.021657666,"about_ca_system_score_codex":0.0009026853,"about_ca_system_score_gemma":0.0010448432,"threshold_uncertainty_score":0.043063223},"labels":[],"label_agreement":null},{"id":"W2288291042","doi":"10.1016/s2352-3026(16)00020-x","title":"Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; Victoria Hospital; University of Alberta; London Health Sciences Centre; McMaster University; Canadian Blood Services","funders":"Canadian Institutes of Health Research; Health Canada; Canadian Blood Services","keywords":"Medicine; Hazard ratio; Proportional hazards model; Retrospective cohort study; Blood transfusion; Cohort; Cohort study; Red blood cell; Emergency medicine; Confidence interval; Internal medicine; Pediatrics","score_opus":0.027130346781898834,"score_gpt":0.3432596311308283,"score_spread":0.31612928434892945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2288291042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99788123,0.00021672832,0.00018282078,0.00008680769,0.000024433239,0.000020888536,0.0013055522,0.00001036765,0.0002712444],"genre_scores_gemma":[0.9969132,0.0002791236,0.0003031309,0.00011534423,0.000047198064,0.0000440449,0.0016070307,0.000029035848,0.00066193676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765354,0.00074338354,0.0002711034,0.0006231268,0.00024039764,0.00046848768],"domain_scores_gemma":[0.9919525,0.0010236115,0.002798345,0.0024814645,0.00069023576,0.0010538107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026886298,0.0009874753,0.0011173296,0.0010373752,0.0014387901,0.0026656268,0.0016634958,0.001380314,0.004080217],"category_scores_gemma":[0.0055258623,0.0022002251,0.002439581,0.0031217677,0.000888052,0.002242071,0.0016150913,0.0031665538,0.0011203187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015256838,0.00046935878,0.9929985,0.00004007212,0.0015444729,0.00024627714,0.00058162224,0.00006084984,0.0005493971,0.00006945837,0.00084766163,0.0010667025],"study_design_scores_gemma":[0.00017023018,0.000538881,0.99595046,0.00002680349,0.00079921755,0.00049902435,0.0011401548,0.00021399147,0.00012075802,0.000053749318,0.0004450299,0.000041768173],"about_ca_topic_score_codex":0.015238256,"about_ca_topic_score_gemma":0.01803183,"teacher_disagreement_score":0.015238256,"about_ca_system_score_codex":0.0009082058,"about_ca_system_score_gemma":0.0012887967,"threshold_uncertainty_score":0.030299127},"labels":[],"label_agreement":null},{"id":"W2291152756","doi":"10.1016/s2352-3026(16)00004-1","title":"Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Rituximab; Fludarabine; Clinical endpoint; Cyclophosphamide; Pharmacokinetics; Population; Internal medicine; Clinical trial; Surgery; Chemotherapy; Lymphoma","score_opus":0.06490262390275962,"score_gpt":0.4059350666630088,"score_spread":0.3410324427602492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2291152756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946466,0.0021192336,0.00045313133,0.00045721585,0.00023604554,0.0007744368,0.00031504733,0.00006032703,0.00093785534],"genre_scores_gemma":[0.9931108,0.001278928,0.0010613257,0.00069684593,0.0002874971,0.0010896357,0.00044360975,0.000026558304,0.002004944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99905735,0.00052254583,0.000044004002,0.00019152422,0.00007223276,0.000112310416],"domain_scores_gemma":[0.99837375,0.00061789923,0.00043613694,0.00016381689,0.00006855592,0.0003397616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019156638,0.0013789593,0.0029268167,0.00030709797,0.0003001015,0.0014661603,0.0009829098,0.0020727778,0.0051027415],"category_scores_gemma":[0.0027215611,0.00072933786,0.0017662738,0.00037188517,0.0017031796,0.0016075929,0.00044792882,0.004277778,0.0011108625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97773224,0.004233152,0.0004296238,0.0003412835,0.0006208007,0.000031280306,0.00005503158,0.0002916893,0.0025446299,0.00011192362,0.00036106346,0.013247399],"study_design_scores_gemma":[0.92341995,0.07394079,0.0010282103,0.000023475934,0.00038387786,0.000031958367,0.000022627906,0.00040025893,0.00031096494,0.00015450823,0.0002692339,0.000014214206],"about_ca_topic_score_codex":0.00048244465,"about_ca_topic_score_gemma":0.00076228124,"teacher_disagreement_score":0.0051027415,"about_ca_system_score_codex":0.00086285686,"about_ca_system_score_gemma":0.0008351595,"threshold_uncertainty_score":0.017070413},"labels":[],"label_agreement":null},{"id":"W2296827990","doi":"10.1016/s2352-3026(16)00006-5","title":"Idiopathic multicentric Castleman's disease: a systematic literature review","year":2016,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Castleman disease; Disease; Histopathology; Pathology; Dermatology","score_opus":0.0399324007817195,"score_gpt":0.35000770677926374,"score_spread":0.31007530599754424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296827990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00067444454,0.9987709,0.00003594076,0.00008856029,0.000051961226,0.000057299574,0.00022141755,0.0000022419488,0.00009722894],"genre_scores_gemma":[0.01226211,0.9867383,0.00026578183,0.00037968115,0.000056074743,0.00007886298,0.00015393338,0.0000020307484,0.00006324828],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99781764,0.00045467634,0.0010618606,0.00022739293,0.00031249088,0.00012598278],"domain_scores_gemma":[0.99396306,0.0033994194,0.0020390342,0.000094001654,0.00037655907,0.00012787747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026246656,0.0012460741,0.0065405197,0.011309979,0.0004365832,0.0019582869,0.0012892258,0.0015075031,0.0053883763],"category_scores_gemma":[0.008587276,0.0008446045,0.0047862255,0.010753738,0.00079909305,0.002013403,0.0015601685,0.0009206632,0.000267313],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002857098,0.000025464431,0.0018224434,0.94463456,0.012226733,0.00039306632,0.00019196437,0.000095952484,0.00024659644,0.00027439106,0.0029515997,0.03685165],"study_design_scores_gemma":[0.00073150033,0.00025736672,0.011471857,0.787394,0.15193841,0.0028600546,0.00074281794,0.000093797025,0.00019134465,0.00047760105,0.043744452,0.00009688453],"about_ca_topic_score_codex":0.005401984,"about_ca_topic_score_gemma":0.026123155,"teacher_disagreement_score":0.011309979,"about_ca_system_score_codex":0.0019162912,"about_ca_system_score_gemma":0.005444297,"threshold_uncertainty_score":0.018025935},"labels":[],"label_agreement":null},{"id":"W2299219969","doi":"10.1016/s2352-3026(15)00247-1","title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":431,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Agence Nationale de la Recherche","keywords":"Medicine; Bromodomain; Internal medicine; Leukemia; Oncology","score_opus":0.011626998762010418,"score_gpt":0.2695873245110347,"score_spread":0.2579603257490243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299219969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408877,0.003118577,0.00037779828,0.0003064436,0.00010458394,0.00044334424,0.00044547944,0.00007002897,0.0010449771],"genre_scores_gemma":[0.98793286,0.0041394653,0.0011610995,0.00077938556,0.00013499563,0.0006927825,0.0017988632,0.000025563451,0.0033350822],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997218,0.00011678214,0.000016026463,0.00003884092,0.00003302758,0.00007353363],"domain_scores_gemma":[0.99955314,0.000102667196,0.000082791674,0.000036867077,0.000022088909,0.00020244143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010738913,0.0011726633,0.002122558,0.00031841637,0.00024986325,0.001069375,0.00071967114,0.00068396435,0.0031232433],"category_scores_gemma":[0.0007167363,0.0003356519,0.0013303732,0.00035045997,0.00063254824,0.00065273064,0.00033274858,0.0024287456,0.0006279189],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67542464,0.025213618,0.006932453,0.0019036531,0.0027446242,0.00026887638,0.00043023934,0.0041332883,0.037920244,0.0006941698,0.004556573,0.23977762],"study_design_scores_gemma":[0.5850488,0.37237006,0.028983109,0.00014031323,0.0010317214,0.0005606789,0.00019326789,0.0019826116,0.0033673442,0.0005956614,0.00566627,0.000060121063],"about_ca_topic_score_codex":0.0010213256,"about_ca_topic_score_gemma":0.002723695,"teacher_disagreement_score":0.0031232433,"about_ca_system_score_codex":0.0009494102,"about_ca_system_score_gemma":0.000968034,"threshold_uncertainty_score":0.010448337},"labels":[],"label_agreement":null},{"id":"W2299743455","doi":"10.1016/s2352-3026(16)00007-7","title":"The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research","year":2016,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Disease; Scopus; Clinical trial; Family medicine; MEDLINE; Pathology","score_opus":0.09367360481369282,"score_gpt":0.3704219862791781,"score_spread":0.2767483814654853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299743455","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021491287,0.003436203,0.0034601858,0.96740335,0.02003667,0.000051994335,0.000069488975,0.00010009734,0.005227149],"genre_scores_gemma":[0.020398993,0.010035386,0.021956371,0.847328,0.08174876,0.0006240247,0.000255272,0.00019649568,0.017456708],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9638875,0.023659121,0.0015827104,0.0015891929,0.007169779,0.0021116587],"domain_scores_gemma":[0.81547314,0.11653633,0.004579568,0.00878377,0.016767237,0.037860055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.054880142,0.0008332279,0.001294987,0.0020939051,0.004371691,0.010230716,0.004322151,0.026206398,0.018225882],"category_scores_gemma":[0.14375252,0.000701293,0.0016988025,0.0012555723,0.0065002097,0.016315943,0.01274655,0.028131144,0.0069359615],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006492115,0.000054948316,0.00048302783,0.0002260896,0.00007108536,0.0003365187,0.0003605319,0.00018523881,0.000082125094,0.02909603,0.92220557,0.046833903],"study_design_scores_gemma":[0.00035759827,0.00009584585,0.0006471499,0.0006554159,0.00005121479,0.0003835767,0.0005383669,0.0007214104,0.00010287123,0.0994718,0.89691085,0.00006388517],"about_ca_topic_score_codex":0.0056181205,"about_ca_topic_score_gemma":0.011126902,"teacher_disagreement_score":0.054880142,"about_ca_system_score_codex":0.006751676,"about_ca_system_score_gemma":0.01944078,"threshold_uncertainty_score":0.29023743},"labels":[],"label_agreement":null},{"id":"W2307552230","doi":"10.1016/s2352-3026(16)00023-5","title":"Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital","funders":"","keywords":"Medicine; Edoxaban; Incidence (geometry); Warfarin; Venous thromboembolism; Major bleeding; Surgery; Post-hoc analysis; Cumulative incidence; Internal medicine; Rivaroxaban; Atrial fibrillation; Cohort; Thrombosis","score_opus":0.030735056996386033,"score_gpt":0.30220614690830827,"score_spread":0.27147108991192226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2307552230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579346,0.0028268464,0.00020194807,0.00008678756,0.000099584744,0.000043247677,0.00060980103,0.0000055480905,0.00033277957],"genre_scores_gemma":[0.99793625,0.00051196094,0.00016865203,0.000112085996,0.00012328813,0.00005711394,0.00082488166,0.0000079202155,0.0002578916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969188,0.0016764433,0.00027787682,0.0005212532,0.00023118673,0.00037448018],"domain_scores_gemma":[0.99490756,0.0026494707,0.0009284631,0.00076537783,0.00024569395,0.00050342263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038060776,0.0009365594,0.0030890119,0.0004404045,0.00042451196,0.0016728354,0.0008274032,0.00086431333,0.0014605973],"category_scores_gemma":[0.0050451052,0.0004817542,0.0065951217,0.0009801576,0.00044945552,0.0010295729,0.00092364557,0.0017910253,0.00014851893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39385372,0.00085921,0.51663643,0.0013346061,0.069940455,0.0005437956,0.00037381795,0.0011798932,0.0020971969,0.00032131662,0.0012495389,0.011609966],"study_design_scores_gemma":[0.02427374,0.014953975,0.9065955,0.00016590707,0.048044078,0.00031184388,0.0007527761,0.0021541312,0.000667104,0.00035742047,0.001596646,0.00012677048],"about_ca_topic_score_codex":0.0023866596,"about_ca_topic_score_gemma":0.0038497986,"teacher_disagreement_score":0.0038060776,"about_ca_system_score_codex":0.00047388818,"about_ca_system_score_gemma":0.0008449012,"threshold_uncertainty_score":0.020128727},"labels":[],"label_agreement":null},{"id":"W2328734504","doi":"10.1016/s2352-3026(16)00027-2","title":"Real life studies and good clinical practice – Authors' reply","year":2016,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Rivaroxaban; Medicine; Clinical trial; Major bleeding; Thrombosis; Deep vein; Discontinuation; Apixaban; Surgery; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.11797207888146037,"score_gpt":0.4285029927085008,"score_spread":0.3105309138270404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328734504","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007396486,0.00079998036,0.00002642318,0.9840576,0.014726216,0.0000032310618,0.000018245866,0.000005912785,0.00028850161],"genre_scores_gemma":[0.0018337774,0.0005365746,0.000089881876,0.9539415,0.04269128,0.000025189383,0.000010712646,0.000013385663,0.0008575816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9747911,0.011288384,0.004309955,0.0025402764,0.0053832605,0.0016868798],"domain_scores_gemma":[0.7690807,0.17313446,0.01676647,0.0070929783,0.021143686,0.012781699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0205268,0.00080782606,0.0028802825,0.0015241534,0.0038038888,0.008668168,0.003303653,0.09410692,0.008239853],"category_scores_gemma":[0.21952291,0.0015357193,0.0013163484,0.0016648752,0.010514695,0.0077708787,0.0056880643,0.070515014,0.005648169],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040251907,0.0000127527655,0.0004535919,0.00011090922,0.000040251754,0.0006858406,0.0003505436,0.000037434485,0.0000370934,0.0025059867,0.99218833,0.0035370542],"study_design_scores_gemma":[0.00043211353,0.00007505327,0.0016151678,0.0016716261,0.00014225124,0.0025453826,0.001752617,0.00033726968,0.00023800824,0.02582448,0.965128,0.00023794266],"about_ca_topic_score_codex":0.0025931394,"about_ca_topic_score_gemma":0.004709405,"teacher_disagreement_score":0.09410692,"about_ca_system_score_codex":0.0055934913,"about_ca_system_score_gemma":0.008811833,"threshold_uncertainty_score":0.1085574},"labels":[],"label_agreement":null},{"id":"W2387483003","doi":"10.1016/s2352-3026(16)30020-5","title":"Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Pfizer Canada","keywords":"Medicine; Thrombosis; Portal vein thrombosis; Prospective cohort study; Surgery; Venous thrombosis; Internal medicine","score_opus":0.05248537413696818,"score_gpt":0.33909567047879163,"score_spread":0.28661029634182345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2387483003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557,0.0004935222,0.00030641325,0.00005727516,0.000010338914,0.000030080826,0.0026616317,0.000009471383,0.00086132233],"genre_scores_gemma":[0.99608576,0.00027454481,0.000246049,0.00005423505,0.000022063607,0.000031972566,0.0031205283,0.000010072481,0.00015466832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980975,0.00058037863,0.0002897257,0.0005552332,0.00026146273,0.00021582497],"domain_scores_gemma":[0.99207085,0.0012767671,0.0036594213,0.0014452781,0.00069250393,0.0008550769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015612406,0.00040122046,0.0008736203,0.001365541,0.00058076467,0.0013899237,0.0010447153,0.0007701625,0.0017607437],"category_scores_gemma":[0.005421996,0.0007306047,0.00085538696,0.0033351742,0.00056688435,0.001515196,0.0010265397,0.0010345968,0.0005085737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028618658,0.000027000533,0.9984043,0.000014914183,0.000085173546,0.00012779761,0.00007607913,0.0000303806,0.00014964127,0.000027481314,0.0001832052,0.000587964],"study_design_scores_gemma":[0.000044025688,0.00010451688,0.99852544,0.0000139479625,0.000079563375,0.0006833926,0.0001338373,0.00013064897,0.000053737713,0.000027802318,0.0001936783,0.000009513316],"about_ca_topic_score_codex":0.004225833,"about_ca_topic_score_gemma":0.00442998,"teacher_disagreement_score":0.004225833,"about_ca_system_score_codex":0.00045308593,"about_ca_system_score_gemma":0.0006109713,"threshold_uncertainty_score":0.008402467},"labels":[],"label_agreement":null},{"id":"W2471363772","doi":"10.1016/s2352-3026(16)30057-6","title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Venous thromboembolism; Subgroup analysis; Edoxaban; Randomized controlled trial; Cancer; Internal medicine; Intensive care medicine; Meta-analysis; Warfarin; Rivaroxaban; Thrombosis","score_opus":0.041082264923723126,"score_gpt":0.3122955605451675,"score_spread":0.27121329562144436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2471363772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9307839,0.057478536,0.0030010943,0.0010242816,0.0019619814,0.0015482055,0.0024437858,0.00018026117,0.0015780097],"genre_scores_gemma":[0.98822474,0.006364213,0.0012303528,0.00077610026,0.00048607987,0.0007687208,0.00092838606,0.000044725424,0.0011766427],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959764,0.0022851485,0.0006806275,0.0005313515,0.00022667588,0.0002997471],"domain_scores_gemma":[0.9967134,0.0017532319,0.0006806568,0.00051877357,0.00014541687,0.00018841325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055898908,0.002475517,0.008662512,0.0005881223,0.00038202177,0.002025714,0.0010478431,0.0019817161,0.0038111866],"category_scores_gemma":[0.007053859,0.0008830463,0.012071469,0.00073682726,0.00093464064,0.0012426979,0.00090582704,0.0027531595,0.00045557378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94614506,0.00023344017,0.001467857,0.0033351085,0.04025936,0.00007078402,0.000072648676,0.00035658537,0.0013864185,0.00011581402,0.0004000974,0.0061568287],"study_design_scores_gemma":[0.9015782,0.009338214,0.007970608,0.00027710767,0.07750594,0.000096574215,0.00011691757,0.0009769225,0.0006328499,0.0007508641,0.0006720831,0.00008375955],"about_ca_topic_score_codex":0.0010058432,"about_ca_topic_score_gemma":0.0025090517,"teacher_disagreement_score":0.008662512,"about_ca_system_score_codex":0.00079499435,"about_ca_system_score_gemma":0.0008413987,"threshold_uncertainty_score":0.029562533},"labels":[],"label_agreement":null},{"id":"W2510857252","doi":"10.1016/s2352-3026(16)30080-1","title":"Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute; Ottawa Hospital; University of Ottawa","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Edoxaban; Pulmonary embolism; Warfarin; Internal medicine; Cardiology; Hazard ratio; Deep vein; Thrombosis; Atrial fibrillation; Rivaroxaban; Confidence interval","score_opus":0.009076682641923814,"score_gpt":0.23669895629810483,"score_spread":0.227622273656181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2510857252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986015,0.0006809032,0.00009723146,0.00003807312,0.000033225955,0.000026064336,0.00033957203,0.0000032239977,0.0001802175],"genre_scores_gemma":[0.99892646,0.00013408247,0.00007569954,0.00003647109,0.00004912526,0.000030255065,0.00057783705,0.00000557881,0.00016445544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779737,0.0010533137,0.00019640606,0.00043579,0.00019049768,0.00032657562],"domain_scores_gemma":[0.9977233,0.00095053937,0.00044493246,0.000375311,0.0001647894,0.0003410929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002043917,0.0008151419,0.002408984,0.0006792555,0.0005558033,0.0013360204,0.00082016335,0.0008348937,0.0012710692],"category_scores_gemma":[0.0031548925,0.0005322331,0.0037843445,0.0010884056,0.0004771029,0.0009633082,0.0009580545,0.0013190297,0.00018473489],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038667582,0.0003514332,0.94245094,0.0002408421,0.011465403,0.00040323843,0.0002499365,0.00030615475,0.0012543728,0.00009378816,0.0005450831,0.0039710575],"study_design_scores_gemma":[0.0018046667,0.002626184,0.9875075,0.000022357362,0.0056656557,0.0002148952,0.0005883607,0.0008417428,0.00023449282,0.00006375139,0.00039231865,0.000038053648],"about_ca_topic_score_codex":0.0037695854,"about_ca_topic_score_gemma":0.005649457,"teacher_disagreement_score":0.0037695854,"about_ca_system_score_codex":0.00038568932,"about_ca_system_score_gemma":0.0006968845,"threshold_uncertainty_score":0.010809422},"labels":[],"label_agreement":null},{"id":"W2520058836","doi":"10.1016/s2352-3026(16)30109-0","title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","year":2016,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Blood Services; McMaster University","keywords":"Medicine; Prednisone; Dexamethasone; Internal medicine; Meta-analysis; Corticosteroid; Clinical endpoint; Relative risk; Immune thrombocytopenia; Randomized controlled trial; Platelet; Gastroenterology; Confidence interval","score_opus":0.09557640942711129,"score_gpt":0.35346586600180996,"score_spread":0.25788945657469864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520058836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010084697,0.9884753,0.0003141757,0.00012926148,0.00021821314,0.00018776415,0.00030406783,0.000020022884,0.00026651617],"genre_scores_gemma":[0.3424424,0.65245837,0.0017947719,0.0013929293,0.0003053665,0.00045899273,0.00049806136,0.00003052809,0.00061869755],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9964675,0.0015273548,0.0010002085,0.00047368545,0.00035136883,0.00017985125],"domain_scores_gemma":[0.99516946,0.0032395346,0.0010566293,0.00017206202,0.00023090764,0.00013137187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049207616,0.00234624,0.014562393,0.0022127978,0.000459646,0.0022847403,0.0018351027,0.0020909193,0.005699024],"category_scores_gemma":[0.011869143,0.0011435018,0.02546155,0.0032160836,0.00071878184,0.0015331666,0.0012551652,0.0025002407,0.00035675324],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012228517,0.000081383616,0.0023845746,0.28397846,0.684381,0.00011781187,0.00008984493,0.00042493767,0.0003023027,0.00011823744,0.0005707219,0.015322184],"study_design_scores_gemma":[0.0046271505,0.00056705106,0.0028536366,0.010678888,0.9795585,0.00007957665,0.000058687438,0.00011572162,0.00009206813,0.00016028983,0.001180065,0.00002830857],"about_ca_topic_score_codex":0.006581926,"about_ca_topic_score_gemma":0.020033209,"teacher_disagreement_score":0.014562393,"about_ca_system_score_codex":0.0022049933,"about_ca_system_score_gemma":0.0017410269,"threshold_uncertainty_score":0.026023805},"labels":[],"label_agreement":null},{"id":"W2525440522","doi":"10.1016/s2352-3026(16)30108-9","title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Internal medicine; Hazard ratio; Vinblastine; Oncology; Interim analysis; Cohort; Chemotherapy regimen; Chemotherapy; Clinical trial; Vincristine; Confidence interval; Cyclophosphamide","score_opus":0.023154701309825797,"score_gpt":0.28746616756845117,"score_spread":0.2643114662586254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525440522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986771,0.0005832385,0.00015148439,0.000032344033,0.000008850533,0.0000056152785,0.00031344115,0.0000033241702,0.00022461168],"genre_scores_gemma":[0.999423,0.00008249576,0.00008656182,0.000021131757,0.000009688738,0.0000038609655,0.00030679346,0.0000033347278,0.0000631107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998749,0.00045172495,0.000111231515,0.00036609598,0.0001305122,0.00019142237],"domain_scores_gemma":[0.99773514,0.0005033794,0.00072410353,0.00057060976,0.00023964726,0.00022707811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021198238,0.0005387389,0.00067953067,0.0008042269,0.0004767987,0.0015926658,0.0006586384,0.0009113099,0.000785843],"category_scores_gemma":[0.0037173089,0.00062637083,0.0009554283,0.0013444878,0.0006079913,0.0011927328,0.00075427233,0.0008714558,0.00025090147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012303242,0.000043779408,0.9958198,0.000011546637,0.00041506396,0.00016790383,0.0000796443,0.00009146716,0.0006593227,0.000034887114,0.00008429943,0.00136194],"study_design_scores_gemma":[0.000044976263,0.00025025342,0.99772805,0.000009463226,0.0003417992,0.0006764618,0.00015830285,0.00030367973,0.00014374107,0.0000704394,0.00025888,0.0000139720105],"about_ca_topic_score_codex":0.002312755,"about_ca_topic_score_gemma":0.0025064144,"teacher_disagreement_score":0.002312755,"about_ca_system_score_codex":0.00047295116,"about_ca_system_score_gemma":0.00031786071,"threshold_uncertainty_score":0.011210859},"labels":[],"label_agreement":null},{"id":"W2530375062","doi":"10.1016/s2352-3026(16)30114-4","title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Institute of General Medical Sciences; University of California, San Francisco","keywords":"Busulfan; Medicine; Hazard ratio; Cumulative incidence; Transplantation; Proportional hazards model; Internal medicine; Retrospective cohort study; Survival analysis; Dosing; Surgery; Hematopoietic stem cell transplantation; Oncology; Confidence interval","score_opus":0.004853650410942675,"score_gpt":0.21903164101673758,"score_spread":0.2141779906057949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2530375062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988254,0.00042983462,0.000065777924,0.000023714314,0.0000053952995,0.000008674662,0.0005458565,0.000002452604,0.00009288373],"genre_scores_gemma":[0.9989502,0.00023218752,0.000087284156,0.00002977021,0.000008457817,0.000013405771,0.0005727749,0.0000036739204,0.000102326856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999181,0.00017039858,0.00010620158,0.00025787242,0.00010479097,0.00017962628],"domain_scores_gemma":[0.99858886,0.00019027914,0.0006970205,0.00019223754,0.0001222871,0.00020931805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077152404,0.00040898006,0.0007397344,0.00069018616,0.00044718775,0.0007955824,0.0005071517,0.00058049185,0.0011569043],"category_scores_gemma":[0.0017400758,0.0006279979,0.0013496553,0.0016937153,0.00045132914,0.00068582065,0.00073891814,0.000911679,0.00019515914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004060026,0.0000210466,0.9981571,0.0000192735,0.00033246205,0.00010831832,0.00008088765,0.000029223544,0.00022827456,0.00001486395,0.00008883262,0.00051364617],"study_design_scores_gemma":[0.000024720002,0.00022440894,0.9987801,0.000007835025,0.00017198581,0.00032358617,0.00016841806,0.00006197775,0.000049408918,0.000011443769,0.00016994873,0.0000061521746],"about_ca_topic_score_codex":0.010525714,"about_ca_topic_score_gemma":0.0109723145,"teacher_disagreement_score":0.010525714,"about_ca_system_score_codex":0.0006638479,"about_ca_system_score_gemma":0.0005990664,"threshold_uncertainty_score":0.02092886},"labels":[],"label_agreement":null},{"id":"W2554412408","doi":"10.1016/s2352-3026(16)30131-4","title":"Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Medicine; Deep vein; Placebo; Thrombosis; Double blind; Anticoagulant therapy; Surgery; Warfarin; Randomized controlled trial; Anticoagulant; Cactus; Clinical trial; Internal medicine; Alternative medicine; Atrial fibrillation; Pathology","score_opus":0.06913215043298578,"score_gpt":0.34538233384565553,"score_spread":0.27625018341266977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554412408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91531533,0.05726458,0.002230661,0.0022613353,0.005278048,0.009481696,0.0022205703,0.00051188393,0.0054358966],"genre_scores_gemma":[0.94865465,0.024903102,0.003086849,0.0029873834,0.0026695787,0.008879051,0.0014004789,0.000052798958,0.0073661855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988918,0.00050019176,0.00012748147,0.0002196431,0.00010049945,0.00016037909],"domain_scores_gemma":[0.9987093,0.0005071382,0.00029790594,0.00009249683,0.000087633896,0.00030552718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020858303,0.0022407828,0.0065984083,0.00085980416,0.000686884,0.0016628158,0.0013237024,0.004105361,0.011060189],"category_scores_gemma":[0.0035884022,0.0010210493,0.0028246068,0.0009989124,0.0019184254,0.0015381646,0.0005440486,0.0033640983,0.0013596183],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98939836,0.0011781991,0.00014511055,0.0018651588,0.0011161641,0.000033816865,0.000029246776,0.00006260579,0.00068161386,0.000085236155,0.0004465734,0.004957951],"study_design_scores_gemma":[0.99203134,0.006886738,0.00029623866,0.000048053455,0.0003952971,0.000013410491,0.000007873358,0.00005592551,0.000039394057,0.000043567627,0.00017637169,0.0000057081024],"about_ca_topic_score_codex":0.0018584444,"about_ca_topic_score_gemma":0.0029757272,"teacher_disagreement_score":0.011060189,"about_ca_system_score_codex":0.00081897713,"about_ca_system_score_gemma":0.0012256042,"threshold_uncertainty_score":0.037},"labels":[],"label_agreement":null},{"id":"W2587788787","doi":"10.1016/s2352-3026(17)30014-5","title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Rivaroxaban; Fondaparinux; Pulmonary embolism; Thrombosis; Deep vein; Surgery; Population; Internal medicine; Warfarin; Atrial fibrillation","score_opus":0.10240684985394638,"score_gpt":0.39715872318639955,"score_spread":0.2947518733324532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587788787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97401434,0.011058383,0.0015309379,0.0026916845,0.0015811665,0.0019669002,0.0023463557,0.0002736592,0.004536532],"genre_scores_gemma":[0.9765877,0.0046349987,0.002655777,0.0039190017,0.0013505277,0.0027044243,0.0030271525,0.00008662885,0.005033643],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992169,0.00041677014,0.000047161408,0.00013984903,0.000054957993,0.00012438891],"domain_scores_gemma":[0.99897254,0.00037569943,0.00022284548,0.00012166232,0.000056481353,0.0002508747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020092959,0.002457031,0.0038083221,0.00037254376,0.00045731393,0.0016142619,0.0010378467,0.0025485803,0.008147504],"category_scores_gemma":[0.0028287475,0.0007789655,0.0039897515,0.00038069097,0.0014118549,0.0016493441,0.00060009176,0.004559506,0.0014614975],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9834647,0.0018995837,0.0004628887,0.00058074517,0.0013646223,0.000046513735,0.0000501137,0.00023137585,0.0013846633,0.00015238937,0.0013357296,0.009026625],"study_design_scores_gemma":[0.9877582,0.010081086,0.0010543684,0.000027225668,0.00032682158,0.000028783417,0.000014056227,0.00014889674,0.00008021889,0.00018624167,0.000285079,0.0000089391215],"about_ca_topic_score_codex":0.0012756779,"about_ca_topic_score_gemma":0.0021213898,"teacher_disagreement_score":0.008147504,"about_ca_system_score_codex":0.0007381081,"about_ca_system_score_gemma":0.0009040052,"threshold_uncertainty_score":0.027256131},"labels":[],"label_agreement":null},{"id":"W2594646846","doi":"10.1016/s2352-3026(17)30019-4","title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"Gilead Sciences; Lymphoma Research Foundation","keywords":"Ofatumumab; Idelalisib; Medicine; Internal medicine; Population; IGHV@; Clinical endpoint; Chronic lymphocytic leukemia; Ibrutinib; Rituximab; Clinical trial; Oncology; Gastroenterology; Lymphoma; Leukemia","score_opus":0.09379685803426602,"score_gpt":0.4174588566744332,"score_spread":0.3236619986401672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594646846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98724246,0.0068196743,0.00049090397,0.0007230265,0.00064467086,0.0014637797,0.00080165727,0.00010464415,0.00170924],"genre_scores_gemma":[0.9888263,0.0027181467,0.0009707826,0.0011353215,0.00048013564,0.0020787546,0.0014034223,0.00003472808,0.002352508],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989452,0.0005341771,0.000057633497,0.00018371483,0.00007811447,0.00020117294],"domain_scores_gemma":[0.99879336,0.0003331969,0.0002523516,0.00011267344,0.00006107748,0.0004473242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025779463,0.0024944025,0.004611185,0.00057816994,0.0006681593,0.0019707587,0.0012236981,0.00262363,0.0056174523],"category_scores_gemma":[0.0019275245,0.0010043035,0.0034193925,0.0005901035,0.0021071006,0.00225697,0.0005909182,0.0051900675,0.0016313267],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98102814,0.0031417438,0.0005874559,0.00036443333,0.00115085,0.000049049082,0.000049816124,0.00029593022,0.0018063346,0.00007515772,0.0005856184,0.010865351],"study_design_scores_gemma":[0.946014,0.051069062,0.0013158944,0.00002499535,0.0004462846,0.000047519727,0.000019445544,0.00024868775,0.0001843417,0.000117866555,0.00049496436,0.00001692556],"about_ca_topic_score_codex":0.0012532914,"about_ca_topic_score_gemma":0.0024326376,"teacher_disagreement_score":0.0056174523,"about_ca_system_score_codex":0.0015899901,"about_ca_system_score_gemma":0.0011707341,"threshold_uncertainty_score":0.018792212},"labels":[],"label_agreement":null},{"id":"W2595724571","doi":"10.1016/s2352-3026(17)30042-x","title":"Anti-thymocyte globulin dosing—per kg or per lymphocyte?","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Thymoglobulin; Anti-thymocyte globulin; Medicine; Transplantation; Graft-versus-host disease; Internal medicine; Dosing; Globulin; Randomized controlled trial; Immunology; Gastroenterology; Tacrolimus","score_opus":0.06145293338250934,"score_gpt":0.34101584162831067,"score_spread":0.2795629082458013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2595724571","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044454258,0.51118755,0.020178508,0.24415389,0.092930704,0.0002695867,0.0014234639,0.0011890787,0.08421301],"genre_scores_gemma":[0.43701094,0.22952586,0.028508935,0.16365881,0.048455667,0.00037315534,0.000994489,0.00052255363,0.09094949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991177,0.00043529717,0.000120649165,0.00010584694,0.00014646059,0.00007402482],"domain_scores_gemma":[0.99915886,0.00035599765,0.00015807591,0.000069115245,0.00011560086,0.00014236462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016575697,0.0004577726,0.0014563078,0.0004057387,0.00021728966,0.0013632021,0.00081089674,0.0014849848,0.010546802],"category_scores_gemma":[0.0033146369,0.00016319605,0.00061934796,0.0004316313,0.0008017565,0.0011401263,0.00036432617,0.0035323615,0.0054618693],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007417619,0.0004341054,0.00083546044,0.0015055392,0.0005484117,0.00015490998,0.000042236694,0.00048252448,0.0076116486,0.013774701,0.13456923,0.8326237],"study_design_scores_gemma":[0.0034057007,0.008755734,0.0044012396,0.0023876259,0.00093622034,0.0021033513,0.00016700067,0.0007493206,0.010335809,0.025458315,0.9411984,0.000101274505],"about_ca_topic_score_codex":0.00063552795,"about_ca_topic_score_gemma":0.0012331988,"teacher_disagreement_score":0.010546802,"about_ca_system_score_codex":0.00059466355,"about_ca_system_score_gemma":0.000587185,"threshold_uncertainty_score":0.035282552},"labels":[],"label_agreement":null},{"id":"W2606110123","doi":"10.1016/s2352-3026(17)30052-2","title":"Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Centers for Disease Control and Prevention; Partenariat Canadien Contre Le Cancer; Swiss Re; World Health Organization; Swiss Cancer Research Foundation; Cancer Institute NSW; Cancer Research UK","keywords":"Medicine; Pediatrics; Demography; Childhood leukaemia; Population; Environmental health","score_opus":0.0781453487170645,"score_gpt":0.3765434257869886,"score_spread":0.29839807706992405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606110123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832756,0.0006147023,0.00016085904,0.000060174763,0.0000076093093,0.00003216172,0.010231095,0.000009689807,0.0005560622],"genre_scores_gemma":[0.9784384,0.0005293489,0.00032495605,0.0000670364,0.00001642461,0.000062136336,0.02032193,0.000012346844,0.00022749715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99681264,0.000891095,0.0005367859,0.00096502167,0.0004623004,0.00033221155],"domain_scores_gemma":[0.9917327,0.0012066287,0.004186676,0.0011520261,0.0011186342,0.00060327846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005175938,0.00041294473,0.0007892302,0.0031144533,0.000536407,0.0010952245,0.0011618653,0.0007214528,0.00091303943],"category_scores_gemma":[0.006421026,0.00051250285,0.000909396,0.005641558,0.00048382048,0.0008637802,0.0018563167,0.0005864062,0.00027291282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001721417,0.000013791241,0.9972458,0.000036157988,0.00026062372,0.00006277265,0.0001783439,0.000142516,0.000078056284,0.00004949367,0.0006045247,0.0011558398],"study_design_scores_gemma":[0.000014162892,0.000030368601,0.9989222,0.000018887898,0.000058914426,0.00010099108,0.00017673257,0.00015098901,0.000034518005,0.000006535182,0.00047968977,0.0000059497775],"about_ca_topic_score_codex":0.113425195,"about_ca_topic_score_gemma":0.13900116,"teacher_disagreement_score":0.113425195,"about_ca_system_score_codex":0.002303174,"about_ca_system_score_gemma":0.001357252,"threshold_uncertainty_score":0.22552997},"labels":[],"label_agreement":null},{"id":"W2611645469","doi":"10.1016/s2352-3026(17)30078-9","title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"European Commission; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Follicular lymphoma; Vincristine; Internal medicine; Prednisone; International Prognostic Index; Clinical endpoint; Surgery; Cyclophosphamide; Lymphoma; Oncology; Chemotherapy; Randomized controlled trial","score_opus":0.09747788966554995,"score_gpt":0.3848782168562778,"score_spread":0.2874003271907279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611645469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905172,0.004429663,0.0005509328,0.00055721315,0.0004825636,0.0015396244,0.00047369485,0.000102453174,0.0013467062],"genre_scores_gemma":[0.99313253,0.0014386087,0.0008301046,0.0006745536,0.00035466586,0.0016759693,0.0004673388,0.000025592293,0.0014005658],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986243,0.00081139884,0.000064762324,0.00022665104,0.00008677595,0.00018612556],"domain_scores_gemma":[0.9980562,0.0007842846,0.0004026925,0.00019542663,0.000093878574,0.00046751383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002561139,0.001997415,0.0039172526,0.00049141824,0.00055854785,0.0018401633,0.001373278,0.0029808842,0.0064190184],"category_scores_gemma":[0.003090638,0.00092350354,0.002947645,0.00046788584,0.002213143,0.00169777,0.0006184953,0.0045005986,0.0015251283],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98726475,0.0030380164,0.0002761376,0.000273146,0.0006743278,0.000021748714,0.00005195443,0.0001779515,0.0010251105,0.000057913883,0.00024040103,0.0068985536],"study_design_scores_gemma":[0.94720954,0.050765518,0.0007378465,0.00002520154,0.00035101606,0.000029988938,0.000020372658,0.00027053052,0.00019864843,0.00013993747,0.00023856666,0.000012797342],"about_ca_topic_score_codex":0.0009935531,"about_ca_topic_score_gemma":0.0011692914,"teacher_disagreement_score":0.0064190184,"about_ca_system_score_codex":0.0012682527,"about_ca_system_score_gemma":0.001097007,"threshold_uncertainty_score":0.021473825},"labels":[],"label_agreement":null},{"id":"W2620735312","doi":"10.1016/s2352-3026(17)30079-0","title":"Subcutaneous rituximab—a meaningful advance in care","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; CD20; Lymphoma; Internal medicine; Oncology","score_opus":0.031390697028140034,"score_gpt":0.3347144156308049,"score_spread":0.3033237186026649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620735312","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002136144,0.26429752,0.0035416894,0.6532333,0.054418545,0.0000335635,0.00032098973,0.00027310106,0.021745114],"genre_scores_gemma":[0.08885331,0.25813696,0.008355936,0.41716877,0.21388927,0.00007993549,0.00090671465,0.00020091688,0.012408187],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963768,0.0014755962,0.00033783514,0.0003861528,0.0007764797,0.0006471466],"domain_scores_gemma":[0.9866239,0.006773833,0.0010395537,0.00059128756,0.0019031377,0.0030682865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069959466,0.0011613944,0.002161352,0.0011813106,0.00085764,0.0051485403,0.0016468744,0.011237401,0.016059214],"category_scores_gemma":[0.012987637,0.0004181909,0.0014923406,0.00098011,0.0026074713,0.008477352,0.0023494265,0.016987681,0.008172416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019654087,0.00026369933,0.0009584138,0.0013858834,0.0002546628,0.0014455594,0.00007271625,0.00065546436,0.0018343967,0.046587422,0.503048,0.44152835],"study_design_scores_gemma":[0.0022126266,0.0013654951,0.0029450904,0.0037908708,0.00029842724,0.003323493,0.000250594,0.0009045898,0.00088896835,0.09202645,0.8918681,0.0001252881],"about_ca_topic_score_codex":0.0008142184,"about_ca_topic_score_gemma":0.0017823823,"teacher_disagreement_score":0.016059214,"about_ca_system_score_codex":0.003576606,"about_ca_system_score_gemma":0.0040390943,"threshold_uncertainty_score":0.053723454},"labels":[],"label_agreement":null},{"id":"W2620858201","doi":"10.1016/s2352-3026(17)30086-8","title":"Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply","year":2017,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Medicine; Rivaroxaban; Fondaparinux; Thrombosis; Deep vein; Pulmonary embolism; Surgery; Warfarin; Internal medicine; Atrial fibrillation; Venous thromboembolism","score_opus":0.15771978270394627,"score_gpt":0.3941540336071454,"score_spread":0.23643425090319914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620858201","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006262923,0.0024385452,0.00006855345,0.9655757,0.029780883,0.000010059791,0.00006967552,0.000017505075,0.0014127236],"genre_scores_gemma":[0.009143298,0.0018399189,0.00019940289,0.8863468,0.1001245,0.000033668755,0.00005913498,0.000022573866,0.0022306119],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960716,0.0013900032,0.0008040568,0.00043563344,0.0008667725,0.0004318912],"domain_scores_gemma":[0.9845269,0.009486973,0.0012447281,0.00045183656,0.00283736,0.0014520966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028556935,0.0007668158,0.0019134004,0.0012258728,0.0017268019,0.0037332168,0.0017376554,0.047454294,0.0044786604],"category_scores_gemma":[0.03707191,0.0008122467,0.0010666862,0.0008336763,0.00268802,0.0037129936,0.0016196319,0.029053986,0.004323107],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001162056,0.000046628244,0.0029990133,0.00013854535,0.000050543476,0.009286493,0.0002525651,0.000091053,0.00018293288,0.0014076295,0.9762546,0.009173851],"study_design_scores_gemma":[0.00055617426,0.00023419394,0.0047711567,0.001345685,0.00022116986,0.0226769,0.0015607935,0.0011032043,0.0007404791,0.01126449,0.9552663,0.00025934647],"about_ca_topic_score_codex":0.0023791387,"about_ca_topic_score_gemma":0.0027183378,"teacher_disagreement_score":0.047454294,"about_ca_system_score_codex":0.0024426768,"about_ca_system_score_gemma":0.0025013827,"threshold_uncertainty_score":0.017722905},"labels":[],"label_agreement":null},{"id":"W2759462495","doi":"10.1016/s2352-3026(17)30168-0","title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Celgene","keywords":"Medicine; Lenalidomide; Placebo; Maintenance therapy; Chronic lymphocytic leukemia; Internal medicine; Oncology; Physical therapy; Multiple myeloma; Leukemia; Chemotherapy; Alternative medicine; Pathology","score_opus":0.09344758497031419,"score_gpt":0.39512861509315317,"score_spread":0.301681030122839,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2759462495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97573596,0.014002953,0.00068292336,0.0009011808,0.000697155,0.0037071682,0.0012168013,0.00021178104,0.0028440303],"genre_scores_gemma":[0.9813214,0.0055664177,0.0016080732,0.0018328214,0.00046456498,0.004477524,0.0012300676,0.000026697891,0.0034724895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99948394,0.0002541385,0.000032262233,0.00010687316,0.000039744657,0.000082972794],"domain_scores_gemma":[0.9993292,0.00018880669,0.00014561035,0.00005836021,0.000034354227,0.0002438154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246474,0.0012451012,0.002891802,0.00043308164,0.00051898445,0.0011364683,0.0011818908,0.0018815392,0.006403891],"category_scores_gemma":[0.0014145176,0.00047750687,0.0015629213,0.000468943,0.0013709984,0.0011603002,0.00051670894,0.0023285022,0.0010773491],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97951895,0.0025744261,0.00046884542,0.000715898,0.0007725142,0.000044121116,0.00005030867,0.00016663701,0.001614329,0.00010879821,0.00088836247,0.013076807],"study_design_scores_gemma":[0.9813725,0.016665932,0.0009719335,0.000032061664,0.00016822132,0.000023528284,0.000015097442,0.00009179721,0.00007766774,0.00008576358,0.00048807464,0.000007434386],"about_ca_topic_score_codex":0.0013785937,"about_ca_topic_score_gemma":0.0030153363,"teacher_disagreement_score":0.006403891,"about_ca_system_score_codex":0.0010293198,"about_ca_system_score_gemma":0.0009858782,"threshold_uncertainty_score":0.021423161},"labels":[],"label_agreement":null},{"id":"W2763497846","doi":"10.1016/s2352-3026(17)30169-2","title":"Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Impact; Population Health Research Institute; Canadian Blood Services; McMaster University; University of Waterloo","funders":"Health Canada","keywords":"Medicine; ABO blood group system; Randomized controlled trial; Blood transfusion; Red blood cell; Relative risk; Emergency medicine; Anemia; Pediatrics; Surgery; Internal medicine; Confidence interval","score_opus":0.01867941203148179,"score_gpt":0.28309712518680114,"score_spread":0.26441771315531937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763497846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9364569,0.04255482,0.002246519,0.0020103431,0.0024746638,0.0038545898,0.0051600724,0.0002542113,0.004987867],"genre_scores_gemma":[0.9759389,0.00815544,0.002215081,0.0017279752,0.0015998434,0.004127093,0.0026159391,0.000057557216,0.003562175],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99297124,0.0049655326,0.0005966987,0.00062947953,0.0003899681,0.00044712023],"domain_scores_gemma":[0.9898346,0.0057561235,0.0023361642,0.0010818071,0.00042592693,0.00056533125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006880877,0.0027778575,0.008677795,0.00070436904,0.0006212031,0.002229955,0.0012718702,0.0030732157,0.014090642],"category_scores_gemma":[0.016518196,0.0011502715,0.008337509,0.001023331,0.002106067,0.0025486615,0.0011912204,0.004588664,0.0012281055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9794241,0.0004868714,0.0008869213,0.004429946,0.010582551,0.00004835644,0.0000586206,0.00015095955,0.00029323273,0.00020228901,0.00072783494,0.0027083838],"study_design_scores_gemma":[0.96702564,0.010378133,0.0037772562,0.0003454918,0.016801218,0.000058517962,0.000059747865,0.00020817014,0.00017194661,0.00041714925,0.0007178737,0.000038801812],"about_ca_topic_score_codex":0.0013084412,"about_ca_topic_score_gemma":0.0019877183,"teacher_disagreement_score":0.014090642,"about_ca_system_score_codex":0.0013929722,"about_ca_system_score_gemma":0.0013021239,"threshold_uncertainty_score":0.047137856},"labels":[],"label_agreement":null},{"id":"W2770267496","doi":"10.1016/s2352-3026(17)30210-7","title":"Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Pulmonary embolism; Clinical prediction rule; Observational study; Emergency department; Clinical endpoint; Prospective cohort study; Population; Emergency medicine; Pre- and post-test probability; Pediatrics; Clinical trial; Intensive care medicine; Internal medicine","score_opus":0.10146699731447746,"score_gpt":0.37991003006226565,"score_spread":0.2784430327477882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770267496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986467,0.0003397524,0.00010916061,0.00004483913,0.000015074833,0.000023365843,0.00034714685,0.0000026679886,0.00047133258],"genre_scores_gemma":[0.9985764,0.00013196198,0.00016664418,0.00007945143,0.000035311037,0.000017619093,0.0009048077,0.0000032171138,0.000084557374],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833006,0.00050711853,0.00025252023,0.00043564354,0.00027461184,0.00020005928],"domain_scores_gemma":[0.99508286,0.0013072744,0.0020469856,0.0005213256,0.00046981274,0.00057168654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018292164,0.0004938636,0.0011825812,0.00050735695,0.0005726388,0.0016702318,0.00083874195,0.0012125433,0.0013238468],"category_scores_gemma":[0.00905912,0.00045052124,0.0008031268,0.0011493433,0.00058556336,0.0009581225,0.00090687757,0.001116271,0.00030687847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022421791,0.00023402733,0.99317366,0.00006168101,0.00037121968,0.0002945433,0.00013535205,0.0000910423,0.00016005001,0.000121036624,0.00046263495,0.0026525448],"study_design_scores_gemma":[0.0006696341,0.00060961983,0.9947208,0.00006093283,0.00051711,0.0016435486,0.00033337765,0.0005798744,0.000072817806,0.00022749217,0.00054335623,0.000021440737],"about_ca_topic_score_codex":0.0032171754,"about_ca_topic_score_gemma":0.0030210027,"teacher_disagreement_score":0.0032171754,"about_ca_system_score_codex":0.00041494772,"about_ca_system_score_gemma":0.00053022365,"threshold_uncertainty_score":0.009673953},"labels":[],"label_agreement":null},{"id":"W2778275419","doi":"10.1016/s2352-3026(17)30237-5","title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Clinical endpoint; Anemia; Clinical trial; Phases of clinical research; Intention-to-treat analysis; Janus kinase inhibitor; Surgery; Gastroenterology; Janus kinase; Bone marrow","score_opus":0.11587736312776528,"score_gpt":0.37323862342992187,"score_spread":0.25736126030215656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2778275419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98058414,0.010417553,0.00059792795,0.0015828736,0.0007873816,0.0015390674,0.0011370586,0.00017862061,0.0031754733],"genre_scores_gemma":[0.9877487,0.0037188912,0.0009906972,0.0013881268,0.0006138676,0.0013009502,0.0012277305,0.000029024994,0.0029821037],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995278,0.00023919181,0.000023792494,0.00008154111,0.000029120885,0.00009857144],"domain_scores_gemma":[0.9992963,0.00023352132,0.00015869917,0.00005131686,0.000028443375,0.0002316636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001587702,0.0016579956,0.0030978704,0.0004467625,0.00035804152,0.001518318,0.0008479313,0.0017453508,0.0063906126],"category_scores_gemma":[0.0016408992,0.000655961,0.0027378974,0.0003731261,0.001021381,0.0015628017,0.0004888111,0.003607293,0.0009068849],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97426105,0.0033121328,0.0006523333,0.000614606,0.001366941,0.000065476685,0.00006303386,0.0005265172,0.0017238293,0.00016335322,0.0011228906,0.016127761],"study_design_scores_gemma":[0.95965034,0.036928393,0.0013825394,0.000036739202,0.0005024286,0.000053222506,0.000026488286,0.00039639155,0.00019065275,0.00019686067,0.00062021,0.000015642181],"about_ca_topic_score_codex":0.0007816933,"about_ca_topic_score_gemma":0.0020289063,"teacher_disagreement_score":0.0063906126,"about_ca_system_score_codex":0.0008001777,"about_ca_system_score_gemma":0.0006784083,"threshold_uncertainty_score":0.021378696},"labels":[],"label_agreement":null},{"id":"W2796060639","doi":"10.1016/s2352-3026(18)30033-4","title":"Defining clinically relevant measures of iron overload around haemopoietic stem cell transplantation","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Transferrin; Medicine; Myelodysplastic syndromes; Transferrin saturation; Thalassemia; Transplantation; Hepcidin; Internal medicine; Anemia; Immunology; Bone marrow; Iron deficiency","score_opus":0.032589941141006724,"score_gpt":0.2934212889216883,"score_spread":0.26083134778068157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796060639","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89670575,0.045920324,0.023259303,0.008213787,0.0018322448,0.0003328031,0.000625009,0.00024186267,0.022868942],"genre_scores_gemma":[0.989979,0.00275029,0.004339157,0.0010672259,0.00058894797,0.00007759666,0.0002325542,0.0000324952,0.00093282945],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983897,0.000888,0.00013625977,0.0001428735,0.00030364384,0.00013948946],"domain_scores_gemma":[0.9956429,0.0017957787,0.0013647052,0.0002033522,0.0006674629,0.0003257434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004040593,0.0004843093,0.000827975,0.0009421783,0.00050329434,0.0028420286,0.000678708,0.0011202024,0.0010670811],"category_scores_gemma":[0.008286283,0.00017941948,0.00027763628,0.00062044716,0.0012897514,0.0011670269,0.0008141257,0.0018706494,0.00037829028],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011885593,0.00074444205,0.55207163,0.0015273961,0.000523653,0.0031575302,0.0031895216,0.0036967148,0.041173745,0.0133469105,0.016578384,0.35210449],"study_design_scores_gemma":[0.00031273926,0.0087229535,0.832116,0.0017618353,0.0009067084,0.0068029733,0.0068523553,0.006341313,0.054610748,0.038657106,0.042646345,0.00026899533],"about_ca_topic_score_codex":0.0007389167,"about_ca_topic_score_gemma":0.001233809,"teacher_disagreement_score":0.004040593,"about_ca_system_score_codex":0.00080309814,"about_ca_system_score_gemma":0.0006156414,"threshold_uncertainty_score":0.02136898},"labels":[],"label_agreement":null},{"id":"W2799781194","doi":"10.1016/s2352-3026(18)30048-6","title":"Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Children's Hospital of Eastern Ontario; McMaster Children's Hospital; McMaster University; Laurentian University; Thunder Bay Regional Health Sciences Centre; Hôpital de l'Enfant-Jésus; University of Manitoba; Izaak Walton Killam Health Centre; Alberta Children's Hospital; Hospital for Sick Children; University of Saskatchewan; Dalhousie University; British Columbia Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; Public Health Ontario; University of Ottawa; Institute for Clinical Evaluative Sciences; SickKids Foundation; University of Toronto","funders":"Baxalta; Medical Research Council Canada; CSL Behring","keywords":"Medicine; Haemophilia; Clotting factor; Haemophilia A; Hemarthrosis; Cohort; Pediatrics; Clinical endpoint; Physical therapy; Clinical trial; Surgery; Internal medicine","score_opus":0.04112767167180755,"score_gpt":0.30516733662658213,"score_spread":0.2640396649547746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799781194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863542,0.0012585168,0.00023247981,0.00079357537,0.000080858576,0.00012791714,0.010052174,0.00002028608,0.0010799109],"genre_scores_gemma":[0.98497677,0.00097583677,0.0008095338,0.0005322552,0.000049319493,0.00016577006,0.009568168,0.00001890459,0.0029034347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979773,0.00036647468,0.00009955474,0.0003789753,0.00048399667,0.00069368805],"domain_scores_gemma":[0.99615556,0.00030542383,0.0007739665,0.0006830116,0.0012484232,0.0008335697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035753506,0.00086690113,0.0010206768,0.0006627318,0.0025764266,0.0018630727,0.0025014195,0.001789022,0.0023404697],"category_scores_gemma":[0.0065380232,0.0009002537,0.0015170636,0.0024230727,0.000911729,0.0008676502,0.0017279225,0.0021831007,0.00044663093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043349667,0.0004944782,0.9742828,0.0000856491,0.0016344672,0.00015890361,0.0011532641,0.0002845869,0.00047087335,0.00038575818,0.007440543,0.009273797],"study_design_scores_gemma":[0.0003546178,0.0002082767,0.99616086,0.00004604621,0.0004394519,0.0000644142,0.00057264435,0.00024069633,0.000053904267,0.00008939249,0.0017338897,0.000035745452],"about_ca_topic_score_codex":0.9236245,"about_ca_topic_score_gemma":0.9178573,"teacher_disagreement_score":0.076375484,"about_ca_system_score_codex":0.011184426,"about_ca_system_score_gemma":0.0151443845,"threshold_uncertainty_score":0.15365052},"labels":[],"label_agreement":null},{"id":"W2807247022","doi":"10.1016/s2352-3026(18)30069-3","title":"Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada","year":2018,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Public Health Ontario; Manitoba Health; University of Manitoba; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Venous thromboembolism; Abortion; Cohort study; Cohort; Obstetrics; Population; Internal medicine; Pregnancy; Thrombosis; Environmental health","score_opus":0.054458499810033645,"score_gpt":0.2942833932425204,"score_spread":0.23982489343248675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807247022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993733,0.0013125859,0.00029028708,0.00051618356,0.000045180335,0.000062867424,0.0027587756,0.000014252638,0.0012668286],"genre_scores_gemma":[0.99759513,0.00060616614,0.00017334154,0.00013854817,0.000013493255,0.000016424134,0.000868153,0.000007667935,0.0005810593],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981652,0.00018549382,0.0001353666,0.00047185514,0.00039950976,0.0006426036],"domain_scores_gemma":[0.9972861,0.0001970042,0.0005776504,0.00028948026,0.000996359,0.00065336114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010040628,0.00049377204,0.0009660168,0.0012709129,0.003743866,0.001933187,0.0019069767,0.0012069949,0.0022817792],"category_scores_gemma":[0.0029341034,0.0008359971,0.0012075756,0.0056584245,0.001186619,0.0006190316,0.001009671,0.0015029009,0.0002945682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023293086,0.00005409133,0.9954482,0.000031408952,0.0002685406,0.00022601293,0.00044555397,0.00009629772,0.00018976303,0.0002456447,0.0010500625,0.0017114093],"study_design_scores_gemma":[0.000065837885,0.000057880065,0.99664575,0.000051031315,0.00021971113,0.00022354788,0.0011509416,0.00048663642,0.000044647622,0.0001047518,0.00092454214,0.000024683814],"about_ca_topic_score_codex":0.9846978,"about_ca_topic_score_gemma":0.9876302,"teacher_disagreement_score":0.018370815,"about_ca_system_score_codex":0.018370815,"about_ca_system_score_gemma":0.028074462,"threshold_uncertainty_score":0.13329023},"labels":[],"label_agreement":null},{"id":"W2808391935","doi":"10.1016/s2352-3026(18)30051-6","title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","year":2018,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Research England; U.S. Food and Drug Administration; Aalborg Universitetshospital; Astellas Pharma; Eisai; Aalborg Universitet; Genentech; Celgene; Gilead Sciences; National Institutes of Health; Laura and John Arnold Foundation; Pfizer","keywords":"Medicine; Adverse effect; Intensive care medicine; Context (archaeology); Clinical trial; Multiple myeloma; Cancer; Population; Hematology; Disease; Transplantation; Internal medicine; Oncology","score_opus":0.16852219324577863,"score_gpt":0.42282099634139564,"score_spread":0.25429880309561703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808391935","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013587758,0.99722195,0.00042014944,0.0015116237,0.00029194984,0.000020106188,0.000060217044,0.000007653044,0.00033050936],"genre_scores_gemma":[0.004447514,0.99057674,0.0015978392,0.0022923234,0.0007639559,0.000046978377,0.00009973484,0.000005266974,0.00016966325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9849076,0.007931357,0.0031258366,0.0006938554,0.0031054064,0.00023598956],"domain_scores_gemma":[0.945775,0.042650957,0.0072654136,0.00094039156,0.0030088222,0.0003593637],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01987571,0.000908962,0.0045518056,0.0028086249,0.0002730315,0.00347893,0.0027620057,0.0024470412,0.0036026733],"category_scores_gemma":[0.048259184,0.0004938756,0.00350878,0.0028532422,0.001501489,0.00407054,0.0020566904,0.0047743632,0.0006541238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017955179,0.000033747623,0.00071396015,0.0677226,0.0010802341,0.000053260173,0.00017471217,0.00040321363,0.00018547765,0.004802881,0.012992376,0.91165805],"study_design_scores_gemma":[0.00046262072,0.0006129494,0.010927011,0.22107837,0.005576281,0.0014505476,0.00061205897,0.0008214859,0.0006055773,0.03052927,0.7270842,0.00023948887],"about_ca_topic_score_codex":0.0024875812,"about_ca_topic_score_gemma":0.0048576114,"teacher_disagreement_score":0.9801243,"about_ca_system_score_codex":0.0013572352,"about_ca_system_score_gemma":0.004120897,"threshold_uncertainty_score":0.10511404},"labels":[],"label_agreement":null},{"id":"W2811238399","doi":"10.1016/s2352-3026(18)30093-0","title":"Rituximab as a first step in tackling transformation","year":2018,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; European Hematology Association","keywords":"Follicular lymphoma; Medicine; Lymphoma; Population; Rituximab; Biopsy; Internal medicine","score_opus":0.029958309741099653,"score_gpt":0.29690645844765395,"score_spread":0.2669481487065543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811238399","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008426951,0.02027823,0.0006730993,0.9404447,0.030202137,0.000022199856,0.000048628706,0.000096336276,0.0073920465],"genre_scores_gemma":[0.024407128,0.012158644,0.0014155386,0.819371,0.12973937,0.00007413448,0.00007542849,0.000063882566,0.012694792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99811566,0.00065256347,0.00023416345,0.00019479558,0.00047086863,0.00033203856],"domain_scores_gemma":[0.9953974,0.0030594543,0.0002901326,0.00021883259,0.00042686035,0.00060739723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022724497,0.0008439296,0.0014947718,0.0007555237,0.0016235558,0.004014125,0.0011029299,0.02836799,0.00751191],"category_scores_gemma":[0.01514112,0.00039855507,0.0011345845,0.00031108645,0.0027438528,0.004496499,0.0020932716,0.032431558,0.0053959386],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019494149,0.00009584806,0.00062345114,0.0003334615,0.00007195096,0.0070481934,0.00015924747,0.0002632266,0.0007380518,0.02021032,0.903612,0.06664932],"study_design_scores_gemma":[0.00046629863,0.00019445097,0.00044481544,0.0006140613,0.000073149524,0.008611903,0.00018182075,0.0006172954,0.0009006937,0.045703143,0.942133,0.000059250604],"about_ca_topic_score_codex":0.0008416641,"about_ca_topic_score_gemma":0.0015327535,"teacher_disagreement_score":0.02836799,"about_ca_system_score_codex":0.0025758296,"about_ca_system_score_gemma":0.0018070637,"threshold_uncertainty_score":0.025129855},"labels":[],"label_agreement":null},{"id":"W2890868314","doi":"10.1016/s2352-3026(18)30137-6","title":"Splanchnic vein thrombosis: what are the long-term risks?","year":2018,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Thrombosis; Population; Portal vein thrombosis; Internal medicine; Splanchnic; Incidence (geometry); Surgery; Radiology; Hemodynamics","score_opus":0.09497659565922568,"score_gpt":0.3454642917907541,"score_spread":0.25048769613152844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890868314","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039230715,0.013593844,0.00008136887,0.9770274,0.0077843233,0.000002269296,0.000030756986,0.000008815361,0.0010788488],"genre_scores_gemma":[0.015668448,0.026533762,0.00031282014,0.69610727,0.258905,0.000020594203,0.000067302375,0.000021206515,0.002363498],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.995981,0.0018384531,0.00045045966,0.00039580427,0.000927324,0.00040700648],"domain_scores_gemma":[0.9809702,0.012552411,0.0013218068,0.0004811698,0.002205631,0.0024687906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045398367,0.0006328712,0.002655333,0.00089369336,0.0018083086,0.004610765,0.0017016107,0.04157001,0.0068769124],"category_scores_gemma":[0.030972494,0.0005749829,0.0011517972,0.0009240642,0.0033269897,0.0072438377,0.001123474,0.043389503,0.0051977322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044840702,0.00013295152,0.0066480297,0.00056699227,0.00024080103,0.009405426,0.0003243863,0.00024076772,0.0005235752,0.013940349,0.888428,0.07910037],"study_design_scores_gemma":[0.0009414844,0.00035759129,0.008969434,0.0049854666,0.00034616835,0.024730422,0.0025357674,0.0013638947,0.00039750503,0.12679283,0.8282075,0.00037201488],"about_ca_topic_score_codex":0.0020566697,"about_ca_topic_score_gemma":0.0035251381,"teacher_disagreement_score":0.04157001,"about_ca_system_score_codex":0.0029334119,"about_ca_system_score_gemma":0.002632728,"threshold_uncertainty_score":0.024009228},"labels":[],"label_agreement":null},{"id":"W2911409482","doi":"10.1016/s2352-3026(18)30224-2","title":"Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Children's Hospital of Eastern Ontario; Hospital for Sick Children","funders":"","keywords":"Medicine; Pulmonary embolism; Retrospective cohort study; Internal medicine; Pediatrics","score_opus":0.014408017769814511,"score_gpt":0.2722228802423039,"score_spread":0.2578148624724894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911409482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868053,0.00026871412,0.00007467418,0.0000423874,0.0000091956645,0.000009681105,0.00073470245,0.000003628414,0.00017642934],"genre_scores_gemma":[0.99885046,0.00022217448,0.00007874099,0.00003055049,0.000011822852,0.000015172781,0.0006661009,0.0000054645975,0.00011949201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987197,0.00020715766,0.00016234239,0.00039909082,0.00015775589,0.0003539313],"domain_scores_gemma":[0.99703455,0.00040511964,0.0014065407,0.00039261536,0.00024248289,0.00051870325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086626865,0.00076245115,0.00108256,0.0013595044,0.0009412859,0.001468735,0.0010090354,0.0011666074,0.0018199389],"category_scores_gemma":[0.0029156583,0.0011966423,0.001761536,0.0027726528,0.0009975515,0.0014973747,0.0013565782,0.00195882,0.0004916869],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001062434,0.000030442496,0.9989998,0.000009791209,0.000113210655,0.00019748375,0.00011188872,0.000022935435,0.00010288443,0.000021126554,0.00007730566,0.00020685878],"study_design_scores_gemma":[0.00001264999,0.00014065467,0.9979297,0.000011554737,0.00007919677,0.000917486,0.00060922094,0.000067685505,0.000039643364,0.000021236936,0.00016037215,0.000010638592],"about_ca_topic_score_codex":0.013608848,"about_ca_topic_score_gemma":0.010214969,"teacher_disagreement_score":0.013608848,"about_ca_system_score_codex":0.0010747879,"about_ca_system_score_gemma":0.0010902907,"threshold_uncertainty_score":0.027059257},"labels":[],"label_agreement":null},{"id":"W2914073197","doi":"10.1016/s2352-3026(19)30010-9","title":"Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Eltrombopag; Thrombopoietin; Medicine; Thrombopoietin receptor; Myeloid; Lenalidomide; Myelodysplastic syndromes; Internal medicine; Cancer research; Pharmacology; Haematopoiesis; Bone marrow; Immunology; Platelet; Stem cell; Biology; Cell biology; Multiple myeloma","score_opus":0.0568963901246791,"score_gpt":0.32652688668588453,"score_spread":0.2696304965612054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914073197","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070124185,0.162564,0.0011225669,0.7838736,0.028840333,0.000041746778,0.00068529585,0.00015546486,0.015704509],"genre_scores_gemma":[0.16116564,0.26418474,0.0051061045,0.4580065,0.098016046,0.00018902596,0.0009218046,0.00044516928,0.011965019],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9969709,0.0017020411,0.00034317165,0.00031093907,0.00039399645,0.00027902718],"domain_scores_gemma":[0.98888576,0.0071494044,0.0011592847,0.00040099304,0.0013856072,0.0010190086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007059248,0.0005293435,0.0017807523,0.0009172798,0.0010090133,0.0044898638,0.0013454618,0.0056204656,0.018544352],"category_scores_gemma":[0.024691774,0.0005229394,0.0012093841,0.0014000861,0.0024337233,0.0072333664,0.0019666464,0.008202157,0.0049644397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026330992,0.0002030671,0.009140713,0.0021067555,0.00052617124,0.00039330462,0.0005604665,0.00027715604,0.000474401,0.015373917,0.5293389,0.43897203],"study_design_scores_gemma":[0.0034944632,0.0015404073,0.02887923,0.018015023,0.0024830727,0.0012662354,0.0050567267,0.0012500065,0.00068079313,0.07738665,0.85963666,0.00031069177],"about_ca_topic_score_codex":0.0037142532,"about_ca_topic_score_gemma":0.005743182,"teacher_disagreement_score":0.018544352,"about_ca_system_score_codex":0.00083565386,"about_ca_system_score_gemma":0.0020960106,"threshold_uncertainty_score":0.06203699},"labels":[],"label_agreement":null},{"id":"W2934686121","doi":"10.1016/s2352-3026(19)30026-2","title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; BC Cancer Agency","funders":"Celgene; MorphoSys; Servier; Innovative Research Group Project of the National Natural Science Foundation of China; F. Hoffmann-La Roche; Genentech; AstraZeneca; Gilead Sciences; TG Therapeutics; Pfizer; Takeda Oncology; Amgen","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Rituximab; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Hodgkin lymphoma; Clinical trial","score_opus":0.029094146801748787,"score_gpt":0.30191791391980216,"score_spread":0.2728237671180534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2934686121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825926,0.008908659,0.00063341885,0.0010791743,0.00053074973,0.0014784845,0.001509205,0.000114766306,0.0031529674],"genre_scores_gemma":[0.9857405,0.0039162207,0.0013790876,0.0014296109,0.00048712597,0.0015700964,0.002003398,0.000043462278,0.00343059],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991984,0.00045114662,0.000036418307,0.00011740758,0.000043874523,0.00015278191],"domain_scores_gemma":[0.99936706,0.00021325824,0.000111499336,0.000052810494,0.00002449591,0.0002307814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016276311,0.0013399484,0.0025114717,0.00037121587,0.00027532925,0.0012997066,0.0010233066,0.0012977837,0.0056031537],"category_scores_gemma":[0.0013267335,0.0006023165,0.0021104529,0.00039778682,0.0010793081,0.0013041749,0.0005638548,0.0027769632,0.0008771335],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9562484,0.0034899039,0.0010059793,0.0008180087,0.0020608536,0.00007503438,0.00008934574,0.0006251193,0.004495409,0.00017986377,0.0012327057,0.029679362],"study_design_scores_gemma":[0.93874514,0.055000752,0.0034370166,0.000040230203,0.00082869874,0.00006150407,0.000029160054,0.0002032791,0.0003437846,0.00015207792,0.0011409984,0.000017313147],"about_ca_topic_score_codex":0.001019013,"about_ca_topic_score_gemma":0.0026942203,"teacher_disagreement_score":0.0056031537,"about_ca_system_score_codex":0.00091751234,"about_ca_system_score_gemma":0.0008939902,"threshold_uncertainty_score":0.018744469},"labels":[],"label_agreement":null},{"id":"W2943259648","doi":"10.1016/s2352-3026(19)30029-8","title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Agios Pharmaceuticals; European Hematology Association; Stand Up To Cancer; Entertainment Industry Foundation; Celgene; Astex Pharmaceuticals; Van Andel Research Institute; Pfizer; Amgen","keywords":"Decitabine; Medicine; Myelodysplastic syndromes; Hypomethylating agent; International Prognostic Scoring System; Azacitidine; Internal medicine; Clinical endpoint; Phases of clinical research; Clinical trial; Chronic myelomonocytic leukemia; Oncology; Bone marrow","score_opus":0.044043358952204334,"score_gpt":0.35056373520004225,"score_spread":0.3065203762478379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943259648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841456,0.008693282,0.00051366596,0.0011730179,0.00045551622,0.0012296509,0.0015010755,0.00017202226,0.0021161584],"genre_scores_gemma":[0.9820957,0.0058031324,0.0017355835,0.0018994577,0.00023600804,0.0014693487,0.0029421158,0.000040647665,0.0037778702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99967873,0.00015617922,0.000015000062,0.000054771805,0.000023969162,0.00007139422],"domain_scores_gemma":[0.9995876,0.00010497307,0.000081050865,0.000026356662,0.000022478462,0.00017756839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010335344,0.0015563027,0.0023485303,0.00026048056,0.00022274614,0.0008708427,0.00063057477,0.001290566,0.0043329173],"category_scores_gemma":[0.0009905192,0.00042237944,0.0011984006,0.00034329624,0.0008771757,0.00083235267,0.00037216375,0.003010402,0.00089046045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9338112,0.0042989915,0.0012754947,0.0012651656,0.0013397936,0.000118486554,0.00009577798,0.00064584054,0.008145758,0.00022967858,0.003456266,0.04531749],"study_design_scores_gemma":[0.94985807,0.04478189,0.0025696757,0.000043744385,0.00034160676,0.00010763227,0.000029729066,0.00033519664,0.0005191531,0.00019020298,0.0012050456,0.000017969242],"about_ca_topic_score_codex":0.0010737128,"about_ca_topic_score_gemma":0.0032808539,"teacher_disagreement_score":0.0043329173,"about_ca_system_score_codex":0.0007500473,"about_ca_system_score_gemma":0.00082262146,"threshold_uncertainty_score":0.014495075},"labels":[],"label_agreement":null},{"id":"W2944123298","doi":"10.1016/s2352-3026(19)30080-8","title":"Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.06047060005823637,"score_gpt":0.30675337853288115,"score_spread":0.24628277847464478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944123298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9592325,0.0010231333,0.017062504,0.00049268466,0.0003388921,0.0030237779,0.0070068026,0.00011318958,0.011706478],"genre_scores_gemma":[0.969663,0.00028616816,0.012398665,0.00027318753,0.00007012531,0.0029562854,0.013281012,0.00009515936,0.00097645144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96411127,0.01791784,0.006916476,0.003926523,0.0054459344,0.0016820057],"domain_scores_gemma":[0.8953042,0.03126504,0.017534046,0.018278038,0.035624593,0.0019941835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.057545006,0.00073672266,0.0011517489,0.0041830703,0.002017292,0.0033439335,0.0032224124,0.0014073725,0.0024569938],"category_scores_gemma":[0.09150715,0.00073357567,0.0019056303,0.0022893636,0.0016634713,0.0024861854,0.00422202,0.0016779589,0.0008786919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007612788,0.00030152622,0.97511286,0.00026381676,0.00044467614,0.00017203647,0.0035742985,0.00056846964,0.0006434041,0.0014666339,0.005560602,0.011130477],"study_design_scores_gemma":[0.00034832297,0.00047786967,0.9754564,0.0006005443,0.0007701489,0.00096812507,0.0026694525,0.005044309,0.0012221034,0.0009184233,0.011451691,0.000072621566],"about_ca_topic_score_codex":0.0072857314,"about_ca_topic_score_gemma":0.009030972,"teacher_disagreement_score":0.057545006,"about_ca_system_score_codex":0.002107615,"about_ca_system_score_gemma":0.0035174433,"threshold_uncertainty_score":0.3043307},"labels":[],"label_agreement":null},{"id":"W2944405756","doi":"10.1016/s2352-3026(19)30081-x","title":"Building consensus: steps toward standardised haemovigilance reporting","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood transfusion and management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"","keywords":"Medicine; Medical emergency; Intensive care medicine; Incidence (geometry)","score_opus":0.08805528011199608,"score_gpt":0.3442539045282208,"score_spread":0.2561986244162247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944405756","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006072139,0.00026439282,0.0004756734,0.99466115,0.0040507386,0.000011034485,0.000010980067,0.000016976539,0.00044829887],"genre_scores_gemma":[0.003400762,0.00050652726,0.0035913023,0.97602606,0.014764927,0.00011100885,0.00004647147,0.0000401799,0.0015127505],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8778687,0.06475191,0.016308842,0.0069408375,0.022998057,0.011131631],"domain_scores_gemma":[0.6528595,0.19379328,0.015772576,0.010730905,0.06452266,0.06232112],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.08916385,0.0010780657,0.0027180742,0.0030906147,0.010504044,0.018953787,0.007277669,0.13311431,0.0126921255],"category_scores_gemma":[0.2894987,0.0022418534,0.0032355909,0.001974897,0.015345911,0.022178799,0.018076187,0.12949713,0.00936376],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000314936,0.00006881795,0.00052490743,0.00019549053,0.000035737063,0.0007835058,0.00097492966,0.00014245302,0.00020370609,0.012161915,0.96789986,0.016977161],"study_design_scores_gemma":[0.00023197298,0.00009884412,0.0019307713,0.0023208375,0.000063221756,0.0010991115,0.0036742105,0.0016336304,0.00028366415,0.16596852,0.8223982,0.0002969856],"about_ca_topic_score_codex":0.011195162,"about_ca_topic_score_gemma":0.012611612,"teacher_disagreement_score":0.91083616,"about_ca_system_score_codex":0.0128601035,"about_ca_system_score_gemma":0.060317032,"threshold_uncertainty_score":0.47154915},"labels":[],"label_agreement":null},{"id":"W2951038309","doi":"10.1016/s2352-3026(19)30112-7","title":"The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Life expectancy; Imatinib; Myeloid leukemia; Population; Chronic myeloid leukaemia; Myeloid; Oncology; Internal medicine; Immunology","score_opus":0.04028012513636689,"score_gpt":0.30244136964268353,"score_spread":0.2621612445063166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951038309","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028489257,0.0054622483,0.000053374457,0.9806512,0.010479334,0.0000034118284,0.000046579917,0.000009019076,0.0030099652],"genre_scores_gemma":[0.0070159677,0.0050210315,0.00015969622,0.9243198,0.057805043,0.000020878679,0.000038431994,0.000020151361,0.005598898],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99484813,0.0019916876,0.00047094366,0.00039674345,0.0017327727,0.0005597218],"domain_scores_gemma":[0.9830331,0.012198725,0.0010855596,0.00034197766,0.0015198383,0.0018207361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051905275,0.000520961,0.0014597407,0.00077555794,0.001909854,0.004852234,0.0011572356,0.03780498,0.006500724],"category_scores_gemma":[0.029439434,0.0004971211,0.0010617186,0.0007250617,0.0038332974,0.0045089666,0.0016293639,0.031172482,0.005033149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023766648,0.000036294678,0.00047603864,0.00015535482,0.000028738355,0.0012558566,0.00012315366,0.00013802109,0.00032910987,0.009467515,0.95323664,0.034515616],"study_design_scores_gemma":[0.00034374814,0.00013378527,0.0009603509,0.00051914586,0.00004148401,0.001338764,0.00016587165,0.00045424158,0.00023857923,0.020580793,0.9751726,0.000050680614],"about_ca_topic_score_codex":0.004318502,"about_ca_topic_score_gemma":0.008828346,"teacher_disagreement_score":0.03780498,"about_ca_system_score_codex":0.006557027,"about_ca_system_score_gemma":0.0043909373,"threshold_uncertainty_score":0.047574818},"labels":[],"label_agreement":null},{"id":"W2956888684","doi":"10.1016/s2352-3026(19)30109-7","title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":242,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Merck Sharp and Dohme","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Clinical endpoint; Internal medicine; Interim analysis; Pembrolizumab; Adverse effect; Clinical trial; Oncology; Surgery; Cancer; Immunotherapy","score_opus":0.07617864432414798,"score_gpt":0.37293546761854046,"score_spread":0.29675682329439246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956888684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724576,0.011198143,0.0010428464,0.0018742542,0.0013971311,0.004800695,0.0024711355,0.0002462283,0.00451201],"genre_scores_gemma":[0.97943944,0.0049482714,0.0018075539,0.0026819136,0.00055496633,0.0039488175,0.0017909646,0.000038395097,0.0047896393],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994295,0.00026359444,0.000031242533,0.00011594434,0.00004042575,0.00011929328],"domain_scores_gemma":[0.99939716,0.00016862211,0.00012604918,0.0000457142,0.000027984162,0.00023449473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018113875,0.0019331503,0.0027773373,0.00044760274,0.0005469251,0.0016733325,0.0011374836,0.0018298511,0.010658794],"category_scores_gemma":[0.0015576674,0.00084345724,0.0026981528,0.00048036608,0.0013211677,0.0019090471,0.00063735887,0.0044491,0.0016708203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9785138,0.003699188,0.00028410953,0.0008297282,0.0010670301,0.000041135263,0.00006197347,0.00033171405,0.0013888112,0.00017239396,0.0012525194,0.012357616],"study_design_scores_gemma":[0.97641003,0.021705499,0.0006805485,0.000034369612,0.00027111088,0.000023822986,0.000020441148,0.00014259481,0.00009190471,0.00014276925,0.0004657298,0.000011095232],"about_ca_topic_score_codex":0.00170332,"about_ca_topic_score_gemma":0.0038996688,"teacher_disagreement_score":0.010658794,"about_ca_system_score_codex":0.0012061329,"about_ca_system_score_gemma":0.0013012022,"threshold_uncertainty_score":0.035657227},"labels":[],"label_agreement":null},{"id":"W2966090323","doi":"10.1016/s2352-3026(19)30162-0","title":"Ironing out frequent blood donation","year":2019,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of British Columbia","funders":"","keywords":"Medicine; Blood donor; Donation; Intensive care medicine; Family medicine; Internal medicine; Immunology; Law","score_opus":0.047024923479655006,"score_gpt":0.2652828661624125,"score_spread":0.21825794268275747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966090323","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022208419,0.09296244,0.006303977,0.78965193,0.026466448,0.00016896795,0.00047595124,0.00043105552,0.06133083],"genre_scores_gemma":[0.2815301,0.13580553,0.012096762,0.511235,0.034968447,0.00048826335,0.00088472915,0.000680408,0.022310678],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98104364,0.010564108,0.0015824272,0.0009602534,0.0046807253,0.0011688947],"domain_scores_gemma":[0.93779916,0.03336164,0.008514158,0.0038028138,0.009920054,0.0066021713],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019368928,0.00045760025,0.000927563,0.0013113992,0.0027096265,0.004772878,0.0020009114,0.0042963866,0.024277514],"category_scores_gemma":[0.12086352,0.00038311005,0.00097246194,0.00092557224,0.0032608528,0.0052145007,0.004666748,0.0074044857,0.0059597213],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022837611,0.000111401976,0.014421714,0.0022668662,0.00016274782,0.0005649577,0.0036616586,0.00012047413,0.00021484814,0.016092358,0.57726675,0.38488778],"study_design_scores_gemma":[0.00014348402,0.0002691932,0.016750716,0.020752788,0.00018001013,0.0031801993,0.006701871,0.00032427793,0.00052477565,0.043980394,0.9070889,0.000103406026],"about_ca_topic_score_codex":0.0057795644,"about_ca_topic_score_gemma":0.009562817,"teacher_disagreement_score":0.024277514,"about_ca_system_score_codex":0.0023900273,"about_ca_system_score_gemma":0.0058836485,"threshold_uncertainty_score":0.10243392},"labels":[],"label_agreement":null},{"id":"W2968662162","doi":"10.1016/s2352-3026(19)30161-9","title":"Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Janssen Research and Development","keywords":"Medicine; Rivaroxaban; Fondaparinux; Vitamin K antagonist; Regimen; Dosing; Pediatrics; Venous thrombosis; Surgery; Venous thromboembolism; Internal medicine; Warfarin; Thrombosis","score_opus":0.08055790085093029,"score_gpt":0.32520847477519044,"score_spread":0.24465057392426015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968662162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779573,0.017658025,0.0005914689,0.0006207124,0.00014644867,0.00072537985,0.0015706796,0.00007201581,0.0006579869],"genre_scores_gemma":[0.97712713,0.012558422,0.0033666638,0.0012526999,0.0002566231,0.0012138654,0.0034700604,0.00007544072,0.0006790721],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99795544,0.0009706765,0.0002030111,0.0003247659,0.0002943856,0.00025176266],"domain_scores_gemma":[0.9971487,0.00073069497,0.0012347648,0.0002995395,0.00017642468,0.00040987984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045360667,0.0017666195,0.0037257862,0.0004613672,0.00032589378,0.0013949136,0.0008143208,0.0014395474,0.0013242288],"category_scores_gemma":[0.004430409,0.00056590314,0.0048277327,0.0008567798,0.0010806477,0.0009279374,0.0006802181,0.0022476236,0.0002582853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8327505,0.0061141234,0.030685043,0.0041990248,0.03681501,0.00025887715,0.00037350226,0.0012426126,0.012436127,0.00026239024,0.0026251539,0.0722376],"study_design_scores_gemma":[0.7853846,0.08172817,0.109207906,0.00028949484,0.018047713,0.00049812335,0.0001231978,0.00025558114,0.0013269583,0.00016573601,0.0028652463,0.00010730531],"about_ca_topic_score_codex":0.0016005741,"about_ca_topic_score_gemma":0.0040579746,"teacher_disagreement_score":0.0045360667,"about_ca_system_score_codex":0.00096451817,"about_ca_system_score_gemma":0.0015855989,"threshold_uncertainty_score":0.02398926},"labels":[],"label_agreement":null},{"id":"W2987943866","doi":"10.1016/s2352-3026(19)30219-4","title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta; McMaster Children's Hospital","funders":"Actelion Pharmaceuticals; Eli Lilly and Company; CSL Behring; AbbVie; Bristol-Myers Squibb Canada; Boehringer Ingelheim; Alnylam Pharmaceuticals; Bayer; Alexion Pharmaceuticals; Novartis; Pfizer; LEO Pharma Research Foundation","keywords":"Medicine; Rivaroxaban; Vitamin K antagonist; Venous thromboembolism; Randomized controlled trial; Venous thrombosis; Pulmonary embolism; Intention-to-treat analysis; Adverse effect; Surgery; Pediatrics; Internal medicine; Warfarin; Thrombosis","score_opus":0.03540028368779407,"score_gpt":0.33296245962491405,"score_spread":0.29756217593712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987943866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9590483,0.027057968,0.0012091894,0.0017622486,0.0013391236,0.0040778946,0.0028074977,0.00020708723,0.002490792],"genre_scores_gemma":[0.96572113,0.014928336,0.0038743746,0.0019075896,0.0009990161,0.0077166255,0.001786906,0.000077525,0.0029884276],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988274,0.0005938669,0.000099787314,0.00021264586,0.00010562211,0.00016067599],"domain_scores_gemma":[0.99815434,0.0007207177,0.00055957504,0.00013706295,0.00008681273,0.00034138482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021220269,0.0021242606,0.005339552,0.00046792935,0.0004956087,0.001426459,0.0011523552,0.002297069,0.007626943],"category_scores_gemma":[0.0038895279,0.00081626227,0.004516142,0.00066304865,0.0016838947,0.0012196881,0.00060489436,0.0044647437,0.00088397955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9825891,0.0014394808,0.0006467778,0.0018468683,0.0038610592,0.0001132654,0.00008220022,0.00024815288,0.0011932668,0.00021117963,0.0010547332,0.0067138704],"study_design_scores_gemma":[0.98575425,0.011107162,0.001397492,0.00007613896,0.0008075678,0.00007426895,0.000022327247,0.000110744244,0.000093170755,0.00009316267,0.0004507603,0.000013046403],"about_ca_topic_score_codex":0.0024026646,"about_ca_topic_score_gemma":0.0036407853,"teacher_disagreement_score":0.007626943,"about_ca_system_score_codex":0.0012110941,"about_ca_system_score_gemma":0.0016103504,"threshold_uncertainty_score":0.025514662},"labels":[],"label_agreement":null},{"id":"W2989004737","doi":"10.1016/s2352-3026(19)30202-9","title":"Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Institute for Research in Immunology and Cancer; Université de Montréal; Université Laval; Hôpital de l'Enfant-Jésus; Discovery Centre; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Medicine; Cord blood; Transplantation; Stem cell; Hematopoietic stem cell transplantation; Haematopoiesis; Graft-versus-host disease; Surgery; Internal medicine","score_opus":0.07846348006498947,"score_gpt":0.3328566361871404,"score_spread":0.2543931561221509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989004737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883344,0.0029286589,0.0032159658,0.00047580953,0.00019043755,0.0023824275,0.00069165573,0.0001530873,0.0016276287],"genre_scores_gemma":[0.9867079,0.0024770948,0.003921392,0.0010640916,0.00024539148,0.0024560045,0.0012337487,0.000060762573,0.0018336719],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991602,0.00045193528,0.000034980414,0.00012331626,0.000100044046,0.00012954973],"domain_scores_gemma":[0.9991273,0.00022092422,0.00022058464,0.00014879201,0.000056938483,0.00022544467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029809321,0.0016470451,0.0018717927,0.00033561655,0.00039464445,0.00096884085,0.0007478013,0.0013374265,0.0034911693],"category_scores_gemma":[0.0013458739,0.0004668641,0.0016571624,0.000406975,0.0011269351,0.00086670334,0.00032915457,0.0024929899,0.0007931855],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6164082,0.06755126,0.005484223,0.00134352,0.0026713735,0.00046153387,0.00037017267,0.003299252,0.09724402,0.0008698441,0.006685517,0.19761117],"study_design_scores_gemma":[0.20999846,0.75884396,0.008294157,0.00009704742,0.0010422969,0.00055674906,0.00009693633,0.0015269545,0.0141568575,0.0006573399,0.0046754936,0.000053699965],"about_ca_topic_score_codex":0.0005353359,"about_ca_topic_score_gemma":0.0010370654,"teacher_disagreement_score":0.0034911693,"about_ca_system_score_codex":0.0009087776,"about_ca_system_score_gemma":0.0018272357,"threshold_uncertainty_score":0.015764892},"labels":[],"label_agreement":null},{"id":"W2997806446","doi":"10.1016/s2352-3026(19)30206-6","title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Myelodysplastic syndromes; Retrospective cohort study; Myeloid leukaemia; Cohort; Myeloid leukemia; Myeloid; Cohort study; Internal medicine; Pediatrics; Bone marrow","score_opus":0.007303935844791967,"score_gpt":0.2659708146748395,"score_spread":0.2586668788300476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997806446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99914324,0.00022048617,0.000039350667,0.000021944828,0.0000064915694,0.0000089297055,0.00036629307,0.0000019826416,0.00019121489],"genre_scores_gemma":[0.9990734,0.000117639676,0.000040778046,0.000026440255,0.000013832943,0.000011859734,0.0005917371,0.000002528382,0.00012168249],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991666,0.0001733765,0.000083498366,0.00030685053,0.00010336496,0.0001662988],"domain_scores_gemma":[0.998577,0.00018360981,0.0005444772,0.00017326907,0.00012384991,0.00039783595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006847754,0.0006612848,0.0009786582,0.0009191433,0.00078794634,0.0012751743,0.0008066722,0.0012024197,0.0020365044],"category_scores_gemma":[0.0020825942,0.00080537226,0.0010975939,0.0017081943,0.0007395071,0.0014224795,0.001065927,0.0011157565,0.0004786815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065119495,0.00007302301,0.9975925,0.000009923965,0.00015701981,0.0003600456,0.00010823641,0.000046072826,0.00039060615,0.000026931537,0.00009736126,0.0004869545],"study_design_scores_gemma":[0.000047691174,0.0002818739,0.9978276,0.0000064540836,0.000068745736,0.001102776,0.0003512872,0.000109412365,0.000035800338,0.000040727664,0.00011448562,0.000013156287],"about_ca_topic_score_codex":0.005295971,"about_ca_topic_score_gemma":0.0030471266,"teacher_disagreement_score":0.005295971,"about_ca_system_score_codex":0.00066388963,"about_ca_system_score_gemma":0.00042549826,"threshold_uncertainty_score":0.010530293},"labels":[],"label_agreement":null},{"id":"W2998927302","doi":"10.1016/s2352-3026(19)30218-2","title":"Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; Canadian Centre for Applied Research in Cancer Control; University of Toronto","funders":"","keywords":"ABVD; Medicine; Procarbazine; Dacarbazine; Hodgkin's lymphoma; Vinblastine; Brentuximab vedotin; Oncology; Internal medicine; Vinorelbine; Vincristine; Chemotherapy; Hodgkin lymphoma; Lymphoma; Cyclophosphamide","score_opus":0.1019888536688762,"score_gpt":0.3400904008033418,"score_spread":0.2381015471344656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998927302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776465,0.0038291006,0.0039907186,0.0022248942,0.00008658031,0.0002220607,0.005951148,0.00006369114,0.0059852498],"genre_scores_gemma":[0.99546945,0.00080000027,0.00080750557,0.00015243473,0.00002318922,0.00010654311,0.0012756159,0.000016249503,0.0013490276],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99863666,0.00085058645,0.000058089514,0.00012153341,0.000055916054,0.00027720543],"domain_scores_gemma":[0.9825853,0.014964671,0.0011589784,0.00034926514,0.0003312053,0.00061050226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026968457,0.0015428329,0.0020746388,0.0010819853,0.000469326,0.0022057646,0.002364497,0.002750493,0.011738338],"category_scores_gemma":[0.012665874,0.00096168136,0.0057623936,0.0014757927,0.00071198517,0.0017947459,0.00089785893,0.00270996,0.00074179994],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011929438,0.0018493263,0.021078048,0.00061935466,0.0028621303,0.0004126647,0.00012963188,0.9453597,0.0002670035,0.0041638114,0.0024943145,0.008834548],"study_design_scores_gemma":[0.0064671114,0.005869232,0.02868193,0.00036947284,0.003956015,0.00079754967,0.00065089454,0.9400969,0.00036128366,0.009681564,0.0029145817,0.00015347352],"about_ca_topic_score_codex":0.03887071,"about_ca_topic_score_gemma":0.021049216,"teacher_disagreement_score":0.03887071,"about_ca_system_score_codex":0.0050862175,"about_ca_system_score_gemma":0.0017811008,"threshold_uncertainty_score":0.077288926},"labels":[],"label_agreement":null},{"id":"W2999004039","doi":"10.1016/s2352-3026(19)30220-0","title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; BC Children's Hospital; Université Laval; Child and Family Research Institute; Hôtel-Dieu de Québec; CancerCare Manitoba; Capital District Health Authority; Royal Victoria Hospital; Centre hospitalier universitaire de Québec; Vancouver General Hospital; Princess Margaret Cancer Centre; University of British Columbia; Public Health Ontario; Dalhousie University; University of Toronto; McMaster University; Hôpital Maisonneuve-Rosemont; Juravinski Hospital","funders":"Canadian Institutes of Health Research; University of British Columbia; McMaster University; Sanofi","keywords":"Medicine; Anti-thymocyte globulin; Cumulative incidence; Internal medicine; Transplantation; Graft-versus-host disease; Hazard ratio; Surgery; Clinical endpoint; Tacrolimus; Randomized controlled trial; Gastroenterology; Confidence interval","score_opus":0.07633850075544721,"score_gpt":0.3329399635474426,"score_spread":0.25660146279199536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999004039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856156,0.008369062,0.0007808948,0.0008969985,0.0009037372,0.0011499382,0.00061078876,0.00010245261,0.0015704711],"genre_scores_gemma":[0.9919478,0.0023839073,0.001230955,0.00087326823,0.000414589,0.00087408646,0.00059309596,0.000021920549,0.0016604561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99896264,0.0006495629,0.00005158653,0.00015703315,0.00004848066,0.00013069843],"domain_scores_gemma":[0.99857354,0.00070452044,0.00021483802,0.000103600774,0.000063400585,0.00034004034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022085472,0.0017882524,0.0037787869,0.00043425077,0.00036313283,0.0015037984,0.0011339589,0.0018812545,0.005772373],"category_scores_gemma":[0.0023802107,0.0005402888,0.00345905,0.0004675488,0.0015289118,0.0014617933,0.0005084889,0.004225247,0.000852875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98840314,0.0012519382,0.00022615363,0.0003418451,0.0009387652,0.00001929246,0.000034953762,0.00023594206,0.0009595415,0.00006202787,0.00026733518,0.007259073],"study_design_scores_gemma":[0.953767,0.043466926,0.0012861444,0.00003822006,0.00053981773,0.000024732894,0.000019857696,0.00024396366,0.0001872835,0.000164765,0.00024661262,0.000014619683],"about_ca_topic_score_codex":0.0010308508,"about_ca_topic_score_gemma":0.0024238913,"teacher_disagreement_score":0.005772373,"about_ca_system_score_codex":0.0010676647,"about_ca_system_score_gemma":0.0009890245,"threshold_uncertainty_score":0.019310534},"labels":[],"label_agreement":null},{"id":"W3003963919","doi":"10.1016/s2352-3026(20)30001-6","title":"Idiopathic multicentric Castleman disease: bringing order to chaos","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Disease; Castleman disease; Scopus; Dermatology; Pathology; MEDLINE","score_opus":0.039026749861899204,"score_gpt":0.2993517674056224,"score_spread":0.2603250175437232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003963919","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046985853,0.19701752,0.0059719863,0.7034996,0.012583681,0.000042138192,0.00023549824,0.0001814843,0.03348222],"genre_scores_gemma":[0.6756063,0.13781457,0.006284356,0.104870036,0.068014376,0.00005821052,0.00021061664,0.0001345161,0.00700692],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"case_report","domain_scores_codex":[0.9980015,0.00062686554,0.00016133851,0.00027615498,0.00049500953,0.00043907118],"domain_scores_gemma":[0.99293375,0.003729308,0.0008607966,0.00053410186,0.0010017569,0.0009403358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032419115,0.0002955249,0.0011416803,0.001386219,0.0018673561,0.004360314,0.0010453067,0.0038357873,0.0019545876],"category_scores_gemma":[0.008818783,0.00032216794,0.00039732063,0.0009998493,0.0071268114,0.004985147,0.0024653266,0.006984961,0.00061395066],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042533988,0.00014604544,0.02354448,0.0017189612,0.00029089622,0.016130077,0.00733966,0.0023038606,0.0031551488,0.48680454,0.22852363,0.22961742],"study_design_scores_gemma":[0.0000983539,0.00010977121,0.009286752,0.0012494747,0.000070102586,0.012968785,0.005463267,0.0015058899,0.00033412033,0.6963006,0.2724863,0.00012659942],"about_ca_topic_score_codex":0.0023366362,"about_ca_topic_score_gemma":0.005024317,"teacher_disagreement_score":0.004360314,"about_ca_system_score_codex":0.0024560133,"about_ca_system_score_gemma":0.0030475566,"threshold_uncertainty_score":0.017819703},"labels":[],"label_agreement":null},{"id":"W3012570191","doi":"10.1016/s2352-3026(20)30070-3","title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Surgery; Clinical trial; Bortezomib","score_opus":0.08514856475611958,"score_gpt":0.35792034743549933,"score_spread":0.27277178267937974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012570191","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845813,0.006654491,0.0007059145,0.0015906004,0.0011549499,0.0020477218,0.0010254601,0.00017753789,0.002062117],"genre_scores_gemma":[0.9860366,0.0027726565,0.0014482709,0.0019001646,0.0004326287,0.002511414,0.0009806451,0.000041153104,0.0038763448],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992449,0.00040693764,0.000027852324,0.00013148483,0.000045526005,0.00014331097],"domain_scores_gemma":[0.99907136,0.00026973482,0.00021342462,0.00007410191,0.000045812452,0.00032544142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019317688,0.0021044863,0.0030649416,0.00041300122,0.00059686817,0.0019108515,0.001125052,0.0020325533,0.008603855],"category_scores_gemma":[0.0018983551,0.00082473713,0.0029168066,0.00057190575,0.0017578807,0.001361763,0.00078999996,0.004388568,0.00176243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9842098,0.0028344817,0.0003647095,0.0004881272,0.00093263685,0.000037217804,0.00006353201,0.00020269648,0.0016344249,0.00009268738,0.00070972386,0.008429947],"study_design_scores_gemma":[0.9826224,0.015634675,0.00080216536,0.000025815163,0.00024515387,0.000018493904,0.000019627794,0.00013660533,0.000081463404,0.0000941614,0.0003107067,0.000008757723],"about_ca_topic_score_codex":0.002306323,"about_ca_topic_score_gemma":0.004672965,"teacher_disagreement_score":0.008603855,"about_ca_system_score_codex":0.0012346432,"about_ca_system_score_gemma":0.0014104411,"threshold_uncertainty_score":0.028782725},"labels":[],"label_agreement":null},{"id":"W3021441913","doi":"10.1016/s2352-3026(20)30113-7","title":"Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis – Authors' reply","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of Toronto; Public Health Ontario; McMaster University; Juravinski Hospital","funders":"","keywords":"Anti-thymocyte globulin; Medicine; Rituximab; Graft-versus-host disease; Transplantation; Internal medicine; Surgery; Immunology; Lymphoma","score_opus":0.04254126665838657,"score_gpt":0.30224978313135936,"score_spread":0.2597085164729728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021441913","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000321707,0.00150357,0.000056053872,0.9656348,0.031180514,0.0000062811887,0.00005329182,0.000014160857,0.001229579],"genre_scores_gemma":[0.0032934197,0.00063434517,0.00009025407,0.9557218,0.03784318,0.000020273486,0.000027084976,0.000016253223,0.0023533262],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961428,0.0013430648,0.0005324353,0.0004886418,0.0009251293,0.00056782865],"domain_scores_gemma":[0.9893182,0.0071849944,0.00075056806,0.00027205376,0.0012291209,0.0012450548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036147179,0.0007630854,0.0018476687,0.000713213,0.0023606285,0.0037282014,0.0018526113,0.060734272,0.0051270896],"category_scores_gemma":[0.024705648,0.00081095163,0.0012723554,0.00068159093,0.0029751472,0.003043545,0.0016646975,0.046063446,0.0047249235],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014747656,0.000035521316,0.0006797217,0.0000733245,0.000046758596,0.0018873741,0.00014692137,0.00009147967,0.00018713715,0.0021433507,0.9890238,0.005537137],"study_design_scores_gemma":[0.0003419702,0.00013982302,0.0015468711,0.0003461267,0.00010518492,0.0022305534,0.0005173087,0.00047947856,0.000485611,0.010043825,0.98362976,0.00013344448],"about_ca_topic_score_codex":0.0033259385,"about_ca_topic_score_gemma":0.0048740944,"teacher_disagreement_score":0.060734272,"about_ca_system_score_codex":0.0032650663,"about_ca_system_score_gemma":0.0029579634,"threshold_uncertainty_score":0.023689866},"labels":[],"label_agreement":null},{"id":"W3032742617","doi":"10.1016/s2352-3026(20)30081-8","title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Sirius; Refractory (planetary science); Internal medicine; Oncology; Phases of clinical research; Clinical trial; Lenalidomide","score_opus":0.14371685728919703,"score_gpt":0.3637452154296498,"score_spread":0.2200283581404528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032742617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93186957,0.055544525,0.00030618964,0.0034198472,0.0005271755,0.0003147401,0.0021676377,0.00011170015,0.0057385736],"genre_scores_gemma":[0.9648824,0.021588277,0.0011871565,0.003935049,0.00043822365,0.00029954905,0.004479412,0.00004639987,0.0031436319],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996232,0.00018237322,0.000019805797,0.000049394777,0.0000406427,0.00008466039],"domain_scores_gemma":[0.99950373,0.00014048182,0.0001321193,0.000029576619,0.000038627233,0.0001554393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017783137,0.0007437146,0.0014882279,0.0002042123,0.00027171723,0.0012084973,0.00042333174,0.00065544643,0.0016811242],"category_scores_gemma":[0.0009600386,0.00026017576,0.0014593765,0.0003683118,0.0004281707,0.00078460877,0.00035654005,0.0022173517,0.00053635304],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52176386,0.0037329535,0.019940766,0.0032319564,0.009549636,0.00028359052,0.00041611353,0.0033314424,0.013943505,0.00085110514,0.028238205,0.3947169],"study_design_scores_gemma":[0.69228464,0.11735028,0.12136273,0.0008873258,0.010894546,0.00093911035,0.00032371617,0.0022069504,0.0035716966,0.001840954,0.048186466,0.00015163078],"about_ca_topic_score_codex":0.000922109,"about_ca_topic_score_gemma":0.0054515237,"teacher_disagreement_score":0.0017783137,"about_ca_system_score_codex":0.0007669627,"about_ca_system_score_gemma":0.00085560506,"threshold_uncertainty_score":0.0094047785},"labels":[],"label_agreement":null},{"id":"W3036451283","doi":"10.1016/s2352-3026(20)30205-2","title":"Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; National Institutes of Health; Sierra Oncology; National Institute for Health and Care Research; Omeros Corporation; Argenx; Pfizer; Incyte; CTI Biopharma; Astellas Pharma; Eisai; Celltrion; Agios Pharmaceuticals; MEI Pharma; Syndax Pharmaceuticals; Acceleron; Astex Pharmaceuticals; Celgene; PTC Therapeutics; Arog Pharmaceuticals; National Center for Advancing Translational Sciences; Medical Research Council; Teva Pharmaceutical Industries; Helsinn; Jazz Pharmaceuticals; Array BioPharma; University of Toronto; Apellis Pharmaceuticals; Alexion Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; TG Therapeutics; MacroGenics; Celldex Therapeutics; Cardinal Health; Amgen","keywords":"Medicine; Coronavirus disease 2019 (COVID-19); Intensive care medicine; 2019-20 coronavirus outbreak; Myeloid leukemia; Oncology; Internal medicine; Virology; Disease; Outbreak","score_opus":0.15019995941805153,"score_gpt":0.4148418345378975,"score_spread":0.264641875119846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036451283","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008938776,0.962265,0.00028669406,0.032671172,0.0035562862,0.00006100542,0.000098600256,0.000018174258,0.0009536689],"genre_scores_gemma":[0.0012860256,0.9648819,0.002564215,0.027224863,0.0030659798,0.00013795718,0.0001770181,0.000010264996,0.0006518013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953517,0.0017625099,0.0013010126,0.00028916574,0.0010073462,0.00028823485],"domain_scores_gemma":[0.98696727,0.0066920775,0.0019102992,0.00016820479,0.0035189516,0.0007431827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011923834,0.0012433454,0.004206764,0.002362399,0.0006476207,0.0032850886,0.0027899686,0.0060623265,0.004235262],"category_scores_gemma":[0.020682083,0.0006505954,0.003942277,0.00200547,0.0011432127,0.0037852381,0.0025607124,0.010096966,0.0016460998],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035834234,0.00010811445,0.000592596,0.051888417,0.0007058908,0.00025532037,0.00026409625,0.0005496178,0.00045361102,0.005179175,0.26171637,0.67792845],"study_design_scores_gemma":[0.00036062213,0.0001413293,0.0015870521,0.116724074,0.0011534175,0.00043376832,0.00033930404,0.00019931709,0.00016798772,0.00422432,0.8745979,0.000070956485],"about_ca_topic_score_codex":0.008954696,"about_ca_topic_score_gemma":0.023574382,"teacher_disagreement_score":0.011923834,"about_ca_system_score_codex":0.0034170533,"about_ca_system_score_gemma":0.0140462415,"threshold_uncertainty_score":0.063060045},"labels":[],"label_agreement":null},{"id":"W3037937011","doi":"10.1016/s2352-3026(20)30179-4","title":"Hyper-CVAD: a regimen for all seasons","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Oncology; Transplantation; Regimen; Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Chemotherapy regimen; Internal medicine; Leukemia; Chemotherapy; Pediatrics; Immunology; Lymphoblastic Leukemia","score_opus":0.07289611587682732,"score_gpt":0.3215748360427885,"score_spread":0.2486787201659612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037937011","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004587087,0.0023605837,0.00011639879,0.95742124,0.03240702,0.000020519172,0.000051965988,0.00003834185,0.0071252943],"genre_scores_gemma":[0.0028839945,0.00089519634,0.00020456247,0.94413686,0.037798747,0.000039552153,0.000035998084,0.00002328975,0.013981775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982712,0.00052892964,0.00021382267,0.00016417948,0.000423404,0.00039836284],"domain_scores_gemma":[0.9955348,0.0016091235,0.00026913598,0.00018014292,0.0004157891,0.0019909297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019303793,0.00068979594,0.00096697075,0.00062681426,0.0044797086,0.0035200382,0.001433217,0.051316846,0.01950468],"category_scores_gemma":[0.013000394,0.0005472737,0.0013674494,0.0005205468,0.002276844,0.0032549084,0.0026428855,0.04169795,0.010144724],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012798476,0.000066267436,0.0004655996,0.000047296686,0.000019147808,0.0015677719,0.000061618484,0.00006275188,0.00021497736,0.0039911913,0.98001224,0.013363145],"study_design_scores_gemma":[0.0003531263,0.00010370326,0.0011934795,0.00031347765,0.000029178493,0.001877708,0.00014623415,0.0002076558,0.00012985613,0.008906057,0.9867006,0.000038957805],"about_ca_topic_score_codex":0.0060614822,"about_ca_topic_score_gemma":0.014038043,"teacher_disagreement_score":0.051316846,"about_ca_system_score_codex":0.003307727,"about_ca_system_score_gemma":0.0039924392,"threshold_uncertainty_score":0.06524962},"labels":[],"label_agreement":null},{"id":"W3039544106","doi":"10.1016/s2352-3026(20)30186-1","title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":332,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; University of Toronto; Canadian Blood Services; Héma-Québec","funders":"NHS Blood and Transplant","keywords":"Pandemic; Contingency plan; Economic shortage; Transfusion medicine; Blood transfusion; Coronavirus disease 2019 (COVID-19); Medicine; Business; Intensive care medicine; Public health; Medical emergency; Disease; Infectious disease (medical specialty); Immunology; Computer science; Nursing; Computer security","score_opus":0.10732169656124362,"score_gpt":0.3333454154482485,"score_spread":0.2260237188870049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039544106","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008087566,0.9976324,0.000018321889,0.001321103,0.00035613542,0.0000032969886,0.00010046535,0.0000030253339,0.00048430997],"genre_scores_gemma":[0.001127531,0.99748504,0.000054170072,0.0008845266,0.00023069722,0.000004731401,0.00006286398,0.0000011493917,0.00014933448],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993412,0.00015038885,0.00010878989,0.00006567453,0.00024617536,0.000087847875],"domain_scores_gemma":[0.99708337,0.0014769862,0.00069639593,0.000033402655,0.00053639663,0.00017343595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017971898,0.0006529982,0.0013410125,0.0019494309,0.00022722852,0.0014132244,0.0008586834,0.0016786412,0.0064795646],"category_scores_gemma":[0.006087698,0.00027379786,0.0012831411,0.003079791,0.0005276232,0.0011481073,0.0010410993,0.0021705509,0.0010655569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021356453,0.000040004856,0.0006247568,0.060592517,0.0005212283,0.00012080847,0.00009377338,0.00047682627,0.00024384743,0.006239699,0.09070891,0.8401241],"study_design_scores_gemma":[0.00007252725,0.00016206053,0.0067429147,0.07213427,0.0010353171,0.00041189848,0.00030478844,0.00013610601,0.00013399462,0.0028748058,0.9159409,0.00005048305],"about_ca_topic_score_codex":0.01687086,"about_ca_topic_score_gemma":0.035792395,"teacher_disagreement_score":0.01687086,"about_ca_system_score_codex":0.0020052514,"about_ca_system_score_gemma":0.006041471,"threshold_uncertainty_score":0.033545315},"labels":[],"label_agreement":null},{"id":"W3045883965","doi":"10.1016/s2352-3026(20)30219-2","title":"Is venous thromboembolism a preventable cause of death?","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute; McMaster University","funders":"","keywords":"Medicine; Pulmonary embolism; Deep vein; Venous thrombosis; Perioperative; Surgeon general; Orthopedic surgery; Thrombosis; Randomized controlled trial; Surgery; Intensive care medicine; Public health; Pathology","score_opus":0.0816195909306139,"score_gpt":0.3254530608087744,"score_spread":0.2438334698781605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045883965","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001735186,0.0022736054,0.0000363866,0.98030084,0.014471569,0.000003772483,0.00004766622,0.000009496294,0.002683182],"genre_scores_gemma":[0.004404489,0.004247428,0.00016892265,0.8911453,0.09435905,0.000030418041,0.00005588345,0.000019337336,0.005569166],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957872,0.0013942212,0.0004627557,0.00029133444,0.0014288047,0.0006358058],"domain_scores_gemma":[0.9839653,0.008158851,0.0011173736,0.00040973257,0.0027312678,0.0036174795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004363747,0.00071980426,0.0019061329,0.0013020514,0.0032816788,0.0039271615,0.0018892437,0.052399676,0.01400214],"category_scores_gemma":[0.03725629,0.0006384821,0.001271002,0.0010473108,0.003127626,0.004680991,0.0016133547,0.03510711,0.010368563],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115345545,0.000059862105,0.0013872441,0.00014970431,0.00003139844,0.00088355,0.000120732926,0.000059870395,0.00017904604,0.005542289,0.9720187,0.019452216],"study_design_scores_gemma":[0.00039439896,0.00017868841,0.0042341594,0.0015859748,0.00008326894,0.0021272728,0.00066792924,0.000547984,0.00019280531,0.02724682,0.96263355,0.00010718048],"about_ca_topic_score_codex":0.010189867,"about_ca_topic_score_gemma":0.018803934,"teacher_disagreement_score":0.052399676,"about_ca_system_score_codex":0.0041789287,"about_ca_system_score_gemma":0.008414596,"threshold_uncertainty_score":0.04684186},"labels":[],"label_agreement":null},{"id":"W3081462523","doi":"10.1016/s2352-3026(20)30227-1","title":"Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Alberta; Université de Montréal; University of Toronto; McGill University; Western University; McGill University Health Centre; University of Waterloo; McMaster University; Canadian Blood Services","funders":"Health Canada; Government of Canada; Canadian Blood Services; Australian Government; Pfizer; McMaster University; GlaxoSmithKline; Novartis","keywords":"Medicine; Eltrombopag; Perioperative; Surgery; Internal medicine; Platelet; Immune thrombocytopenia","score_opus":0.027490315801281955,"score_gpt":0.2823031305319179,"score_spread":0.25481281473063594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081462523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95032704,0.035838924,0.001756073,0.0023831767,0.0029441845,0.0027344236,0.0010743057,0.00013647458,0.0028053727],"genre_scores_gemma":[0.97998464,0.008994781,0.0016795364,0.002178357,0.0011616164,0.0025956926,0.0007857454,0.00002879498,0.0025908193],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983046,0.0009984801,0.00015520722,0.0002275117,0.00009515735,0.00021897811],"domain_scores_gemma":[0.998547,0.0006849828,0.00034490216,0.00014464455,0.000058458074,0.00022004735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026841327,0.0021999455,0.0053844447,0.0004011849,0.00041229196,0.001917353,0.0011635775,0.0025861522,0.006872664],"category_scores_gemma":[0.0037213443,0.0007875605,0.004277325,0.00052981946,0.0017584682,0.0017293642,0.0007767958,0.004285495,0.001086953],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98822755,0.0006447488,0.0003262667,0.0011565504,0.002468729,0.00004113232,0.000030763993,0.00013063512,0.000648155,0.00014355453,0.00033702905,0.005844777],"study_design_scores_gemma":[0.9814348,0.014818683,0.00088823156,0.000105168416,0.0018281887,0.000029081539,0.000024300181,0.00017235526,0.00009966979,0.00023911387,0.0003450664,0.000015292513],"about_ca_topic_score_codex":0.00089825894,"about_ca_topic_score_gemma":0.0014931706,"teacher_disagreement_score":0.006872664,"about_ca_system_score_codex":0.0010480748,"about_ca_system_score_gemma":0.0010009501,"threshold_uncertainty_score":0.0229913},"labels":[],"label_agreement":null},{"id":"W3081481587","doi":"10.1016/s2352-3026(20)30258-1","title":"A survey in Nepalese patients with acute leukaemia: a starting point for defining financial toxicity of cancer care in low-income and middle-income countries","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Commission; Cancer; High income countries; Developing country; Family medicine; Economic growth; Finance; Business; Internal medicine; Economics","score_opus":0.033968601225190534,"score_gpt":0.253959741878639,"score_spread":0.2199911406534485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081481587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960031,0.0003105475,0.000056845867,0.0014347681,0.000006933035,0.000028981993,0.00064742664,0.0000011728621,0.0015102867],"genre_scores_gemma":[0.99816704,0.00046997407,0.000049132406,0.0006687094,0.000009563007,0.000030335717,0.00029100897,0.0000010276318,0.00031313053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962306,0.00016025225,0.000041906605,0.000028131033,0.000044228822,0.0001023502],"domain_scores_gemma":[0.99909556,0.00020732776,0.00028380315,0.00002975808,0.00014070408,0.00024288727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005982056,0.00013732805,0.00020978747,0.0004862693,0.00047093214,0.0008394743,0.0003295059,0.00075701694,0.0016111471],"category_scores_gemma":[0.002514112,0.00017840973,0.00022040348,0.0014985572,0.00044156623,0.0010567508,0.00097050756,0.00097157754,0.0002599298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055293356,0.000055345692,0.994938,0.000036270394,0.000021919925,0.0003443099,0.0016891141,0.000034210774,0.00015585599,0.00012574445,0.00042295118,0.0021210061],"study_design_scores_gemma":[0.0000054779907,0.00009631082,0.99214864,0.000030428973,0.000009201,0.00035135122,0.0062284637,0.00006449368,0.000024955325,0.00007457975,0.00096027285,0.0000058036953],"about_ca_topic_score_codex":0.037143026,"about_ca_topic_score_gemma":0.040668026,"teacher_disagreement_score":0.037143026,"about_ca_system_score_codex":0.00081982004,"about_ca_system_score_gemma":0.001037338,"threshold_uncertainty_score":0.07385367},"labels":[],"label_agreement":null},{"id":"W3088801289","doi":"10.1016/s2352-3026(20)30293-3","title":"Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis","year":2020,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Clinical Oncology Group; Western University; University of Ottawa; McMaster University; Impact; St. Joseph’s Healthcare Hamilton; Cochrane","funders":"Universidad de Navarra; Charité – Universitätsmedizin Berlin; Canadian Institutes of Health Research; Sunnybrook Research Institute; Cancer Research UK; GlaxoSmithKline; Marie Curie; Mayo Clinic","keywords":"Medicine; Meta-analysis; Cochrane Library; Randomized controlled trial; Placebo; MEDLINE; Ambulatory; Internal medicine; Relative risk; Intensive care medicine; Confidence interval; Alternative medicine","score_opus":0.49517208088843384,"score_gpt":0.46917878031642946,"score_spread":0.025993300572004385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088801289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010724786,0.9870178,0.00068252266,0.00023374973,0.00028980637,0.00024245381,0.00051174604,0.00003714835,0.00025994706],"genre_scores_gemma":[0.3836108,0.60861015,0.0030791645,0.0021856881,0.00037689134,0.0006650609,0.0008750893,0.00005873332,0.0005382992],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.992702,0.0036359308,0.0019643006,0.00084542966,0.0005718,0.00028046797],"domain_scores_gemma":[0.9878228,0.008548117,0.0023499872,0.0005097416,0.0005583324,0.0002110945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008425756,0.0024274462,0.016112192,0.0022495494,0.0004365761,0.002723762,0.0017851535,0.0026435808,0.0045003984],"category_scores_gemma":[0.025789117,0.0015976134,0.026439117,0.0032463276,0.0007261674,0.0016440363,0.0016218254,0.002678651,0.00044577237],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048785214,0.000035894136,0.003654898,0.2230975,0.75667256,0.000084284366,0.00007776911,0.0003311401,0.00022389015,0.00009811755,0.000615715,0.010229725],"study_design_scores_gemma":[0.0026647046,0.00029809764,0.0031634765,0.010394159,0.98194915,0.000057962454,0.00004160868,0.0001290574,0.00006231322,0.00016627923,0.0010455638,0.000027554135],"about_ca_topic_score_codex":0.006830564,"about_ca_topic_score_gemma":0.021419728,"teacher_disagreement_score":0.016112192,"about_ca_system_score_codex":0.0020238785,"about_ca_system_score_gemma":0.002587929,"threshold_uncertainty_score":0.044560194},"labels":[],"label_agreement":null},{"id":"W3089833778","doi":"10.1016/s2352-3026(20)30321-5","title":"Immunotherapy for older patients with classic Hodgkin lymphoma","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Lymphoma; Immunotherapy; Hodgkin lymphoma; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.027256223858852145,"score_gpt":0.27264843305991515,"score_spread":0.245392209201063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089833778","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4368283,0.48903385,0.0005606131,0.0366661,0.004249389,0.000056106775,0.0003663254,0.000084069194,0.032155257],"genre_scores_gemma":[0.8501923,0.11516479,0.00052230444,0.017238634,0.010301768,0.000046117675,0.00036774302,0.000014835089,0.006151537],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99992216,0.000022456046,0.0000099102035,0.000009428745,0.000015371108,0.000020738424],"domain_scores_gemma":[0.9995944,0.000131693,0.00011886107,0.00001321127,0.000024878305,0.00011695483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029201832,0.00015174987,0.00046404402,0.00020679775,0.00019631232,0.000349172,0.00014172886,0.0004190145,0.0028833533],"category_scores_gemma":[0.0011006204,0.00006440013,0.0002485979,0.00028427583,0.00016249948,0.00036970028,0.00028997473,0.00086959236,0.0004673113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004711214,0.00043317178,0.089202195,0.0022672403,0.000503144,0.0025449428,0.0004384152,0.00031197543,0.005450369,0.0014432224,0.054008562,0.8386855],"study_design_scores_gemma":[0.0034564636,0.00807864,0.57069695,0.0024327796,0.00152264,0.021092786,0.0010555028,0.0006333244,0.0014727024,0.007775464,0.38172388,0.00005892154],"about_ca_topic_score_codex":0.00031697768,"about_ca_topic_score_gemma":0.00062777445,"teacher_disagreement_score":0.0028833533,"about_ca_system_score_codex":0.00026821063,"about_ca_system_score_gemma":0.0002271447,"threshold_uncertainty_score":0.00964576},"labels":[],"label_agreement":null},{"id":"W3093752978","doi":"10.1016/s2352-3026(20)30285-4","title":"Mortality benefits of thromboprophylaxis","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Venous thromboembolism; Pulmonary embolism; Scopus; Overdiagnosis; MEDLINE; Intensive care medicine; Meta-analysis; Surgery; Internal medicine; Thrombosis","score_opus":0.08385518034055514,"score_gpt":0.31413435795413247,"score_spread":0.23027917761357733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093752978","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001120852,0.0071130753,0.00006102126,0.9705692,0.00970982,0.0000050165595,0.00017556157,0.000017480183,0.011227907],"genre_scores_gemma":[0.031721227,0.006155789,0.00018313972,0.79110795,0.16221806,0.00003137454,0.00023200428,0.00002829055,0.008322192],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99623054,0.0017311987,0.0003508865,0.0002918769,0.00088818494,0.00050722755],"domain_scores_gemma":[0.9819926,0.012382563,0.0011278604,0.0005238874,0.0014795952,0.0024935107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003995332,0.0005246246,0.0011842342,0.0008370967,0.0013383611,0.002763268,0.0011284223,0.023162104,0.013331125],"category_scores_gemma":[0.034978077,0.00036524358,0.0011444231,0.000706098,0.0018841657,0.001603654,0.0009865899,0.016799945,0.005759498],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018725906,0.00015189646,0.0039791944,0.00027476845,0.00019649499,0.001593305,0.00008201854,0.00026663824,0.00058196,0.013038992,0.92137,0.056592014],"study_design_scores_gemma":[0.0030101654,0.00065623736,0.0208052,0.0015726681,0.00039078842,0.0038115596,0.00028455636,0.0012150668,0.0005959238,0.057432406,0.910106,0.000119426084],"about_ca_topic_score_codex":0.0034934743,"about_ca_topic_score_gemma":0.0063828323,"teacher_disagreement_score":0.023162104,"about_ca_system_score_codex":0.0029685108,"about_ca_system_score_gemma":0.0025860919,"threshold_uncertainty_score":0.04459703},"labels":[],"label_agreement":null},{"id":"W3111617049","doi":"10.1016/s2352-3026(20)30368-9","title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Children's Hospital of Eastern Ontario; Hospital for Sick Children; University of Ottawa","funders":"","keywords":"Dabigatran; Venous thromboembolism; Medicine; Open label; Randomized controlled trial; Intensive care medicine; Internal medicine; Atrial fibrillation; Warfarin; Thrombosis","score_opus":0.09972071038314155,"score_gpt":0.36821511905063026,"score_spread":0.2684944086674887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111617049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761653,0.015997423,0.000602955,0.0013370421,0.00051251467,0.0013586753,0.0017981611,0.00006426859,0.0021637855],"genre_scores_gemma":[0.97755665,0.010368738,0.0022384375,0.0022504716,0.00049587066,0.0025432415,0.0016935412,0.00002756273,0.002825511],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993856,0.00031920214,0.000046514226,0.000085632906,0.000049051425,0.00011403624],"domain_scores_gemma":[0.99924976,0.0002483644,0.00019807287,0.000056358134,0.000035516914,0.00021195874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012539165,0.0010181924,0.0022327355,0.00025260713,0.00026023458,0.0009468285,0.00039572455,0.0011308005,0.004765429],"category_scores_gemma":[0.0017452684,0.00030840744,0.0021876167,0.00036370984,0.0009646206,0.00066738634,0.0004350073,0.0021199458,0.0005682105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9544471,0.0019074762,0.0027595195,0.0018384897,0.0037912452,0.00024224765,0.00012315586,0.00045383247,0.0036490418,0.00049797894,0.002197532,0.028092364],"study_design_scores_gemma":[0.9797363,0.014206932,0.0032075436,0.00008231375,0.00079727644,0.00015569302,0.000031640855,0.00010078677,0.00022921413,0.00018688831,0.0012525687,0.000012836348],"about_ca_topic_score_codex":0.0010251631,"about_ca_topic_score_gemma":0.0028037399,"teacher_disagreement_score":0.004765429,"about_ca_system_score_codex":0.00061176287,"about_ca_system_score_gemma":0.0009818283,"threshold_uncertainty_score":0.015941918},"labels":[],"label_agreement":null},{"id":"W3116889989","doi":"10.1016/s2352-3026(20)30375-6","title":"PARP inhibitors—understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia","year":2020,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Olaparib; Medicine; PARP inhibitor; Oncology; Veliparib; Internal medicine; Ovarian cancer; Cancer research; Carboplatin; Cancer; Chemotherapy; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","score_opus":0.05215419540124464,"score_gpt":0.28976288000656997,"score_spread":0.23760868460532533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116889989","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032880052,0.0060758386,0.00008338804,0.98457474,0.006863168,0.000004181627,0.000036429017,0.000009327887,0.0020242347],"genre_scores_gemma":[0.0072884834,0.0064432803,0.00022929274,0.8966553,0.08601007,0.000022495895,0.000035815156,0.000013055496,0.0033021558],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964192,0.0015656636,0.0003965069,0.00029371775,0.0010188025,0.00030612122],"domain_scores_gemma":[0.98906624,0.0075824712,0.0008029307,0.00025149583,0.00093118584,0.001365641],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037898747,0.00071187963,0.00175549,0.00071335025,0.0020254306,0.0029431332,0.0013892753,0.048867725,0.0055036834],"category_scores_gemma":[0.027351666,0.0006140756,0.0011964206,0.0006767574,0.0034505134,0.0046698037,0.0018406773,0.038354654,0.0040773363],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031425347,0.00008800425,0.001748456,0.00021297771,0.00007092628,0.0043106033,0.00016826377,0.00025723036,0.0005733866,0.012404856,0.9263741,0.05347693],"study_design_scores_gemma":[0.00044191975,0.00026670608,0.0021177786,0.0006816976,0.000090700734,0.0076712267,0.00032477232,0.0009923349,0.00032291203,0.06453862,0.92246366,0.000087778804],"about_ca_topic_score_codex":0.0032240408,"about_ca_topic_score_gemma":0.0048982534,"teacher_disagreement_score":0.048867725,"about_ca_system_score_codex":0.0036506427,"about_ca_system_score_gemma":0.0035155169,"threshold_uncertainty_score":0.02648735},"labels":[],"label_agreement":null},{"id":"W3135992090","doi":"10.1016/s2352-3026(21)00067-3","title":"A century between pandemics and poisonings","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Hepatic veno-occlusive disease; Hematopoietic stem cell transplantation; Chemotherapy; Disease; Haematopoiesis; Liver transplantation; Pandemic; Intensive care medicine; Transplantation; Stem cell; Internal medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.040178080253992526,"score_gpt":0.30416510258695245,"score_spread":0.2639870223329599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135992090","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042114984,0.15055381,0.00083972915,0.7725962,0.03760672,0.00001264825,0.00031826322,0.00011164976,0.033749495],"genre_scores_gemma":[0.13014905,0.1604956,0.0011712719,0.59672785,0.08092381,0.00007763145,0.00039539798,0.00026682595,0.029792545],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99562365,0.0012832778,0.00024719824,0.0004853163,0.001353612,0.0010069216],"domain_scores_gemma":[0.98997074,0.0045393,0.0010492468,0.0008219336,0.0013502553,0.0022684557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006626097,0.0007801084,0.0011064443,0.0015183259,0.0038941072,0.009757722,0.0011419376,0.012761481,0.025392767],"category_scores_gemma":[0.022781959,0.00063913566,0.0007121483,0.0018574763,0.012925089,0.016526332,0.007038236,0.01490516,0.00491611],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036186998,0.00011299264,0.0021769996,0.0008563009,0.0001241398,0.0013705491,0.005474767,0.00023468751,0.00071850757,0.24971388,0.61838156,0.12047366],"study_design_scores_gemma":[0.00003550936,0.00003871344,0.0011128754,0.00067804934,0.0000124175685,0.0003972654,0.0034371014,0.00002915015,0.0000763805,0.05860585,0.9355454,0.000031161904],"about_ca_topic_score_codex":0.0052238214,"about_ca_topic_score_gemma":0.00744894,"teacher_disagreement_score":0.025392767,"about_ca_system_score_codex":0.0049788738,"about_ca_system_score_gemma":0.005668873,"threshold_uncertainty_score":0.08494729},"labels":[],"label_agreement":null},{"id":"W3143101252","doi":"10.1016/s2352-3026(17)30177-1","title":"Erythropoietin on cycling performance","year":2017,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Erythropoietin; Placebo; Cycling; Double blind; Internal medicine; Physical therapy; Alternative medicine; Pathology","score_opus":0.06843412221406373,"score_gpt":0.32916519119568516,"score_spread":0.26073106898162146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143101252","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00072560966,0.0038707426,0.000023874623,0.97655576,0.013086452,0.000008959528,0.00006739116,0.000009693176,0.005651509],"genre_scores_gemma":[0.012121791,0.0041956683,0.00006934286,0.9113672,0.061923917,0.00004002841,0.00006119153,0.000022809372,0.010198123],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9979482,0.0008098406,0.00021654021,0.000174378,0.0004456892,0.00040534997],"domain_scores_gemma":[0.9943902,0.0035215276,0.0003126796,0.00012072762,0.00056705147,0.0010877089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018324857,0.0005502323,0.0012465774,0.0005938513,0.003096666,0.002225043,0.0011310293,0.031148082,0.008216529],"category_scores_gemma":[0.022731196,0.0003624354,0.00091916736,0.0005660674,0.002276203,0.0017209239,0.0015898946,0.02645352,0.003705691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013851085,0.0000555586,0.0010793409,0.000064788415,0.000023193668,0.0020864042,0.000099769044,0.000053871994,0.00009769994,0.005314578,0.9691442,0.021842107],"study_design_scores_gemma":[0.000739373,0.00023211152,0.0035625545,0.0013803074,0.00011000053,0.0037780856,0.00058760965,0.0005350775,0.0003363356,0.031090962,0.957568,0.00007958194],"about_ca_topic_score_codex":0.009668892,"about_ca_topic_score_gemma":0.014829858,"teacher_disagreement_score":0.031148082,"about_ca_system_score_codex":0.004330223,"about_ca_system_score_gemma":0.004710925,"threshold_uncertainty_score":0.031418085},"labels":[],"label_agreement":null},{"id":"W3155195921","doi":"10.1016/s2352-3026(21)00060-0","title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Canada Research Chairs; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Intensive care; Intensive care unit; Cytokine release syndrome; Cohort study; Cohort; Observational study; Proportional hazards model; Internal medicine; Retrospective cohort study; Emergency medicine; Chimeric antigen receptor; Pediatrics; Intensive care medicine; Confidence interval; Immunotherapy","score_opus":0.05996188039825393,"score_gpt":0.35537644755280046,"score_spread":0.2954145671545465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155195921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856454,0.00026389176,0.00004823062,0.000076225406,0.000024552804,0.00001336922,0.0007492812,0.000002300002,0.00025764995],"genre_scores_gemma":[0.9984118,0.00020635745,0.0000451208,0.000104545456,0.000036458,0.000021951297,0.0010327742,0.000003074283,0.00013805399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992467,0.00016914317,0.00006202061,0.00021677605,0.00007545795,0.00022993007],"domain_scores_gemma":[0.99836606,0.00021370007,0.00075222715,0.00015850413,0.00010434046,0.0004052253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062787224,0.0005370447,0.00076413614,0.0005466723,0.000689419,0.001727221,0.000728387,0.0011737909,0.0019627102],"category_scores_gemma":[0.002181564,0.00057191006,0.0013523251,0.0014709998,0.0004854637,0.001008641,0.0009223656,0.0017568609,0.00029422858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017328083,0.00018270651,0.9953497,0.000029359857,0.00051305024,0.00026511183,0.00015141818,0.000081537044,0.0004004329,0.000069887006,0.00054208393,0.00068194576],"study_design_scores_gemma":[0.00020769802,0.0004853712,0.997361,0.000023983524,0.00026007378,0.0003896485,0.0006053688,0.00025481766,0.000046688776,0.000075737844,0.00026787329,0.000021646098],"about_ca_topic_score_codex":0.009317999,"about_ca_topic_score_gemma":0.008105292,"teacher_disagreement_score":0.009317999,"about_ca_system_score_codex":0.0007418904,"about_ca_system_score_gemma":0.0006633821,"threshold_uncertainty_score":0.018527508},"labels":[],"label_agreement":null},{"id":"W3155992812","doi":"10.1016/s2352-3026(21)00056-9","title":"Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management","year":2021,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"IgG4-Related and Inflammatory Diseases","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Vancouver General Hospital","funders":"","keywords":"Medicine; Polyclonal antibodies; Hypergammaglobulinemia; Immunology; Plasmacytosis; Immune dysregulation; Castleman disease; Pathology; Disease; Antibody; Multiple myeloma","score_opus":0.09329584682208628,"score_gpt":0.456191901175889,"score_spread":0.3628960543538027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155992812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028438515,0.99952495,0.000033831242,0.00021332428,0.00010009403,0.0000018162632,0.000006314733,0.0000020680534,0.00008912478],"genre_scores_gemma":[0.00053384784,0.9985556,0.00012140133,0.00030973108,0.00038185075,0.000004638586,0.0000210228,8.3193504e-7,0.00007100821],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991628,0.00021045106,0.00017942987,0.00012536252,0.0002675502,0.000054449203],"domain_scores_gemma":[0.99693847,0.0018648907,0.0004935774,0.00004782632,0.00051980646,0.00013540282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022119768,0.0012736693,0.0038154451,0.0028982686,0.00025702946,0.0017388295,0.0017118752,0.001892877,0.002466888],"category_scores_gemma":[0.00429056,0.00051100773,0.0011338698,0.0023483112,0.000900484,0.0013824182,0.0010127998,0.0033086909,0.0010814943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021392113,0.000054910262,0.0006360718,0.031109886,0.00037010547,0.00023920315,0.000046822468,0.00037313384,0.00034886182,0.001221789,0.029662827,0.9357225],"study_design_scores_gemma":[0.00037981992,0.00031716292,0.009363926,0.08462951,0.002900535,0.007121458,0.00029716804,0.00059980724,0.00044192313,0.005695924,0.8881074,0.00014528494],"about_ca_topic_score_codex":0.0025319902,"about_ca_topic_score_gemma":0.0048717014,"teacher_disagreement_score":0.0038154451,"about_ca_system_score_codex":0.0011862603,"about_ca_system_score_gemma":0.0020996921,"threshold_uncertainty_score":0.011698186},"labels":[],"label_agreement":null},{"id":"W3165566500","doi":"10.1016/s2352-3026(21)00102-2","title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Pharmacyclics; Genentech; Bayer Fund; Seattle Genetics; Janssen Pharmaceuticals; Gilead Sciences; Roche; Johnson and Johnson; AbbVie; Merck; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Brentuximab vedotin; Open label; Oncology; Internal medicine; Chemotherapy; Hodgkin lymphoma; Phases of clinical research; Lymphoma; Randomized controlled trial","score_opus":0.07474879554476967,"score_gpt":0.39146995681349683,"score_spread":0.3167211612687272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165566500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9096637,0.06628915,0.0027457348,0.0037104466,0.0029112953,0.003490239,0.0035911507,0.0003639806,0.007234285],"genre_scores_gemma":[0.95659816,0.021546258,0.0033735025,0.0052059703,0.0007495656,0.002984535,0.0036760992,0.00010265764,0.0057633794],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99884284,0.0006537623,0.0000686727,0.000154666,0.000094872215,0.0001850746],"domain_scores_gemma":[0.9986992,0.00050578837,0.00029798673,0.00010737501,0.00007830069,0.00031131122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003238048,0.0015189332,0.0031381606,0.00035004228,0.0003575793,0.0018209802,0.00096132915,0.0017610707,0.0049287137],"category_scores_gemma":[0.0026770208,0.0005358216,0.0029659646,0.0004706974,0.0010402164,0.0019282161,0.0005240748,0.0047190366,0.0010071669],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91128963,0.0026191229,0.0013358634,0.0026803745,0.003915055,0.000082661005,0.00018667015,0.000884142,0.0030673228,0.00049132964,0.0040351204,0.06941271],"study_design_scores_gemma":[0.9551786,0.035230324,0.0030279958,0.00023782792,0.0012796746,0.00009699963,0.000055614095,0.00044496686,0.00037789968,0.0005837424,0.00345367,0.000032722724],"about_ca_topic_score_codex":0.001180023,"about_ca_topic_score_gemma":0.0033001425,"teacher_disagreement_score":0.0049287137,"about_ca_system_score_codex":0.0010356772,"about_ca_system_score_gemma":0.0008350974,"threshold_uncertainty_score":0.017124653},"labels":[],"label_agreement":null},{"id":"W3176370909","doi":"10.1016/s2352-3026(21)00134-4","title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Celator Pharmaceuticals; Jazz Pharmaceuticals","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Chemotherapy; Myeloid leukaemia; Chemotherapy regimen; Oncology; Pediatrics","score_opus":0.03108454719582305,"score_gpt":0.33817549234273164,"score_spread":0.3070909451469086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176370909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941339,0.0032573782,0.00022553206,0.00039435332,0.0002436233,0.0006306386,0.00037101028,0.000043367327,0.0007001265],"genre_scores_gemma":[0.993192,0.0022513033,0.0006174928,0.0006827524,0.0002468578,0.00077473477,0.0007562758,0.000013361281,0.0014652095],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994604,0.00029145106,0.000029006755,0.00009714762,0.00003263199,0.00008940446],"domain_scores_gemma":[0.9991485,0.00023918749,0.000206947,0.000050398696,0.000037939164,0.00031705148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014915692,0.0014472269,0.0025389835,0.00031391083,0.00032572856,0.0009928514,0.0007406037,0.001360895,0.004290611],"category_scores_gemma":[0.0014828828,0.0004340556,0.0020067273,0.00037039543,0.0010020823,0.0010183103,0.00051691436,0.0030992297,0.00064355956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97962874,0.002270392,0.00070617587,0.00038779623,0.000949298,0.000034031444,0.00006181576,0.0003493178,0.0019751661,0.000092184106,0.00047951037,0.01306562],"study_design_scores_gemma":[0.9163465,0.0764741,0.0052060443,0.000038921287,0.0005861479,0.00004947732,0.000042096228,0.0003713426,0.00021188874,0.00015945845,0.00049715355,0.00001681382],"about_ca_topic_score_codex":0.0014643735,"about_ca_topic_score_gemma":0.003000318,"teacher_disagreement_score":0.004290611,"about_ca_system_score_codex":0.0008122006,"about_ca_system_score_gemma":0.00079704734,"threshold_uncertainty_score":0.014353514},"labels":[],"label_agreement":null},{"id":"W3199497677","doi":"10.1016/s2352-3026(21)00269-6","title":"All-trans retinoic acid for treating immune thrombocytopenia: new purpose for an old drug?","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombopoietin; Eltrombopag; Thrombopoietin receptor; Immune system; Internal medicine; Thrombocytopenic purpura; Antibody; Hematology; Immunology; Immune thrombocytopenia","score_opus":0.05526540880039474,"score_gpt":0.3396319064009549,"score_spread":0.2843664976005602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199497677","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012324243,0.838059,0.00091640645,0.14350039,0.00931332,0.000014878752,0.00012104331,0.00007820393,0.0067642825],"genre_scores_gemma":[0.024150647,0.84268755,0.0031064928,0.07923132,0.033300925,0.00005319473,0.00017687396,0.00009171962,0.017201282],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988471,0.00042712738,0.00015321167,0.00014412614,0.00032248214,0.00010590611],"domain_scores_gemma":[0.99688077,0.0017171084,0.0003708685,0.00019810311,0.0005593911,0.00027383005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003269265,0.0006558673,0.0020287037,0.0010469746,0.00058969,0.0031222338,0.0011056114,0.0046218955,0.00985563],"category_scores_gemma":[0.0040729954,0.0003130832,0.0012071397,0.00077780423,0.0025962945,0.005236911,0.0011208,0.007522483,0.004130764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001989891,0.0002694868,0.00096310646,0.0032643783,0.00046331107,0.0009681737,0.00022500935,0.0004058021,0.005401893,0.040720616,0.26449233,0.6808359],"study_design_scores_gemma":[0.0005803261,0.00059913285,0.0007979472,0.0016578787,0.00026675264,0.0010835328,0.0002813981,0.00026950042,0.00086021103,0.018319156,0.97521836,0.00006562883],"about_ca_topic_score_codex":0.0014112089,"about_ca_topic_score_gemma":0.004490844,"teacher_disagreement_score":0.00985563,"about_ca_system_score_codex":0.001334028,"about_ca_system_score_gemma":0.0018213504,"threshold_uncertainty_score":0.03297037},"labels":[],"label_agreement":null},{"id":"W3204272926","doi":"10.1016/s2352-3026(21)00271-4","title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; Mycosis fungoides; Refractory (planetary science); Internal medicine; Cohort; Adverse effect; Gastroenterology; Surgery; Dermatology; Lymphoma","score_opus":0.04827010800737181,"score_gpt":0.3387986010248302,"score_spread":0.2905284930174584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204272926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99473095,0.0031262198,0.00023852612,0.00023198385,0.00007615963,0.0003567898,0.00034969905,0.000050676867,0.00083892886],"genre_scores_gemma":[0.99250895,0.0028428303,0.0006130183,0.00067830674,0.000120338686,0.0005929455,0.001118134,0.000023052224,0.0015023432],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971443,0.00011844815,0.000012757398,0.00004802531,0.000028716959,0.00007754637],"domain_scores_gemma":[0.9996309,0.00007431856,0.0000699005,0.0000373153,0.000019695799,0.00016775857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011020084,0.0013850413,0.0018848188,0.00031125348,0.00028428287,0.00093605893,0.000629439,0.001132432,0.0018040026],"category_scores_gemma":[0.0005920705,0.00041854463,0.0013357017,0.00039296673,0.00078374235,0.00079304597,0.00026077055,0.0022932726,0.00056525925],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68992525,0.03404349,0.012197121,0.0017446892,0.003162,0.00050737796,0.00052295224,0.0032689986,0.07918631,0.00035862013,0.0040020044,0.17108119],"study_design_scores_gemma":[0.53981286,0.41889966,0.031182665,0.000081006125,0.0015781795,0.0005338757,0.00015638392,0.0013980042,0.0034436504,0.0002663554,0.0025811484,0.00006608351],"about_ca_topic_score_codex":0.00077896734,"about_ca_topic_score_gemma":0.0021344968,"teacher_disagreement_score":0.0018848188,"about_ca_system_score_codex":0.00055451214,"about_ca_system_score_gemma":0.0006836623,"threshold_uncertainty_score":0.0060349703},"labels":[],"label_agreement":null},{"id":"W3211623336","doi":"10.1016/s2352-3026(21)00306-9","title":"Vaccine-induced immune thrombotic thrombocytopenia","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Bayer; Bristol-Myers Squibb","keywords":"Immune thrombocytopenia; Antibody; Immune system; Vaccination; Thrombosis; Venous thrombosis; Immunization; Intravenous Immunoglobulins","score_opus":0.07505048938255585,"score_gpt":0.3375881821335542,"score_spread":0.26253769275099836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211623336","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31701306,0.44007894,0.0047415495,0.13376969,0.01986859,0.00026393353,0.002339286,0.00036114058,0.0815638],"genre_scores_gemma":[0.82145864,0.12040252,0.00083555916,0.020923732,0.022616705,0.00008402574,0.0012676986,0.00005054453,0.012360611],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99941266,0.00026800612,0.000040776802,0.000052135925,0.00011171326,0.00011467962],"domain_scores_gemma":[0.9988292,0.0005752607,0.0002675688,0.00010533229,0.00010835136,0.00011431815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091521034,0.0002392761,0.00046766293,0.00036393115,0.00012900417,0.00079868926,0.00031922857,0.001798523,0.0058980486],"category_scores_gemma":[0.0023178835,0.0001344427,0.00039057576,0.00031491497,0.00040037915,0.00034213293,0.00028852254,0.0019717033,0.0009857147],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004885438,0.0008287794,0.04386657,0.0040614223,0.001485899,0.0071440926,0.0001972754,0.0013697833,0.011797262,0.028362636,0.18154791,0.714453],"study_design_scores_gemma":[0.0065968796,0.012790135,0.2705602,0.004244813,0.0021097385,0.041593935,0.0006944359,0.004491599,0.012106959,0.04233207,0.6023571,0.00012209722],"about_ca_topic_score_codex":0.0003080416,"about_ca_topic_score_gemma":0.0003615289,"teacher_disagreement_score":0.0058980486,"about_ca_system_score_codex":0.0003716502,"about_ca_system_score_gemma":0.0004370579,"threshold_uncertainty_score":0.019730985},"labels":[],"label_agreement":null},{"id":"W3217353697","doi":"10.1016/s2352-3026(21)00311-2","title":"Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Lenalidomide; Medicine; Follicular lymphoma; Obinutuzumab; Internal medicine; Rituximab; Oncology; Lymphoma; Cohort; Neutropenia; Tolerability; Brentuximab vedotin; Gastroenterology; Chemotherapy; Adverse effect; Multiple myeloma; CD30","score_opus":0.02440419732320716,"score_gpt":0.28496713509118393,"score_spread":0.2605629377679768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217353697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963271,0.002108525,0.00011175104,0.00015541293,0.000059358175,0.00022819638,0.0004746596,0.000012219685,0.00052288227],"genre_scores_gemma":[0.99635917,0.00079510035,0.00024393888,0.0004121342,0.000121398785,0.0002423875,0.0012127792,0.0000126948435,0.00060046033],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99846053,0.0007076357,0.000090202084,0.00030816396,0.00014166602,0.00029177326],"domain_scores_gemma":[0.9986014,0.00030251898,0.0003101183,0.00021794031,0.00011220435,0.00045584003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026510656,0.0012089078,0.002460734,0.00032921231,0.00054002675,0.0020243928,0.0007956461,0.0010842407,0.0015106596],"category_scores_gemma":[0.0024901442,0.00062659,0.002205645,0.00069209735,0.0008926645,0.0013365281,0.0004940995,0.0022602428,0.00046300853],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8225631,0.009662134,0.087796114,0.00059179735,0.010280994,0.00043568574,0.0005118678,0.0012790204,0.012226861,0.00023822243,0.00289818,0.051516004],"study_design_scores_gemma":[0.50160825,0.19979572,0.27699146,0.00012763894,0.009784328,0.0010143558,0.0005372345,0.0013266712,0.0018101154,0.0006149332,0.0062375264,0.00015173409],"about_ca_topic_score_codex":0.0016554821,"about_ca_topic_score_gemma":0.0024703848,"teacher_disagreement_score":0.0026510656,"about_ca_system_score_codex":0.001300431,"about_ca_system_score_gemma":0.0012212866,"threshold_uncertainty_score":0.014020324},"labels":[],"label_agreement":null},{"id":"W4200016924","doi":"10.1016/s2352-3026(21)00351-3","title":"Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Public health; Pregnancy; Injustice; Anemia; Pathological; Epidemiology","score_opus":0.05165800612500909,"score_gpt":0.32285333895385526,"score_spread":0.27119533282884617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200016924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9096908,0.014046498,0.0047983294,0.02855938,0.000715395,0.000061960534,0.0015505181,0.000020353242,0.04055684],"genre_scores_gemma":[0.9969228,0.000972416,0.0004436693,0.00076551567,0.00012192112,0.000015856815,0.00016292288,0.000008564469,0.0005863733],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9956607,0.0024167167,0.0003715957,0.00032682743,0.00067715754,0.0005469526],"domain_scores_gemma":[0.9852609,0.005988217,0.004543631,0.0014340852,0.0017771136,0.0009959572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045459066,0.0002173516,0.00035847662,0.0015705237,0.00096713885,0.0017111828,0.0007184062,0.00076638366,0.00455111],"category_scores_gemma":[0.025640236,0.00021062665,0.0005459803,0.0023540815,0.0017898038,0.0016767653,0.0024045592,0.0023106479,0.0001824301],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018443196,0.000108318716,0.8808989,0.0003166133,0.0005924602,0.0002006721,0.008998034,0.00032174555,0.00016591587,0.05489085,0.005448774,0.047873452],"study_design_scores_gemma":[0.000023185985,0.0000960369,0.89469486,0.0011349499,0.0002343806,0.0009873543,0.01579337,0.0010748861,0.00022605929,0.07266451,0.013006061,0.00006434419],"about_ca_topic_score_codex":0.015113115,"about_ca_topic_score_gemma":0.022019153,"teacher_disagreement_score":0.015113115,"about_ca_system_score_codex":0.00079475995,"about_ca_system_score_gemma":0.0013278428,"threshold_uncertainty_score":0.030050278},"labels":[],"label_agreement":null},{"id":"W4200347843","doi":"10.1016/s2352-3026(21)00349-5","title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Lymphoma Research Foundation; Children’s Oncology Group; Irving Medical Center, Columbia University; St. Baldrick's Foundation","keywords":"Pooled analysis; Lymphoma; Meta-analysis; Retrospective cohort study; Survival analysis; Hodgkin lymphoma; MEDLINE; Clinical trial","score_opus":0.019518349032160386,"score_gpt":0.28792850178472795,"score_spread":0.2684101527525676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200347843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6441819,0.34778476,0.0010430625,0.0004533232,0.00028254642,0.00016923297,0.004965559,0.000031151307,0.0010883629],"genre_scores_gemma":[0.97422194,0.02227682,0.00044288675,0.0004330826,0.00018539494,0.0001463708,0.0020116495,0.000023407647,0.00025847327],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98997986,0.006441706,0.0012785542,0.0013884446,0.0004695428,0.00044180572],"domain_scores_gemma":[0.98564166,0.0076409867,0.0045959037,0.0012009655,0.00043906562,0.00048136964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009006586,0.00095109193,0.0038328222,0.0011917691,0.00024505315,0.0016958509,0.00070740766,0.0011414237,0.0012732319],"category_scores_gemma":[0.015149834,0.00074159424,0.010070488,0.0024542406,0.00059220573,0.0011993593,0.0010198774,0.001443305,0.00014579527],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0829506,0.00009026763,0.41560543,0.011936656,0.46152812,0.00034079724,0.00024199758,0.0023421904,0.0009004296,0.00043569368,0.0027263286,0.020901604],"study_design_scores_gemma":[0.017326927,0.0056637786,0.55713224,0.0024589817,0.40685153,0.0009385592,0.00039985828,0.0011326288,0.00050745293,0.0009929108,0.0064702122,0.0001249239],"about_ca_topic_score_codex":0.0025836085,"about_ca_topic_score_gemma":0.004718378,"teacher_disagreement_score":0.009006586,"about_ca_system_score_codex":0.0007310121,"about_ca_system_score_gemma":0.00064006954,"threshold_uncertainty_score":0.04763198},"labels":[],"label_agreement":null},{"id":"W4210632919","doi":"10.1016/s2352-3026(21)00283-0","title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Context (archaeology); Vaccination; Disease; Immunology; Internal medicine","score_opus":0.33242502555324743,"score_gpt":0.45737459681764064,"score_spread":0.12494957126439321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210632919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021288295,0.9731568,0.0012959153,0.018944114,0.0031672206,0.00040320857,0.0011566589,0.000059655347,0.0016034675],"genre_scores_gemma":[0.0021056058,0.9763658,0.008020775,0.0094759045,0.00076341076,0.0007325658,0.001499012,0.000024688694,0.0010122467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991743,0.0021981478,0.0025627033,0.00065496087,0.0023454828,0.00049572386],"domain_scores_gemma":[0.9800013,0.00905558,0.0033280386,0.00033541792,0.0062815365,0.0009981464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024405189,0.002070875,0.006475213,0.008302419,0.00090629153,0.0043400964,0.006479205,0.0067547434,0.0051632323],"category_scores_gemma":[0.027013054,0.0011648401,0.008897354,0.007293354,0.0012887114,0.0032537174,0.0036008474,0.008552802,0.0024490664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052770873,0.00023272823,0.0009971336,0.17027725,0.0025331178,0.00025912546,0.0005025971,0.0010521353,0.0008353121,0.0061549777,0.21389681,0.6027311],"study_design_scores_gemma":[0.000750335,0.00020641004,0.0044015036,0.28834003,0.008268429,0.0003918315,0.00038707085,0.00037969468,0.0005762625,0.0057521346,0.690412,0.00013425133],"about_ca_topic_score_codex":0.016529107,"about_ca_topic_score_gemma":0.018690243,"teacher_disagreement_score":0.024405189,"about_ca_system_score_codex":0.005734282,"about_ca_system_score_gemma":0.025563175,"threshold_uncertainty_score":0.12906855},"labels":[],"label_agreement":null},{"id":"W4210694747","doi":"10.1016/s2352-3026(21)00366-5","title":"Malignancy-associated haemophagocytic lymphohistiocytosis","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Vancouver Hospital and Health Sciences Centre; BC Children's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Macrophage activation syndrome; Hemophagocytic lymphohistiocytosis; Cytokine storm; Immune system; Cytokine; Chemokine; Lymphoma; Cancer","score_opus":0.04493415929046922,"score_gpt":0.3097292743034708,"score_spread":0.26479511501300157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210694747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8592603,0.06936824,0.001137937,0.009726081,0.0012405483,0.000075483396,0.0011906954,0.00016504695,0.05783563],"genre_scores_gemma":[0.9888498,0.0066455593,0.00012966983,0.0007784435,0.0015467767,0.000004719859,0.00026243483,0.000011370149,0.0017711169],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9996972,0.00007693813,0.00003161047,0.000039315717,0.00005509727,0.00009991499],"domain_scores_gemma":[0.99919444,0.00030590477,0.00021083157,0.00010811018,0.00006218739,0.000118570824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028630573,0.0002645512,0.0003378459,0.0006142149,0.00027546185,0.00081438484,0.00023797198,0.0012585531,0.0063772765],"category_scores_gemma":[0.0017693993,0.00022829174,0.00023384801,0.0006542325,0.00061458995,0.00041205288,0.00048698735,0.0008206551,0.0013334544],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002441303,0.0001936823,0.5891742,0.0015584042,0.0003742516,0.24045612,0.00046464312,0.0005056684,0.013993698,0.004630752,0.033905648,0.11230164],"study_design_scores_gemma":[0.00023000725,0.000595992,0.48942223,0.0005848855,0.000315771,0.46089533,0.00055326807,0.00072330626,0.0023853737,0.0031777998,0.04108103,0.00003503267],"about_ca_topic_score_codex":0.000606236,"about_ca_topic_score_gemma":0.0006736054,"teacher_disagreement_score":0.0063772765,"about_ca_system_score_codex":0.00029649425,"about_ca_system_score_gemma":0.00027006507,"threshold_uncertainty_score":0.021334112},"labels":[],"label_agreement":null},{"id":"W4221022237","doi":"10.1016/s2352-3026(22)00053-9","title":"Sex specific definitions of anaemia reflect androgen production – Authors' reply","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hormonal and reproductive studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Erythropoiesis; Medicine; Androgen; Testosterone (patch); Androgen deficiency; Endocrinology; Internal medicine; Anemia; Physiology; Hormone","score_opus":0.11654895895473834,"score_gpt":0.3203843541744941,"score_spread":0.2038353952197558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221022237","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016122285,0.0016749318,0.000041455354,0.9644895,0.03315471,0.0000042464208,0.000035176865,0.0000069091598,0.00043179822],"genre_scores_gemma":[0.0016767485,0.0006456407,0.00007614014,0.94110245,0.055254504,0.000018974408,0.000017260681,0.000012648676,0.0011956652],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937177,0.0023786472,0.0010937843,0.00088925555,0.0012018117,0.0007189005],"domain_scores_gemma":[0.9653526,0.02420145,0.0020886771,0.0011304765,0.0047034062,0.0025234567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072284886,0.00087764097,0.002845375,0.001560063,0.003793792,0.00445773,0.0023924536,0.059733443,0.0055420697],"category_scores_gemma":[0.05238772,0.0013090333,0.0014014136,0.0014555182,0.00561656,0.0048957025,0.0034836612,0.06398141,0.0048029493],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006913856,0.000013707313,0.00081635226,0.00009906532,0.000036383637,0.000856173,0.00029422907,0.0000310185,0.00008087952,0.0018838276,0.9914171,0.0044022063],"study_design_scores_gemma":[0.00034868147,0.000070931004,0.003388707,0.00094441464,0.00013661635,0.00350567,0.0016080792,0.00031258288,0.0003358985,0.01744926,0.9716874,0.00021177217],"about_ca_topic_score_codex":0.004683476,"about_ca_topic_score_gemma":0.0069886697,"teacher_disagreement_score":0.059733443,"about_ca_system_score_codex":0.0035936574,"about_ca_system_score_gemma":0.0031648658,"threshold_uncertainty_score":0.038228393},"labels":[],"label_agreement":null},{"id":"W4224529699","doi":"10.1016/s2352-3026(22)00045-x","title":"Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chemotherapy-related skin toxicity","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"National Center for Research Resources; National Heart, Lung, and Blood Institute; Genentech; Center for Clinical and Translational Science, Mayo Clinic; U.S. Food and Drug Administration; Medac; Swedish Orphan Biovitrum; Daiichi-Sankyo; Energy Market Authority of Singapore; Pfizer; Incyte; Yorkshire Cancer Research; Bayer Fund; TG Therapeutics; MorphoSys; UCB; National Institutes of Health; Regeneron Pharmaceuticals; Breast Cancer Now; Kræftens Bekæmpelse; Takeda Pharmaceuticals U.S.A.; Novartis; Celgene; Alnylam Pharmaceuticals; Sanofi; National Center for Advancing Translational Sciences; Teva Pharmaceutical Industries; Astellas Pharma; Georgia Clinical and Translational Science Alliance; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Bristol-Myers Squibb; Roche; Astellas Pharma US; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences","keywords":"Adverse effect; Context (archaeology); Clinical trial; Cancer; Hematology; Patient safety","score_opus":0.06402545302891255,"score_gpt":0.3630694404143654,"score_spread":0.29904398738545285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224529699","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015708597,0.4989907,0.07387093,0.3745851,0.010429876,0.0007371211,0.0038714577,0.0013959116,0.020410206],"genre_scores_gemma":[0.2473894,0.41281545,0.17049235,0.13086177,0.02684889,0.0011192954,0.0043994896,0.000745105,0.0053281826],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9001338,0.061137255,0.017931478,0.0041066017,0.015064004,0.0016267534],"domain_scores_gemma":[0.61708355,0.21951139,0.055521544,0.0230912,0.07824301,0.0065492284],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.12113467,0.0012686375,0.004501567,0.004166361,0.0008273559,0.012373518,0.0052198037,0.004172897,0.005606739],"category_scores_gemma":[0.24913853,0.0006967437,0.003091321,0.00449772,0.003558021,0.014559805,0.00656642,0.012942092,0.0020466635],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005510283,0.00019597798,0.02604366,0.009784389,0.00062796805,0.000101149984,0.0013721636,0.0018564283,0.001193406,0.017775543,0.069841996,0.8706563],"study_design_scores_gemma":[0.0004413544,0.002709661,0.09738961,0.04566126,0.0014682743,0.002052929,0.004086077,0.005670593,0.004097456,0.18535998,0.6502893,0.0007735709],"about_ca_topic_score_codex":0.008757194,"about_ca_topic_score_gemma":0.01185082,"teacher_disagreement_score":0.87886536,"about_ca_system_score_codex":0.004618284,"about_ca_system_score_gemma":0.00720378,"threshold_uncertainty_score":0.64062905},"labels":[],"label_agreement":null},{"id":"W4229458082","doi":"10.1016/s2352-3026(22)00103-x","title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Princess Margaret Cancer Centre; Institute of Cancer Research; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Celgene; European Hematology Association; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Clinical endpoint; Transplantation; Autologous stem-cell transplantation; Oncology; Surgery; Clinical trial","score_opus":0.062251826724128344,"score_gpt":0.36570004295411734,"score_spread":0.303448216229989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229458082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810157,0.009366122,0.0006189468,0.0017080236,0.0010208582,0.0019937914,0.0014007448,0.00019791146,0.002678089],"genre_scores_gemma":[0.98532087,0.0032260483,0.0013702157,0.0024714977,0.0005184247,0.0016133959,0.001537997,0.000035465655,0.0039061161],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999302,0.0003524396,0.000030617695,0.00013724397,0.000040228966,0.00013737452],"domain_scores_gemma":[0.99905664,0.00034938304,0.00016985675,0.0000677768,0.000041340823,0.00031508575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001908108,0.002059309,0.0029555117,0.0003928126,0.00043333502,0.0016407478,0.0014096603,0.002193376,0.008278829],"category_scores_gemma":[0.0017648309,0.00071386946,0.002865864,0.0003980901,0.0015272471,0.0017020523,0.00063306896,0.0048266333,0.0013680278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97914326,0.002794787,0.0004759702,0.0005048738,0.00095187046,0.000035137018,0.00005972728,0.00037461723,0.0009482712,0.00012176177,0.0009256947,0.013664028],"study_design_scores_gemma":[0.97486037,0.023037225,0.0009129437,0.000027952648,0.00026158566,0.000025230389,0.00001942662,0.00017047925,0.00010140122,0.00013071185,0.000440013,0.000012682862],"about_ca_topic_score_codex":0.0014195936,"about_ca_topic_score_gemma":0.0036364237,"teacher_disagreement_score":0.008278829,"about_ca_system_score_codex":0.0013497743,"about_ca_system_score_gemma":0.0010422912,"threshold_uncertainty_score":0.027695417},"labels":[],"label_agreement":null},{"id":"W4280594357","doi":"10.1016/s2352-3026(22)00102-8","title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Ruxolitinib; Medicine; Polycythaemia; Clinical endpoint; Internal medicine; Phlebotomy; Myelofibrosis; Polycythemia vera; Clinical trial; Randomized controlled trial; Pediatrics; Surgery; Bone marrow","score_opus":0.08405562557028219,"score_gpt":0.35526130428884,"score_spread":0.27120567871855783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280594357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874692,0.0069508604,0.00046779378,0.0009032423,0.00044363635,0.000767282,0.00138649,0.00011202634,0.0014994892],"genre_scores_gemma":[0.98939556,0.002751364,0.000739941,0.0012006965,0.00050637865,0.00094431144,0.0016289108,0.000044119093,0.0027887719],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852055,0.0008267212,0.00006248998,0.00020011175,0.000087338856,0.0003027808],"domain_scores_gemma":[0.9977877,0.0007303657,0.00051019015,0.0002513948,0.00010795314,0.00061230647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003764342,0.0022088059,0.004748315,0.00049513415,0.00053231174,0.0021443225,0.0012750985,0.0027303344,0.005078533],"category_scores_gemma":[0.0026257855,0.000819802,0.0042078267,0.00052424043,0.0015028451,0.002087883,0.0005634366,0.004731173,0.001377318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9753425,0.0040493687,0.00090610253,0.00041657785,0.0014375411,0.000072282484,0.00007199903,0.00050689885,0.0019331281,0.000075883705,0.0008571356,0.014330549],"study_design_scores_gemma":[0.91872674,0.07285008,0.005778559,0.00005460557,0.0009084132,0.000090000605,0.000052243922,0.0004257834,0.00029971523,0.00019079132,0.0005920504,0.000031075004],"about_ca_topic_score_codex":0.0014336052,"about_ca_topic_score_gemma":0.0024117415,"teacher_disagreement_score":0.005078533,"about_ca_system_score_codex":0.0011267489,"about_ca_system_score_gemma":0.00077080826,"threshold_uncertainty_score":0.019908011},"labels":[],"label_agreement":null},{"id":"W4281792225","doi":"10.1016/s2352-3026(22)00174-0","title":"Climate change and haematology: perspectives from the Philippines","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hematology; Internal medicine; Intensive care medicine","score_opus":0.11915282715021121,"score_gpt":0.3209336407305177,"score_spread":0.20178081358030653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281792225","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007519019,0.4957922,0.0001614865,0.48575103,0.0037345989,0.0000056157382,0.00039064814,0.000023585646,0.006621799],"genre_scores_gemma":[0.12059472,0.7770231,0.00039004305,0.07944761,0.019899664,0.000023636061,0.00016342496,0.000040234525,0.0024177015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885833,0.00052551733,0.000057012956,0.000077213386,0.00016439905,0.00031752425],"domain_scores_gemma":[0.9934975,0.0025695406,0.00081212725,0.00015152492,0.0014018463,0.0015673768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039840275,0.00092540827,0.00097282004,0.0014019861,0.0014856078,0.005467363,0.0009828709,0.005061333,0.011572458],"category_scores_gemma":[0.005387063,0.00026718996,0.0007981346,0.0034452772,0.003893526,0.00480147,0.0050044185,0.0070340517,0.0007844712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012283324,0.0003260596,0.036965836,0.010775122,0.0005311654,0.005164048,0.019285867,0.0026589418,0.0029760876,0.053928997,0.3985951,0.46756452],"study_design_scores_gemma":[0.00008390067,0.00024101978,0.049938057,0.006438737,0.00020582568,0.0010992708,0.02460364,0.00033835307,0.00030845718,0.021968229,0.89463466,0.00013982077],"about_ca_topic_score_codex":0.042819872,"about_ca_topic_score_gemma":0.05738275,"teacher_disagreement_score":0.042819872,"about_ca_system_score_codex":0.004675139,"about_ca_system_score_gemma":0.008023998,"threshold_uncertainty_score":0.08514124},"labels":[],"label_agreement":null},{"id":"W4283658919","doi":"10.1016/s2352-3026(22)00037-0","title":"Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute; VGH and UBC Hospital Foundation","keywords":"Medicine; Disease; Pathology","score_opus":0.016508713768927985,"score_gpt":0.25100828575868805,"score_spread":0.23449957198976007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283658919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9147889,0.011307359,0.0021723537,0.0041913087,0.0009664665,0.00032315095,0.00080786005,0.000306644,0.06513597],"genre_scores_gemma":[0.99520725,0.00068657566,0.00043915075,0.0006032032,0.0014500221,0.00001307835,0.00009466312,0.000021657828,0.0014844403],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9986111,0.00019277606,0.00013200419,0.00020173457,0.0002765095,0.00058586063],"domain_scores_gemma":[0.9961086,0.0015033166,0.0008452706,0.00047978645,0.00022364015,0.00083950086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008111534,0.0025637394,0.001658186,0.0027125878,0.00218173,0.0015717555,0.0019000191,0.0051376247,0.006854131],"category_scores_gemma":[0.004193113,0.001314098,0.0010081951,0.0024859407,0.0024691136,0.0012912404,0.0016710081,0.0030033104,0.0014261894],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023318225,0.00006447551,0.007926692,0.00013842668,0.00003745111,0.98756975,0.00009874857,0.00007423995,0.0009912046,0.0005715306,0.00066656276,0.0016277527],"study_design_scores_gemma":[0.00008563912,0.0000815121,0.017567938,0.000022052398,0.00003999565,0.98012596,0.00009194565,0.00022024078,0.0003833929,0.00040448664,0.0009605448,0.000016279022],"about_ca_topic_score_codex":0.002287824,"about_ca_topic_score_gemma":0.0020755967,"teacher_disagreement_score":0.006854131,"about_ca_system_score_codex":0.001292061,"about_ca_system_score_gemma":0.0008559353,"threshold_uncertainty_score":0.02292931},"labels":[],"label_agreement":null},{"id":"W4283744395","doi":"10.1016/s2352-3026(22)00173-9","title":"Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Heparin-Induced Thrombocytopenia and Thrombosis","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"LEO Pharma; Daiichi Sankyo Europe; Sanofi; Bayer HealthCare; University of Oxford; National Institute for Health and Care Research; Norgine; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Low molecular weight heparin; Population; Clinical endpoint; Randomized controlled trial; Adverse effect; Internal medicine; Clinical trial; Surgery; Pediatrics; Heparin","score_opus":0.06402574084759774,"score_gpt":0.3857780231439044,"score_spread":0.3217522822963067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283744395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98715997,0.007889811,0.00045132864,0.0006598933,0.0006802872,0.0012368044,0.0006104272,0.000076977136,0.0012344801],"genre_scores_gemma":[0.9891593,0.0037046557,0.0012169458,0.0011035893,0.0005266208,0.0017099493,0.0007520925,0.000018990602,0.0018078197],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992747,0.00039562458,0.00003931769,0.00011871205,0.000049113474,0.00012264999],"domain_scores_gemma":[0.9991417,0.0003062798,0.00018693836,0.00005284765,0.00004132156,0.00027098396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012330431,0.0014347791,0.0029821992,0.000361019,0.00039050743,0.0011141059,0.0009743506,0.0018185923,0.005559086],"category_scores_gemma":[0.002031885,0.00053292373,0.0017396972,0.0004259524,0.0012156316,0.00086227205,0.00039821744,0.003225923,0.00062229636],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9809021,0.0034834777,0.00047276227,0.00075893017,0.0009460057,0.000031333722,0.000042902237,0.0001571392,0.0010167367,0.0000872181,0.0005373859,0.011563946],"study_design_scores_gemma":[0.9580308,0.03961157,0.001304872,0.00004687566,0.0003258769,0.000023663493,0.00002202569,0.00021579117,0.00010198251,0.000088102424,0.00021948808,0.000009046113],"about_ca_topic_score_codex":0.0015454008,"about_ca_topic_score_gemma":0.0028491116,"teacher_disagreement_score":0.005559086,"about_ca_system_score_codex":0.00080621964,"about_ca_system_score_gemma":0.00087840477,"threshold_uncertainty_score":0.018597007},"labels":[],"label_agreement":null},{"id":"W4286264839","doi":"10.1016/s2352-3026(22)00240-x","title":"Reducing toxic waste: improving toxicity capture in childhood cancer","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Toxicity; Childhood cancer; Oncology; Intensive care medicine; Cancer; Environmental health; Internal medicine","score_opus":0.0343898653313362,"score_gpt":0.30899161107644463,"score_spread":0.2746017457451084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286264839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066808343,0.0019329828,0.00008266756,0.9900649,0.00576681,0.0000055325954,0.000030331725,0.000012730619,0.0014359072],"genre_scores_gemma":[0.011239759,0.0046776934,0.0004436415,0.9565351,0.019836724,0.0000456843,0.000043959055,0.000032842436,0.0071446393],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973502,0.00091593055,0.00028295317,0.00019972173,0.0008452228,0.00040593682],"domain_scores_gemma":[0.9921429,0.004447667,0.0005815319,0.00017169815,0.001236781,0.0014193645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003374524,0.0005491956,0.0009835056,0.000456332,0.002223335,0.0025997865,0.0014863437,0.027715754,0.0079554105],"category_scores_gemma":[0.020355685,0.00045057194,0.0013708129,0.0006099049,0.0022989626,0.0029012703,0.0022684615,0.027291398,0.002746884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012921156,0.000112566595,0.0026402394,0.00026283224,0.000054270367,0.0011685203,0.00033185811,0.00027702856,0.000623174,0.00624348,0.9447869,0.0433699],"study_design_scores_gemma":[0.0002579379,0.0002859025,0.004239684,0.0005288435,0.00008920261,0.0016618406,0.0009851495,0.00046664488,0.0008089419,0.016109202,0.9745079,0.000058778543],"about_ca_topic_score_codex":0.013289648,"about_ca_topic_score_gemma":0.02333223,"teacher_disagreement_score":0.027715754,"about_ca_system_score_codex":0.0044906223,"about_ca_system_score_gemma":0.007395488,"threshold_uncertainty_score":0.032581925},"labels":[],"label_agreement":null},{"id":"W4293708357","doi":"10.1016/s2352-3026(22)00215-0","title":"Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; Queen's University; Ottawa Hospital; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"Leids Universitair Medisch Centrum; LEO Pharma; Boston Scientific Corporation; Universiteit Leiden; King's College London; National Institute for Health and Care Research","keywords":"Medicine; Benchmarking; Venous thromboembolism; Outcome (game theory); Outcomes research; Set (abstract data type); Intensive care medicine; Health care; MEDLINE; Inclusion (mineral); Alternative medicine; Surgery","score_opus":0.22475972025404756,"score_gpt":0.429903519425277,"score_spread":0.20514379917122944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708357","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048449496,0.7457484,0.032862924,0.15493935,0.026120838,0.009972308,0.01335969,0.00057110866,0.011580564],"genre_scores_gemma":[0.041266695,0.5688235,0.2452383,0.08917224,0.0042479387,0.019625288,0.02717281,0.00036002434,0.0040930863],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.94576836,0.01640188,0.019867504,0.0033748432,0.012652652,0.0019348221],"domain_scores_gemma":[0.8938247,0.04540363,0.013355945,0.003249169,0.040539272,0.0036273692],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.084214434,0.0027947738,0.014129679,0.007563971,0.0019414427,0.0059964885,0.009093687,0.008210621,0.0032869347],"category_scores_gemma":[0.12150962,0.0019172848,0.021095492,0.0063242125,0.0022818532,0.0034602026,0.005248248,0.017363228,0.0019235068],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001269392,0.0005417064,0.011993881,0.20892547,0.02057985,0.00020048702,0.0007595704,0.0013166899,0.0009944529,0.018784937,0.19212851,0.54250497],"study_design_scores_gemma":[0.004635696,0.00072317215,0.030936299,0.4961465,0.055491522,0.00049326825,0.001113851,0.001962811,0.0022313986,0.013569747,0.39224985,0.00044588625],"about_ca_topic_score_codex":0.03905331,"about_ca_topic_score_gemma":0.046509206,"teacher_disagreement_score":0.91578555,"about_ca_system_score_codex":0.013394198,"about_ca_system_score_gemma":0.07196909,"threshold_uncertainty_score":0.44537383},"labels":[],"label_agreement":null},{"id":"W4293708402","doi":"10.1016/s2352-3026(22)00209-5","title":"Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years","year":2022,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; Population Health Research Institute; Canadian Hemophilia Society","funders":"Novo Nordisk; National Institutes of Health; World Federation of Hemophilia; CSL Behring; Roche; Bayer; Takeda Pharmaceutical Company; Women's Fund of Hawaii","keywords":"Medicine; Haemophilia; Middle income; Low and middle income countries; Family medicine; Economic growth; Pediatrics; Developing country; Demographic economics","score_opus":0.06779054807722965,"score_gpt":0.3846574054554025,"score_spread":0.3168668573781729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293708402","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059512404,0.9993475,0.000015689038,0.00028871853,0.00010779193,0.0000031880936,0.000019660927,0.0000017491251,0.00015620432],"genre_scores_gemma":[0.0007332925,0.9987841,0.00006549485,0.00024519206,0.00005765966,0.000005636183,0.00003192065,6.7906836e-7,0.00007603328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963415,0.00008624314,0.00006631392,0.00004446115,0.00009827873,0.00007062232],"domain_scores_gemma":[0.9993325,0.00035225507,0.00012063724,0.000011292983,0.00011901127,0.00006420893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014527327,0.00078072894,0.0020152156,0.001402513,0.00022299499,0.0012271636,0.0009437586,0.001315958,0.0035411944],"category_scores_gemma":[0.002036578,0.00023939155,0.0010370694,0.0020749192,0.00039956282,0.0012471777,0.0009132905,0.0017960815,0.0006402535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018041093,0.000053132804,0.00031121421,0.05948116,0.0004891597,0.00006623909,0.00007766581,0.00034460233,0.0002465363,0.0036044272,0.039834317,0.8953112],"study_design_scores_gemma":[0.00030001643,0.0003715052,0.0055809543,0.10013589,0.0016103258,0.0007424628,0.00041672404,0.0001729679,0.00029508624,0.0035532177,0.88676375,0.000057000103],"about_ca_topic_score_codex":0.0073477942,"about_ca_topic_score_gemma":0.012670382,"teacher_disagreement_score":0.0073477942,"about_ca_system_score_codex":0.0011956077,"about_ca_system_score_gemma":0.0036085134,"threshold_uncertainty_score":0.014610052},"labels":[],"label_agreement":null},{"id":"W4296817009","doi":"10.1016/s2352-3026(22)00317-9","title":"Blueprint for greater security of immunoglobulins for patients in Canada","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Blood Services","funders":"","keywords":"Medicine; Blueprint; Interim; Political science; Law","score_opus":0.028063324179270523,"score_gpt":0.24185357750828582,"score_spread":0.2137902533290153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296817009","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017142718,0.0019438365,0.00018170425,0.96007,0.013897287,0.000071174254,0.000298852,0.00008408096,0.021738734],"genre_scores_gemma":[0.00929318,0.0009903461,0.00047923127,0.9018594,0.004978089,0.00005059922,0.000091068876,0.000050248087,0.082207955],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99208856,0.00065254164,0.00043567398,0.00048639296,0.0027800743,0.0035567426],"domain_scores_gemma":[0.97260624,0.0043374957,0.0008574183,0.0005586368,0.0076509165,0.013989408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039647943,0.00070766156,0.0010553253,0.0012892681,0.009788704,0.0069931815,0.0023406749,0.062127925,0.0248322],"category_scores_gemma":[0.016605929,0.0011004842,0.0018578006,0.0012590926,0.005374911,0.0022952983,0.0027423603,0.030744296,0.0051865354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004234174,0.000031839045,0.00067453133,0.000042954867,0.000017462506,0.00048625973,0.00016108209,0.00013168657,0.00023597325,0.004390228,0.9895695,0.0042162593],"study_design_scores_gemma":[0.0001593358,0.00004573784,0.006649263,0.00023301365,0.00003954628,0.0003312019,0.0007159951,0.0004382949,0.00017012935,0.003570379,0.9875354,0.000111582594],"about_ca_topic_score_codex":0.9092057,"about_ca_topic_score_gemma":0.9625809,"teacher_disagreement_score":0.9552882,"about_ca_system_score_codex":0.0447118,"about_ca_system_score_gemma":0.18763103,"threshold_uncertainty_score":0.3244083},"labels":[],"label_agreement":null},{"id":"W4296901367","doi":"10.1016/s2352-3026(22)00297-6","title":"Prioritising health equity alongside donation safety","year":2022,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network","funders":"","keywords":"Medicine; Scopus; Family medicine; Donation; MEDLINE; Political science","score_opus":0.0733045916659028,"score_gpt":0.3590316530727404,"score_spread":0.28572706140683757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296901367","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017237905,0.0006147051,0.000058203597,0.9844258,0.012144302,0.000007939696,0.00002082214,0.000008642006,0.0025471465],"genre_scores_gemma":[0.0017268978,0.00031612924,0.00007992938,0.97477573,0.018056884,0.000020904383,0.0000111990885,0.000015281581,0.0049969847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859389,0.0037742143,0.001192063,0.0014319586,0.003705944,0.0039569726],"domain_scores_gemma":[0.9594419,0.020365162,0.0024626194,0.0009477102,0.0038870159,0.012895607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012367018,0.001245807,0.0021315333,0.00101461,0.01070364,0.015024406,0.0035610234,0.20528129,0.016435321],"category_scores_gemma":[0.06584262,0.0014915734,0.0021139686,0.0011878522,0.009455997,0.008552652,0.007746053,0.1187926,0.008416221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039563663,0.000029065695,0.00038144353,0.00006111556,0.000024713085,0.0010169583,0.000336439,0.00006203053,0.00020042098,0.013072225,0.97908795,0.005688093],"study_design_scores_gemma":[0.00019747586,0.000062377694,0.0009466181,0.00060446194,0.00006436674,0.0011835853,0.001246499,0.0004824781,0.00029371894,0.04670768,0.9480999,0.000110785324],"about_ca_topic_score_codex":0.015008206,"about_ca_topic_score_gemma":0.02576184,"teacher_disagreement_score":0.20528129,"about_ca_system_score_codex":0.008808981,"about_ca_system_score_gemma":0.024382042,"threshold_uncertainty_score":0.06540388},"labels":[],"label_agreement":null},{"id":"W4296932772","doi":"10.1016/s2352-3026(22)00214-9","title":"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Open label; Pyruvate kinase; Clinical trial; Internal medicine; Pediatrics; Surgery","score_opus":0.05312475385225649,"score_gpt":0.3087857028299263,"score_spread":0.2556609489776698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296932772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97821236,0.015149699,0.0008513185,0.0012589238,0.00055070926,0.0009373018,0.0008641592,0.0001846125,0.0019909611],"genre_scores_gemma":[0.9849172,0.007175603,0.0012495124,0.0016599868,0.00047691926,0.0011797186,0.0011548478,0.000026481568,0.0021597166],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997638,0.000110501445,0.000012229813,0.000042175496,0.000016749109,0.000054471402],"domain_scores_gemma":[0.9995963,0.00010849976,0.00009682303,0.000031637865,0.00002198304,0.00014478565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009159344,0.001095952,0.0022172313,0.00018411134,0.00025124667,0.0012093494,0.0005259938,0.0009953058,0.0035493472],"category_scores_gemma":[0.000955838,0.00029308742,0.0015147856,0.00028688033,0.00065859605,0.0008483819,0.00029988497,0.0029930538,0.00068039674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9147233,0.0038710563,0.00199622,0.0013105915,0.0026044373,0.00012433792,0.0000979819,0.0009058436,0.0051148525,0.0003703099,0.003218054,0.065662995],"study_design_scores_gemma":[0.91283804,0.07773066,0.004814673,0.000094352436,0.0009663933,0.00018399148,0.00005062469,0.00062430097,0.000515093,0.00041197106,0.0017420205,0.000027841443],"about_ca_topic_score_codex":0.0004422052,"about_ca_topic_score_gemma":0.0010140811,"teacher_disagreement_score":0.0035493472,"about_ca_system_score_codex":0.0004655267,"about_ca_system_score_gemma":0.0006328618,"threshold_uncertainty_score":0.011873722},"labels":[],"label_agreement":null},{"id":"W4303473194","doi":"10.1016/s2352-3026(22)00284-8","title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Multiple myeloma; Quality of life (healthcare); Refractory (planetary science); Clinical trial; Cancer; Chimeric antigen receptor; Oncology; Immunotherapy","score_opus":0.19861245780340173,"score_gpt":0.447965213090437,"score_spread":0.2493527552870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303473194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997773,0.0009363822,0.00010101236,0.00013965827,0.00005680249,0.00029151255,0.00033771445,0.000016429758,0.0003472969],"genre_scores_gemma":[0.99556476,0.00070415396,0.00036665154,0.00056029065,0.00018539453,0.0007020448,0.0010432706,0.0000072387465,0.0008661121],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955124,0.00020613598,0.000019632458,0.000077255085,0.000044213582,0.0001014887],"domain_scores_gemma":[0.99932194,0.00014057299,0.00016990835,0.00006071936,0.000037521128,0.0002694039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013555075,0.0012430298,0.001925508,0.0003106348,0.00038351273,0.00085130235,0.0006341904,0.0013277467,0.002656318],"category_scores_gemma":[0.0006639669,0.00043027438,0.0019199774,0.0004008546,0.00093864306,0.0008419721,0.00038272602,0.0028097255,0.0005135752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89837366,0.034948237,0.012045609,0.0005827651,0.0017821756,0.00010433885,0.0001401269,0.0007261273,0.0107960375,0.00008048238,0.0011791195,0.0392413],"study_design_scores_gemma":[0.5009291,0.44538197,0.049080882,0.000040847804,0.0011074417,0.000113115966,0.00006731358,0.00079827075,0.0012238366,0.0001119997,0.0011004076,0.00004496298],"about_ca_topic_score_codex":0.0007332192,"about_ca_topic_score_gemma":0.0013158728,"teacher_disagreement_score":0.002656318,"about_ca_system_score_codex":0.00069828564,"about_ca_system_score_gemma":0.00063319,"threshold_uncertainty_score":0.008886218},"labels":[],"label_agreement":null},{"id":"W4310121312","doi":"10.1016/s2352-3026(22)00247-2","title":"25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Compression stockings; Post-thrombotic syndrome; Deep vein; Thrombosis; Intention-to-treat analysis; Randomized controlled trial; Venous thrombosis; Confidence interval; Adverse effect; Internal medicine; Surgery","score_opus":0.045653173306074456,"score_gpt":0.32720634785827124,"score_spread":0.2815531745521968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310121312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962015,0.020338356,0.0013024596,0.0022523701,0.004086138,0.003652786,0.001453797,0.00032832118,0.0045708604],"genre_scores_gemma":[0.97210187,0.008719371,0.0018944863,0.0024698724,0.0021670402,0.0039012495,0.00096564536,0.00005009585,0.0077304537],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99914944,0.00039960063,0.00006809396,0.00016501975,0.00005638941,0.0001614865],"domain_scores_gemma":[0.9988024,0.0005107823,0.00024889922,0.00010012599,0.00005719874,0.0002807187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018070326,0.002485852,0.0054275123,0.0006988448,0.0005861055,0.0018577105,0.0012228725,0.0034486745,0.0114752315],"category_scores_gemma":[0.0027846075,0.0010513008,0.0033175193,0.0006094281,0.0018947265,0.0016035319,0.0005985547,0.004091999,0.0016441264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99239665,0.0011847214,0.00009731609,0.0006964771,0.0006609541,0.000028493329,0.000021746027,0.00008603674,0.000656651,0.00009591723,0.00035669503,0.003718177],"study_design_scores_gemma":[0.99214303,0.006974761,0.0002693341,0.000025868316,0.00027237769,0.000009840206,0.000007896074,0.000070496586,0.00004524971,0.000068097936,0.00010692374,0.000006021132],"about_ca_topic_score_codex":0.0016536878,"about_ca_topic_score_gemma":0.0027150824,"teacher_disagreement_score":0.0114752315,"about_ca_system_score_codex":0.0007143046,"about_ca_system_score_gemma":0.0009001331,"threshold_uncertainty_score":0.03838849},"labels":[],"label_agreement":null},{"id":"W4312211847","doi":"10.1016/s2352-3026(22)00373-8","title":"Towards reparatory measures: blood donation, health systems, and men who have sex with men","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood donation and transfusion practices","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"Medicine; Blood donor; Internal medicine; Gerontology; Intensive care medicine; Immunology","score_opus":0.03326485270114383,"score_gpt":0.2728790389968272,"score_spread":0.23961418629568337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312211847","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04159165,0.035294402,0.00023265679,0.911643,0.0018010559,0.000019816434,0.00005012666,0.000011341765,0.009355908],"genre_scores_gemma":[0.63140035,0.06497585,0.000767735,0.28806192,0.00619622,0.00008273551,0.00007747004,0.000027065278,0.008410681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872113,0.008915953,0.0005361557,0.000345283,0.0015023198,0.001488857],"domain_scores_gemma":[0.96101415,0.020215837,0.0074580004,0.0010886693,0.0029546784,0.0072687124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019778954,0.00031763382,0.0005263476,0.001154517,0.005599369,0.008587491,0.0012739185,0.00954669,0.009122701],"category_scores_gemma":[0.057156395,0.00047990205,0.00051627576,0.0024027296,0.013907714,0.013433222,0.005865775,0.014894219,0.0007431825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041743714,0.0006459828,0.110649094,0.0024019396,0.00037497235,0.0010688541,0.22617942,0.0002965789,0.00097287935,0.15906076,0.194181,0.303751],"study_design_scores_gemma":[0.0001671382,0.00070351944,0.13878633,0.008262162,0.00022020748,0.0011004881,0.3099726,0.0003675416,0.000865716,0.101457834,0.4378642,0.00023234537],"about_ca_topic_score_codex":0.017758768,"about_ca_topic_score_gemma":0.030756675,"teacher_disagreement_score":0.019778954,"about_ca_system_score_codex":0.0027767639,"about_ca_system_score_gemma":0.012896983,"threshold_uncertainty_score":0.10460234},"labels":[],"label_agreement":null},{"id":"W4318302179","doi":"10.1016/s2352-3026(22)00377-5","title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Hospices Civils de Lyon; F. Hoffmann-La Roche","keywords":"Medicine; Open label; Haemophilia; Physical therapy; Pediatrics; Internal medicine; Clinical trial","score_opus":0.18999977330478884,"score_gpt":0.4239973036752933,"score_spread":0.23399753037050447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318302179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99256456,0.0035720903,0.00036624033,0.00040473687,0.00014394452,0.0010232806,0.00053499785,0.000041956933,0.0013480678],"genre_scores_gemma":[0.9910535,0.0022912954,0.0012079258,0.0009952126,0.00017352868,0.0012717023,0.00059084437,0.000014417121,0.0024016222],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995042,0.00027187323,0.000020111273,0.00006405787,0.000047913665,0.00009185987],"domain_scores_gemma":[0.99943787,0.0001347796,0.00013134854,0.00003643402,0.00003092283,0.0002286043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018408116,0.0009814972,0.0018428629,0.00023424278,0.00043658112,0.0007754475,0.0004984926,0.0013620517,0.004224228],"category_scores_gemma":[0.0011399406,0.00044462213,0.0016483723,0.000250213,0.000799959,0.0009864268,0.00039762774,0.0022366256,0.0007935952],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91965246,0.017777056,0.004177203,0.0009208805,0.0015389407,0.00013426585,0.00020547229,0.00038007397,0.007542565,0.00017786842,0.0017184407,0.04577493],"study_design_scores_gemma":[0.8410363,0.13961902,0.016143514,0.00007484684,0.00072861556,0.00016086649,0.00006132653,0.00028954033,0.00045068175,0.00018005904,0.0012226796,0.000032582673],"about_ca_topic_score_codex":0.00077424437,"about_ca_topic_score_gemma":0.0019565467,"teacher_disagreement_score":0.004224228,"about_ca_system_score_codex":0.00040571552,"about_ca_system_score_gemma":0.00058438635,"threshold_uncertainty_score":0.014131486},"labels":[],"label_agreement":null},{"id":"W4318922870","doi":"10.1016/s2352-3026(22)00371-4","title":"Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"National Institutes of Health; National Cancer Institute; St. Baldrick's Foundation","keywords":"Medicine; Ethnic group; Cohort; Racial differences; Cohort study; Childhood leukaemia; Internal medicine; Acute lymphocytic leukemia; Demography; Oncology; Pediatrics; Gerontology; Leukemia; Lymphoblastic Leukemia","score_opus":0.0638022391813319,"score_gpt":0.39692676790558484,"score_spread":0.3331245287242529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318922870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97770864,0.017443372,0.00032400776,0.00033576775,0.00012362293,0.00016695392,0.0031291996,0.000016906122,0.0007514779],"genre_scores_gemma":[0.9949537,0.0022331984,0.0002846342,0.00034112975,0.00008348454,0.00019917419,0.0014705707,0.000016387645,0.00041773496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387556,0.0039393855,0.00047578028,0.0007801222,0.00030058526,0.0006285129],"domain_scores_gemma":[0.9933693,0.0024147746,0.001832294,0.0013617135,0.00035521944,0.0006666777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006467502,0.00070509204,0.0015536324,0.00043738735,0.00069222297,0.0016042984,0.0009439753,0.0009982255,0.0020296643],"category_scores_gemma":[0.00949548,0.0006580066,0.004277723,0.0015414834,0.00071560364,0.0007259131,0.0012704331,0.0017149429,0.00020691789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09069219,0.00081485324,0.7805918,0.0024126053,0.1045603,0.00027858187,0.00058907515,0.0006872932,0.0015881809,0.0008076431,0.004306485,0.012670991],"study_design_scores_gemma":[0.01699006,0.0034647568,0.91641515,0.0004556637,0.056254983,0.00027121784,0.00077615416,0.00047782186,0.00048487965,0.00055447605,0.0037834744,0.000071305294],"about_ca_topic_score_codex":0.012348713,"about_ca_topic_score_gemma":0.024589093,"teacher_disagreement_score":0.012348713,"about_ca_system_score_codex":0.00081955094,"about_ca_system_score_gemma":0.0013808202,"threshold_uncertainty_score":0.034203827},"labels":[],"label_agreement":null},{"id":"W4360821291","doi":"10.1016/s2352-3026(23)00036-4","title":"Superficial vein thrombosis in pregnancy: what we did not know could hurt our patients","year":2023,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Thrombosis; Venous thrombosis; Deep vein; Population; Internal medicine; Surgery","score_opus":0.07184835124389331,"score_gpt":0.32752685008460647,"score_spread":0.25567849884071314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360821291","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044179114,0.0024781364,0.000032200278,0.98679477,0.0086038895,0.000003789663,0.000011209965,0.000005763872,0.0016284286],"genre_scores_gemma":[0.010546828,0.0056951162,0.0001663081,0.90891874,0.07116647,0.000020823863,0.000018382287,0.000022367456,0.0034449983],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9959906,0.001459463,0.00057242747,0.0003104811,0.00095191045,0.00071517477],"domain_scores_gemma":[0.9835323,0.0075067617,0.0015837265,0.00040971226,0.0015963594,0.0053711683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030797601,0.00069043523,0.0011913775,0.0009870017,0.0050065606,0.0045158314,0.0013860388,0.061773885,0.0069088293],"category_scores_gemma":[0.044883817,0.0008308443,0.0010081081,0.0010656639,0.0037211145,0.0045085317,0.0019539702,0.052856904,0.0034187913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012187945,0.00009200944,0.004873849,0.00024408121,0.000069437934,0.027748216,0.0012963773,0.00012602902,0.00037423873,0.006371181,0.93510467,0.023578027],"study_design_scores_gemma":[0.00052191166,0.00034375268,0.007342044,0.003414644,0.00019356937,0.058757495,0.004994625,0.0007020223,0.0003798839,0.035658162,0.887445,0.0002468896],"about_ca_topic_score_codex":0.0065658414,"about_ca_topic_score_gemma":0.010096223,"teacher_disagreement_score":0.061773885,"about_ca_system_score_codex":0.004490929,"about_ca_system_score_gemma":0.0060685705,"threshold_uncertainty_score":0.03258413},"labels":[],"label_agreement":null},{"id":"W4361027080","doi":"10.1016/s2352-3026(23)00069-8","title":"Global representation among journal editors in haematology: are we diverse, equitable, and inclusive?","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Context (archaeology); Inclusion (mineral); Paragraph; Medicine; Diversity (politics); Sentence; Psychology; Political science; Law; Social psychology; History; Computer science","score_opus":0.06796460172463388,"score_gpt":0.37329474496606785,"score_spread":0.305330143241434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361027080","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.026920129,0.013752715,0.00057482615,0.9426884,0.005435617,0.000023867007,0.00015097798,0.000039923507,0.010413582],"genre_scores_gemma":[0.6370646,0.022738297,0.0016845084,0.3093129,0.024708312,0.00013195096,0.00032345182,0.00018022627,0.003855676],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.96238095,0.018303381,0.0018685412,0.0023853718,0.0073124124,0.007749296],"domain_scores_gemma":[0.8281824,0.06629186,0.019877406,0.00730157,0.013669695,0.06467713],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.05641255,0.0005252826,0.0013906334,0.0034500626,0.005567646,0.014577748,0.0023019786,0.007349781,0.011209989],"category_scores_gemma":[0.13530359,0.0007065632,0.0008337589,0.0038128146,0.012878712,0.017046867,0.018708142,0.010646939,0.0011176841],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004272198,0.00036016127,0.12312571,0.0024941836,0.0006079055,0.00080928125,0.05583679,0.0003722452,0.0009556749,0.083618656,0.43810672,0.2932855],"study_design_scores_gemma":[0.00042372366,0.0005131241,0.21272786,0.0056813643,0.0003445028,0.0009908325,0.074245565,0.00039294516,0.0005335578,0.11639764,0.5874429,0.00030603158],"about_ca_topic_score_codex":0.004939253,"about_ca_topic_score_gemma":0.0070291907,"teacher_disagreement_score":0.9435874,"about_ca_system_score_codex":0.004279913,"about_ca_system_score_gemma":0.016750356,"threshold_uncertainty_score":0.29834163},"labels":[],"label_agreement":null},{"id":"W4362510065","doi":"10.1016/s2352-3026(23)00061-3","title":"A long-awaited benchmark in lymphomatoid granulomatosis","year":2023,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Mononucleosis; Lymphomatoid granulomatosis; Immunology; Dermatology; Virus; Lymphoma","score_opus":0.0285397734106393,"score_gpt":0.28640031190840426,"score_spread":0.25786053849776497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362510065","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018632188,0.0018960198,0.000052876956,0.9803561,0.016222792,0.0000036760312,0.000012751685,0.000010734575,0.0012586855],"genre_scores_gemma":[0.005527061,0.0018519303,0.00022287431,0.8852943,0.10448327,0.000016876424,0.000025824313,0.000024639357,0.0025532884],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98954237,0.0039159195,0.0013034892,0.00086579024,0.0023685182,0.0020038327],"domain_scores_gemma":[0.95749533,0.021614373,0.0020847735,0.0013604163,0.0062441533,0.01120088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009903509,0.00091515156,0.0023533504,0.0012231626,0.006244939,0.010481389,0.0026022953,0.11972407,0.008512624],"category_scores_gemma":[0.057671692,0.00084420346,0.0019345989,0.0010404642,0.009273996,0.008405403,0.003974859,0.073600404,0.005876437],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077582576,0.00004488893,0.0006403891,0.00012999949,0.000025679179,0.004627331,0.00021841336,0.00009214749,0.00022158201,0.006699029,0.9764578,0.010765251],"study_design_scores_gemma":[0.00031277907,0.00014044448,0.0019790514,0.0015552704,0.00006147941,0.0061487625,0.0013604694,0.0006843866,0.00018645462,0.043615256,0.94381833,0.00013727811],"about_ca_topic_score_codex":0.0059629283,"about_ca_topic_score_gemma":0.013389913,"teacher_disagreement_score":0.11972407,"about_ca_system_score_codex":0.009073391,"about_ca_system_score_gemma":0.01069726,"threshold_uncertainty_score":0.06583238},"labels":[],"label_agreement":null},{"id":"W4366607155","doi":"10.1016/s2352-3026(23)00062-5","title":"Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Medical Research Council; National Institute for Health and Care Research; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Internal medicine; Population; Lymphoma; Oncology; Chemotherapy; Immunology; Immune system","score_opus":0.010968648447637177,"score_gpt":0.27560009410366065,"score_spread":0.2646314456560235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366607155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843797,0.011158263,0.00028971315,0.0006616136,0.00027821906,0.00016321718,0.0010411573,0.000051392468,0.0019767482],"genre_scores_gemma":[0.9952775,0.0015277155,0.0002623217,0.00062118226,0.00020873998,0.0001885751,0.0010475236,0.000015666923,0.00085083506],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9977087,0.0015678571,0.000088779256,0.00026662913,0.00010652616,0.00026147105],"domain_scores_gemma":[0.998116,0.0007933686,0.00045281326,0.00021230664,0.00007662942,0.00034879387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025175654,0.0012370404,0.0028052481,0.00019274285,0.00024376939,0.001193567,0.00087708666,0.0011718174,0.0021223794],"category_scores_gemma":[0.0027925996,0.0003624014,0.003723341,0.00026626684,0.0009656248,0.0010988011,0.00056572654,0.0035845814,0.00044177272],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94605905,0.0012637737,0.008162918,0.0013747293,0.010274177,0.00016755458,0.00008346392,0.0014329954,0.0023523376,0.00046964877,0.0028132552,0.025546053],"study_design_scores_gemma":[0.7743528,0.1262961,0.072751194,0.00053632905,0.014796351,0.00062789925,0.00016946386,0.0018629144,0.0021338142,0.0014019663,0.0049860356,0.00008503927],"about_ca_topic_score_codex":0.0011235591,"about_ca_topic_score_gemma":0.0023043468,"teacher_disagreement_score":0.0028052481,"about_ca_system_score_codex":0.0009786782,"about_ca_system_score_gemma":0.00064956944,"threshold_uncertainty_score":0.013314307},"labels":[],"label_agreement":null},{"id":"W4367673623","doi":"10.1016/s2352-3026(23)00030-3","title":"European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Ministero della Salute; Regeneron Pharmaceuticals; Associazione Italiana per la Ricerca sul Cancro; Celgene; Society of Nuclear Medicine and Molecular Imaging; Gilead Sciences; Sanofi; Siemens Healthineers; Bristol-Myers Squibb; Amgen","keywords":"Appropriate Use Criteria; Medicine; Delphi method; Medical physics; Evidence-based medicine; MEDLINE; Interim; Expert opinion; Consensus conference; Family medicine; Alternative medicine; Artificial intelligence; Computer science; Pathology; Political science; Intensive care medicine; Internal medicine","score_opus":0.09752737482974728,"score_gpt":0.374843280926998,"score_spread":0.2773159060972507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367673623","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008242559,0.9847551,0.0003397312,0.0087953545,0.0027680155,0.000074189076,0.0002841857,0.00003560846,0.0028654465],"genre_scores_gemma":[0.00074069866,0.9871831,0.0011633805,0.007835455,0.0009716446,0.00010154779,0.00043844094,0.000011488948,0.0015541575],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979964,0.00057417323,0.00042679207,0.00015481019,0.0006430352,0.00020486733],"domain_scores_gemma":[0.9936972,0.0032077758,0.0010231321,0.00010732782,0.0015929134,0.000371721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006958499,0.0010458042,0.0035208513,0.0054677967,0.0005526683,0.0023223548,0.002430804,0.004984835,0.008234003],"category_scores_gemma":[0.008835137,0.0005488171,0.0024914665,0.004078018,0.00083646836,0.0016090798,0.0022320587,0.0044483095,0.0035762188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024978438,0.00007763579,0.00025289803,0.05419729,0.00040670738,0.00019927067,0.00009501909,0.00039374176,0.00081379036,0.0043880334,0.26324517,0.67568076],"study_design_scores_gemma":[0.0001712356,0.00010521245,0.0009997446,0.047975723,0.00086258654,0.00037601212,0.000064149135,0.00008804388,0.00018733124,0.002423657,0.94671685,0.000029579365],"about_ca_topic_score_codex":0.007275289,"about_ca_topic_score_gemma":0.011198262,"teacher_disagreement_score":0.008234003,"about_ca_system_score_codex":0.003250932,"about_ca_system_score_gemma":0.010912039,"threshold_uncertainty_score":0.036800504},"labels":[],"label_agreement":null},{"id":"W4378979009","doi":"10.1016/s2352-3026(23)00094-7","title":"Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute; University of California, San Francisco; Centers for Disease Control and Prevention; Dana-Farber/Harvard Cancer Center; University of Southern California; California Department of Public Health; American Society of Hematology","keywords":"Medicine; Lymphoma; Diffuse large B-cell lymphoma; Mental health; Gerontology; Internal medicine; Pediatrics; Oncology; Psychiatry","score_opus":0.015844687599885176,"score_gpt":0.28512575649984684,"score_spread":0.2692810688999617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378979009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985422,0.0002618757,0.00002863177,0.00009768677,0.000012110478,0.0000068728373,0.00066746346,0.0000019907013,0.00038115197],"genre_scores_gemma":[0.9991517,0.00017189434,0.000022863465,0.00009860223,0.000018977105,0.000007803154,0.0004182669,0.000001089843,0.00010873971],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99969614,0.00007891264,0.000031603624,0.00007627498,0.000045453875,0.000071680224],"domain_scores_gemma":[0.9992636,0.000076733035,0.0002880763,0.000047157268,0.000078742305,0.00024572702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032254105,0.00032645694,0.0004385039,0.0008352912,0.00053847244,0.00085836597,0.00037038588,0.0008540452,0.0011226882],"category_scores_gemma":[0.000982342,0.00041125782,0.0007132048,0.001919949,0.0003288707,0.000880772,0.0005340152,0.0010322728,0.00019408319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000904976,0.00007169047,0.99892503,0.000007220691,0.00012253704,0.000049662234,0.000072117684,0.000017173992,0.00008326263,0.0000079003175,0.00014908484,0.00040375322],"study_design_scores_gemma":[0.000007652776,0.00004367985,0.99946445,0.000004264529,0.000040695,0.00007076147,0.00022968842,0.000051029532,0.000005371379,0.0000111905065,0.000067833054,0.0000033723297],"about_ca_topic_score_codex":0.020922642,"about_ca_topic_score_gemma":0.027081344,"teacher_disagreement_score":0.020922642,"about_ca_system_score_codex":0.00045013576,"about_ca_system_score_gemma":0.00031051753,"threshold_uncertainty_score":0.041601717},"labels":[],"label_agreement":null},{"id":"W4380986318","doi":"10.1016/s2352-3026(23)00118-7","title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":666,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sistema Nacional de Investigadores; Warwick Medical School; National Health and Medical Research Council; Medical Research Council; Universidad Autónoma de Sinaloa; Secretaría Nacional de Ciencia, Tecnología e Innovación; Shahid Beheshti University of Medical Sciences; Universidad Nacional Autónoma de México; University of Jordan; Universitetet i Bergen; Jawaharlal Institute Of Postgraduate Medical Education and Research; Ahvaz Jundishapur University of Medical Sciences; Tehran University of Medical Sciences and Health Services; Sultan Qaboos University; Shiraz University of Medical Sciences; Shiraz University; Uniwersytet Łódzki; King Abdulaziz University; Manipal Academy of Higher Education; Isfahan University of Medical Sciences; Banaras Hindu University; Department of Sport and Recreation, Government of Western Australia; University of Sydney; Ministero della Salute; Southern Cross University; University Grants Commission; Indian Council of Medical Research; National Institute for Health and Care Research; Ministry of Health and Medical Education; University of Pretoria; Babol University of Medical Sciences; Cleveland Clinic; York University; Science and Technology Development Fund; University of Toronto; Macquarie University; Imperial College London; Philadelphia University; University of Technology Sydney; University of Warwick; Høgskulen på Vestlandet; University of Central Punjab; University of Aberdeen; Universidade de São Paulo; South Eastern Sydney Local Health District; Cleveland Clinic Foundation; Florida International University; Ain Shams University; King Abdulaziz City for Science and Technology; Academy of Scientific Research and Technology; Shaqra University; Tulane University; Iran University of Medical Sciences; Chandigarh University; Trường Đại học Duy Tân; Alfaisal University; Kasturba Medical College, Manipal; University of New South Wales; Yale University; Karolinska Institutet; Bill and Melinda Gates Foundation","keywords":"Medicine; Disease; Epidemiology; Population; Incidence (geometry); Disease burden; Mortality rate; Pediatrics; Acute chest syndrome; Sickle cell anemia; Demography; Environmental health; Internal medicine","score_opus":0.026363326781828348,"score_gpt":0.3061564235177414,"score_spread":0.27979309673591307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380986318","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19508864,0.7115671,0.0045777727,0.0023056914,0.0003107481,0.0006953803,0.083984055,0.0001588274,0.001311759],"genre_scores_gemma":[0.7122841,0.24338251,0.0066628256,0.0015508531,0.00020200315,0.0017055653,0.033661216,0.00006660607,0.000484372],"study_design_codex":"observational","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9940976,0.0024286015,0.0014300136,0.0009402873,0.00089671125,0.00020682029],"domain_scores_gemma":[0.9912873,0.0030875967,0.0027480233,0.0006492312,0.00198127,0.00024658116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009907521,0.0009912414,0.0027203707,0.00863581,0.00028986472,0.00092702976,0.00075130205,0.0007932331,0.0009770887],"category_scores_gemma":[0.015525255,0.0008160189,0.009189009,0.010383261,0.0005342295,0.0006042447,0.001701844,0.0007192111,0.00023062013],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018981459,0.00006292534,0.5782081,0.14802985,0.13453163,0.00065486535,0.0020061957,0.00436499,0.0010974186,0.0012271082,0.026375424,0.10154344],"study_design_scores_gemma":[0.00088061934,0.00036776884,0.7894903,0.04752217,0.13223535,0.0010971741,0.0009345072,0.0025165058,0.0005478977,0.0010655129,0.0231413,0.00020096144],"about_ca_topic_score_codex":0.036303382,"about_ca_topic_score_gemma":0.064515375,"teacher_disagreement_score":0.036303382,"about_ca_system_score_codex":0.0014426234,"about_ca_system_score_gemma":0.0049351696,"threshold_uncertainty_score":0.072184145},"labels":[],"label_agreement":null},{"id":"W4382934820","doi":"10.1016/s2352-3026(23)00088-1","title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Dasatinib; Internal medicine; Chemotherapy; Minimal residual disease; Clinical endpoint; Acute lymphocytic leukemia; Imatinib; Induction chemotherapy; Hematopoietic stem cell transplantation; Oncology; Chemotherapy regimen; Transplantation; Surgery; Pediatrics; Clinical trial; Leukemia; Lymphoblastic Leukemia","score_opus":0.035050732731479066,"score_gpt":0.3213202882339479,"score_spread":0.28626955550246885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382934820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839236,0.008779677,0.0005247629,0.0012258147,0.00029267458,0.0007133624,0.0013034153,0.00014964773,0.003087166],"genre_scores_gemma":[0.98780084,0.004753162,0.0010277146,0.0012528832,0.0001276326,0.00083231507,0.0016615856,0.000027921087,0.0025159398],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955815,0.0002201429,0.000024210813,0.00007629296,0.00003692578,0.00008422855],"domain_scores_gemma":[0.9995382,0.000083574036,0.000099606375,0.000044541503,0.000022372962,0.00021167909],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097208127,0.0012217212,0.0024645668,0.0002294181,0.00023424144,0.0010127254,0.00075300504,0.0009482458,0.0036277717],"category_scores_gemma":[0.00089908525,0.00029661442,0.0014380923,0.00043789073,0.0008042997,0.00093624805,0.00042749877,0.0031070611,0.00085661083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7515615,0.0065075657,0.004715171,0.0026641989,0.005244608,0.0003238271,0.00030180922,0.004993618,0.010922496,0.0009776166,0.010374238,0.20141341],"study_design_scores_gemma":[0.91495687,0.06583187,0.009726974,0.00009091638,0.00090466766,0.0004771291,0.000092312,0.001036546,0.0009154572,0.00096755475,0.004957354,0.000042426458],"about_ca_topic_score_codex":0.0007304188,"about_ca_topic_score_gemma":0.0026043952,"teacher_disagreement_score":0.0036277717,"about_ca_system_score_codex":0.0009215556,"about_ca_system_score_gemma":0.00083734526,"threshold_uncertainty_score":0.012136102},"labels":[],"label_agreement":null},{"id":"W4383873996","doi":"10.1016/s2352-3026(23)00158-8","title":"Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Disease; Psychological intervention; Public health; Quality of life (healthcare); Gerontology; Pediatrics; Intensive care medicine; Family medicine; Internal medicine; Psychiatry; Pathology; Nursing","score_opus":0.06994973778607058,"score_gpt":0.29291467049328573,"score_spread":0.22296493270721515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383873996","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08007385,0.06923822,0.00064961024,0.82730114,0.0034135005,0.0001358272,0.0004420137,0.000037941023,0.018707821],"genre_scores_gemma":[0.8471777,0.07471661,0.0029676964,0.059730586,0.0022335497,0.00039538956,0.00034900662,0.000049287453,0.012380194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971234,0.0012353206,0.00012539834,0.00014911203,0.00019356467,0.0011731958],"domain_scores_gemma":[0.9879638,0.0041169883,0.0013336403,0.00031880147,0.0008498758,0.005416863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074387444,0.00050416845,0.000478344,0.0009251891,0.0020044586,0.0038122388,0.00094323535,0.0030405642,0.008906218],"category_scores_gemma":[0.012483614,0.00036004148,0.00026990188,0.0016288782,0.0049993023,0.0039093327,0.006410809,0.0045042518,0.00034102978],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007529078,0.0010503795,0.08853605,0.0075820354,0.00027719996,0.0085426755,0.05414442,0.0018154122,0.0043069087,0.1804924,0.19332485,0.45917478],"study_design_scores_gemma":[0.00059037114,0.0007936297,0.23140539,0.010653943,0.0001683545,0.0014909338,0.0693114,0.0006598329,0.0011123638,0.042684935,0.6409786,0.00015022632],"about_ca_topic_score_codex":0.039277513,"about_ca_topic_score_gemma":0.052424062,"teacher_disagreement_score":0.039277513,"about_ca_system_score_codex":0.008993126,"about_ca_system_score_gemma":0.032893367,"threshold_uncertainty_score":0.07809782},"labels":[],"label_agreement":null},{"id":"W4383874164","doi":"10.1016/s2352-3026(23)00096-0","title":"Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Medical Research Council; Fondation Pierre Fabre; TauRx Pharmaceuticals; bluebird bio; Sangamo Therapeutics; Les Laboratories Pierre Fabre; Vertex Pharmaceuticals; National Institute for Health and Care Excellence; European Hematology Association; European Commission; World Health Organization; GlaxoSmithKline; National Heart, Lung, and Blood Institute; Pfizer; Northwestern University; Doris Duke Charitable Foundation; American Society of Hematology; HORIZON EUROPE Framework Programme; Health Resources and Services Administration; Agios Pharmaceuticals; Wellcome Trust","keywords":"Medicine; Hematology; Intensive care medicine; Disease; Internal medicine","score_opus":0.04810619309733443,"score_gpt":0.37523118629591523,"score_spread":0.3271249931985808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383874164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034329714,0.97846276,0.000077583965,0.01621945,0.004497197,0.0000067472333,0.000043727305,0.000011237632,0.0006469062],"genre_scores_gemma":[0.00087894604,0.981389,0.00026073708,0.013700691,0.0030341833,0.000021939237,0.000065869666,0.000006226695,0.0006424089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980586,0.0006264759,0.00025738412,0.00015831697,0.0006046944,0.00029461796],"domain_scores_gemma":[0.9924455,0.0044230083,0.0006021056,0.00015323929,0.0016151736,0.00076103874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007950956,0.0015548569,0.0037436876,0.001972499,0.00056447,0.0030648618,0.0017599947,0.0049598604,0.007027051],"category_scores_gemma":[0.011335964,0.00048972777,0.0014519175,0.0026926128,0.0013417375,0.004077418,0.0026256696,0.008168308,0.0021024453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020967827,0.00006736572,0.00016031087,0.023795955,0.00038888305,0.0001297867,0.00015082983,0.00046516318,0.00029500166,0.01775118,0.40379062,0.5527953],"study_design_scores_gemma":[0.00016492682,0.00008185005,0.0007437377,0.03145489,0.00031345076,0.00015172803,0.0001712632,0.000092830545,0.000056399804,0.008390242,0.9583461,0.000032531007],"about_ca_topic_score_codex":0.006488789,"about_ca_topic_score_gemma":0.012320087,"teacher_disagreement_score":0.007950956,"about_ca_system_score_codex":0.0038657167,"about_ca_system_score_gemma":0.013453718,"threshold_uncertainty_score":0.04204923},"labels":[],"label_agreement":null},{"id":"W4385297552","doi":"10.1016/s2352-3026(23)00174-6","title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Internal medicine; Danazol; Clinical endpoint; Ruxolitinib; Anemia; Post-hoc analysis; Randomized controlled trial; Intention-to-treat analysis; Adverse effect; Placebo; Gastroenterology; Surgery; Bone marrow; Endometriosis","score_opus":0.04147677945176609,"score_gpt":0.34679700797642826,"score_spread":0.3053202285246622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385297552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93296385,0.056534708,0.0011813104,0.0014866004,0.0009842048,0.0010657061,0.0019096038,0.00019471576,0.0036792906],"genre_scores_gemma":[0.9818076,0.011766783,0.001222178,0.0015049312,0.00043093858,0.0005117983,0.0012448197,0.000033815097,0.0014771933],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99895406,0.00061364396,0.00010147509,0.0001324654,0.00009176327,0.00010649682],"domain_scores_gemma":[0.9981468,0.00088505255,0.0005261774,0.00012149174,0.00009716642,0.00022330243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025100028,0.0010659844,0.0034129932,0.0005296256,0.0002797433,0.0013394431,0.0006241484,0.0011404238,0.0034605463],"category_scores_gemma":[0.0034371517,0.0005135461,0.0035037184,0.00064390065,0.00072190666,0.0013440709,0.0004030187,0.0024432614,0.0004472924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94195545,0.00081187184,0.0017032736,0.0021250898,0.0072880317,0.0000644557,0.00007494582,0.00048502476,0.0023267118,0.00016133353,0.0010351992,0.041968517],"study_design_scores_gemma":[0.94767195,0.031972643,0.0088291885,0.00025748747,0.0081043085,0.00013367042,0.00006472255,0.0004663298,0.00040224864,0.0003439791,0.0017029704,0.000050392617],"about_ca_topic_score_codex":0.00079749216,"about_ca_topic_score_gemma":0.002875898,"teacher_disagreement_score":0.0034605463,"about_ca_system_score_codex":0.0007072668,"about_ca_system_score_gemma":0.0007266166,"threshold_uncertainty_score":0.013274312},"labels":[],"label_agreement":null},{"id":"W4385412860","doi":"10.1016/s2352-3026(23)00160-6","title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":551,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; National Health and Medical Research Council; Directorate for Biological Sciences; Uniwersytet Opolski; George Institute for Global Health; Madda Walabu University; Sydney Medical School; Minderoo Foundation; ARC Centre of Excellence for Children and Families over the Life Course; Shahid Sadoughi University of Medical Sciences; Lingnan University; Kurdistan University Of Medical Sciences; Lorestan University of Medical Sciences; University of Thessaly; Alexandria University; University of Colombo; National Institute of Pharmaceutical Education and Research, Raebareli; Jawaharlal Institute Of Postgraduate Medical Education and Research; University of Peradeniya; Xiamen University; University of the Ryukyus; Dire Dawa University; Zanjan University of Medical Sciences; Tarbiat Modares University; National Research, Development and Innovation Office; National Nutrition and Food Technology Research Institute; Alfaisal University; University of Gondar; Ilam University; Universitatea de Medicină şi Farmacie \"Carol Davila\" Bucureşti; University of Sulaimani; Majmaah University; Savitribai Phule Pune University; Shaqra University; Pomorski Uniwersytet Medyczny W Szczecinie; Universidade Federal de Minas Gerais; Universitatea din București; Arak University of Medical Sciences; University of Cape Town; University of California, San Diego; Universidade Federal de Santa Catarina; Technische Universität Berlin; Direktorat Jenderal Pendidikan Tinggi; University of South Carolina; Cooperativa de Ensino Superior Politécnico e Universitário; University of Hail; Universidade do Porto; Centre Hospitalier Universitaire Vaudois; Emory University; United Arab Emirates University; Sabzevar University of Medical Sciences; Bangladesh University of Health Sciences; Cancer Institute NSW; Shahid Beheshti University of Medical Sciences; Gonabad University of Medical Sciences; University of the Philippines; Universidad Nacional Autónoma de México; Universidade de São Paulo; National and Kapodistrian University of Athens; University of Veterinary and Animal Sciences; Chinese University of Hong Kong; Cleveland Clinic; Taipei Medical University; Inyuvesi Yakwazulu-Natali; Universiti Sains Malaysia; Oulun Yliopisto; Isfahan University of Medical Sciences; Universiti Malaya; Ain Shams University; Shiraz University of Medical Sciences; Rajiv Gandhi University of Health Sciences; Uniwersytet Łódzki; King Abdulaziz University; Ilam University of Medical Sciences; Universitas Padjadjaran; University of the Western Cape; Universidad Autónoma de Sinaloa; Università di Catania; Bundesministerium für Gesundheit; Gachon University; Adigrat University; Universitetet i Bergen; King Saud University; Universitas Syiah Kuala; Shiraz University; National Natural Science Foundation of China; Hamadan University of Medical Sciences; Semmelweis Egyetem; Deakin University; Public Health Agency; Wollega University; Universiteit Stellenbosch; University of Leeds; Public Health Foundation of India; Indian Council of Medical Research; Masarykova Univerzita; Guilan University of Medical Sciences; Qazvin University of Medical Sciences; University of Queensland; National Institute for Health and Care Research; University of Toronto; Stanford Cardiovascular Institute, School of Medicine, Stanford University; Macquarie University; Kasturba Medical College, Manipal; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education; Universiteit Utrecht; Nankai University; Banaras Hindu University; Høgskulen på Vestlandet; Coventry University; Babol University of Medical Sciences; Universidad de Colima; Karolinska Institutet; United Nations Population Fund; Universitas Indonesia; University of Technology Sydney; Salahaddin University-Erbil; Uppsala Universitet; University of Embu; Samara University; Jordan University of Science and Technology; McMaster University; Morehouse School of Medicine; Tabriz University of Medical Sciences; Addis Ababa University; Sultan Qaboos University; Canadian Institutes of Health Research; University of Tabriz; Ahmadu Bello University; South Eastern Sydney Local Health District; Nazarbayev University; Charles Sturt University; Student Research Committee, Tabriz University of Medical Sciences; Bahir Dar University; Sheffield Hallam University; New Mexico State University; Trường Đại học Duy Tân; Applied Molecular Biosciences Unit; Iran University of Medical Sciences; University of Zanjan; Florida International University; Amity University; Mazandaran University of Medical Sciences; Zahedan University of Medical Sciences; Harvard University; University of Aberdeen; Case Western Reserve University; International Centre for Diarrhoeal Disease Research, Bangladesh; Washington University in St. Louis; University of New South Wales; Dongguk University; Jazan University; U.S. Department of Veterans Affairs; Akademiska Sjukhuset; Ekiti State University; Public Health Agency of Canada; Anglia Ruskin University; University of Canberra; Dilla University; Universität Basel; Central Taiwan University of Science and Technology; Bill and Melinda Gates Foundation","keywords":"Medicine; Burden of disease; Disease burden; Demography; Population; Disease; Demographics; Global health; Environmental health; Pediatrics; Public health; Internal medicine; Pathology","score_opus":0.02196993615495434,"score_gpt":0.30235018863455443,"score_spread":0.2803802524796001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385412860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88817644,0.009097089,0.001183893,0.0018686113,0.00008472855,0.00011295291,0.095558755,0.000086768276,0.0038307116],"genre_scores_gemma":[0.95991784,0.002977344,0.0007459747,0.0003338653,0.00004975069,0.00014371671,0.035162997,0.000014764456,0.0006537083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934095,0.00019634199,0.000110485365,0.00010443997,0.00015307107,0.00009469955],"domain_scores_gemma":[0.99814165,0.00023060087,0.00086044555,0.000071333816,0.00046465412,0.00023135729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001962303,0.00033393299,0.00039141162,0.0016338223,0.00029455865,0.0006031875,0.00052024896,0.00042124387,0.0011570409],"category_scores_gemma":[0.003695303,0.00029233057,0.0012438259,0.002539126,0.0002472548,0.00078067277,0.0010260801,0.0007301196,0.00042955618],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000832355,0.000019601615,0.9887989,0.00019575619,0.00022315545,0.000035260604,0.0004167554,0.000511474,0.000046112826,0.00007635556,0.0044548893,0.005138352],"study_design_scores_gemma":[0.0000087734825,0.000028770131,0.9976046,0.00008624676,0.00006481082,0.000086589025,0.0002709782,0.00036041602,0.000012706676,0.000054171196,0.0014155443,0.0000063075254],"about_ca_topic_score_codex":0.076515116,"about_ca_topic_score_gemma":0.06926701,"teacher_disagreement_score":0.076515116,"about_ca_system_score_codex":0.00096176344,"about_ca_system_score_gemma":0.0008711287,"threshold_uncertainty_score":0.15213948},"labels":[],"label_agreement":null},{"id":"W4385689290","doi":"10.1016/s2352-3026(23)00159-x","title":"Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Medicine; Myeloid leukaemia; Perspective (graphical); Intensive care medicine; Disease; Drug response; Health care; Clinical trial; Risk analysis (engineering); Drug; Computer science; Immunology; Artificial intelligence; Pathology; Psychiatry","score_opus":0.23415766790350245,"score_gpt":0.4443996815337133,"score_spread":0.21024201363021083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385689290","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016870706,0.9731695,0.00046129138,0.023897279,0.001682457,0.000029430963,0.00006979578,0.000008338789,0.00051310915],"genre_scores_gemma":[0.003819186,0.9777099,0.003691337,0.01242552,0.0018465595,0.00007244936,0.00017641574,0.000014859995,0.0002437634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881328,0.0055797263,0.0024814813,0.0009282633,0.0023283118,0.00054947165],"domain_scores_gemma":[0.944281,0.034616258,0.0035664325,0.0010101547,0.015359616,0.0011664232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052210327,0.0012735485,0.0056363074,0.003493891,0.0005447644,0.0047485293,0.0041468344,0.004878472,0.0020576292],"category_scores_gemma":[0.060747433,0.0005805049,0.0029328247,0.0040093013,0.001994148,0.0047000404,0.002204322,0.009141984,0.0008896459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036853945,0.00006658972,0.0007242512,0.0398897,0.0011503577,0.000097301374,0.00048608068,0.0009758583,0.00056669157,0.01683806,0.070241675,0.8685949],"study_design_scores_gemma":[0.00041461608,0.00035341756,0.0031089433,0.14759012,0.0023785108,0.0003498804,0.00082917325,0.000576118,0.00048440445,0.019462649,0.82432646,0.00012570816],"about_ca_topic_score_codex":0.010389015,"about_ca_topic_score_gemma":0.013718016,"teacher_disagreement_score":0.052210327,"about_ca_system_score_codex":0.006159151,"about_ca_system_score_gemma":0.02023005,"threshold_uncertainty_score":0.27611792},"labels":[],"label_agreement":null},{"id":"W4388736571","doi":"10.1016/s2352-3026(23)00339-3","title":"Thromboprophylaxis in paediatric acute lymphoblastic leukaemia","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Impact; McMaster Children's Hospital","funders":"","keywords":"Medicine; Pediatrics; Venous thromboembolism; Lymphoblastic Leukemia; Internal medicine; Low molecular weight heparin; Thrombosis; Leukemia","score_opus":0.032990869520327475,"score_gpt":0.3218957363652994,"score_spread":0.2889048668449719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388736571","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02138471,0.9027438,0.00022513121,0.06632497,0.0025194844,0.000031038177,0.0004616243,0.0000319533,0.006277387],"genre_scores_gemma":[0.19943723,0.771749,0.0011102108,0.014423174,0.008995908,0.00025253225,0.00071061315,0.000024705327,0.0032965401],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985709,0.0007057268,0.00022368469,0.0000681794,0.00028972083,0.00014169114],"domain_scores_gemma":[0.9936724,0.0039948886,0.0015620333,0.0000939877,0.0002598635,0.00041684898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020066777,0.00027793742,0.0008747223,0.0007379861,0.00028359768,0.0009113598,0.00036617808,0.0013636377,0.0049219877],"category_scores_gemma":[0.010082336,0.00019509142,0.00067408325,0.0011006823,0.0005287041,0.00035411515,0.0004543802,0.0038962027,0.0004707077],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026402532,0.00041499556,0.037794877,0.011851444,0.0012769134,0.00222664,0.00047665057,0.0011419296,0.0014319714,0.013791611,0.10874076,0.818212],"study_design_scores_gemma":[0.0057560108,0.007797351,0.30809978,0.029917791,0.0036039012,0.01818291,0.001280544,0.0015321954,0.0030839178,0.019457873,0.60117435,0.000113436006],"about_ca_topic_score_codex":0.0031876338,"about_ca_topic_score_gemma":0.003968719,"teacher_disagreement_score":0.0049219877,"about_ca_system_score_codex":0.0011744658,"about_ca_system_score_gemma":0.0023753366,"threshold_uncertainty_score":0.016465724},"labels":[],"label_agreement":null},{"id":"W4388736594","doi":"10.1016/s2352-3026(23)00314-9","title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bristol-Myers Squibb","keywords":"Medicine; Apixaban; Population; Internal medicine; Surgery; Pediatrics; Warfarin; Rivaroxaban","score_opus":0.06430429640012142,"score_gpt":0.36798972023862675,"score_spread":0.30368542383850533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388736594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9546308,0.033497326,0.0012331703,0.0016039106,0.0020616835,0.0028084642,0.0012199454,0.00025784172,0.0026868263],"genre_scores_gemma":[0.9744255,0.014201933,0.002129903,0.0014115333,0.0009526011,0.0034053903,0.0007876532,0.000041199408,0.002644115],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99933904,0.00035058957,0.000051904583,0.0001283743,0.00005219287,0.00007782086],"domain_scores_gemma":[0.9990283,0.00046068325,0.00020630872,0.00006516206,0.00003702815,0.00020257937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015234387,0.0018091549,0.00411817,0.0004095618,0.00040319184,0.0015597177,0.0011284895,0.0020727906,0.007091874],"category_scores_gemma":[0.0025693,0.0007855888,0.0028358905,0.00045521156,0.0013136,0.0014105855,0.00044172828,0.0039421045,0.000819811],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98276895,0.0013853954,0.0002750692,0.0017710769,0.0018264406,0.00006316818,0.00005264648,0.00019352518,0.0010270188,0.00016509653,0.0005618544,0.00990984],"study_design_scores_gemma":[0.98296434,0.014885061,0.0006525296,0.00006542834,0.00062903797,0.00004575198,0.00001838419,0.00017931973,0.00009540726,0.00014299453,0.0003121894,0.000009517584],"about_ca_topic_score_codex":0.0009349999,"about_ca_topic_score_gemma":0.0014519867,"teacher_disagreement_score":0.007091874,"about_ca_system_score_codex":0.0006078236,"about_ca_system_score_gemma":0.000705089,"threshold_uncertainty_score":0.023724675},"labels":[],"label_agreement":null},{"id":"W4389068167","doi":"10.1016/s2352-3026(23)00306-x","title":"Life after sickle cell disease, is it really uhuru?","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; University of Toronto; bluebird bio; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Andrew W. Mellon Foundation; National Heart, Lung, and Blood Institute; Pfizer; Health Resources and Services Administration; Agios Pharmaceuticals; Patient-Centered Outcomes Research Institute; Bristol-Myers Squibb; Doris Duke Charitable Foundation","keywords":"Medicine; Disease; Health care; Transplantation; Intensive care medicine; Family medicine; Internal medicine; Political science; Law","score_opus":0.02586312662935763,"score_gpt":0.28567142537998336,"score_spread":0.2598082987506257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389068167","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002289225,0.14159456,0.00014778847,0.80862254,0.03970245,0.000005158161,0.00016284615,0.000028622735,0.007446832],"genre_scores_gemma":[0.048979465,0.22276269,0.00042771493,0.5820789,0.13386954,0.000033869077,0.0002932443,0.00008532015,0.01146931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794894,0.0008547479,0.00016562556,0.00016974255,0.00042051892,0.0004404748],"domain_scores_gemma":[0.99334997,0.0026062937,0.0006902227,0.0002321758,0.00084404135,0.0022773019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003886791,0.00037771335,0.0012390475,0.00070064067,0.0024416253,0.003385649,0.00065599324,0.006992317,0.010093764],"category_scores_gemma":[0.02107719,0.00027529564,0.0006040884,0.0006528283,0.0031120086,0.0055947774,0.0020860028,0.011844043,0.003380005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033457798,0.000082609,0.003913249,0.0010226712,0.000117595846,0.00106615,0.0016963745,0.000038723527,0.00040476525,0.018837467,0.7887496,0.18373628],"study_design_scores_gemma":[0.00013654988,0.00031063866,0.010540488,0.00458528,0.00013472217,0.0027088858,0.007708457,0.00006735334,0.00022855157,0.03197518,0.94151396,0.00008996256],"about_ca_topic_score_codex":0.0027157292,"about_ca_topic_score_gemma":0.0059886607,"teacher_disagreement_score":0.010093764,"about_ca_system_score_codex":0.0014875195,"about_ca_system_score_gemma":0.0027738714,"threshold_uncertainty_score":0.033767045},"labels":[],"label_agreement":null},{"id":"W4389304091","doi":"10.1016/s2352-3026(23)00305-8","title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group","year":2023,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; International Prognostic Scoring System; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Disease; Oncology; Intensive care medicine; Bone marrow; Myelodysplastic syndromes","score_opus":0.0847614625065938,"score_gpt":0.356447509342724,"score_spread":0.2716860468361302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389304091","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011184798,0.99631774,0.00024591695,0.0017539245,0.00078032113,0.000024410387,0.00020186217,0.000014223319,0.00054967153],"genre_scores_gemma":[0.00077779155,0.9948107,0.0010129218,0.0021361634,0.00046603402,0.000042833133,0.0003289768,0.0000061304363,0.00041836975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929595,0.00014043642,0.00025626115,0.000090013455,0.00017403596,0.000043262637],"domain_scores_gemma":[0.9986796,0.0005118451,0.0004161077,0.000021095166,0.00029488507,0.00007647405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022285902,0.001037093,0.003170477,0.0029242854,0.00026619955,0.0015308989,0.0018220606,0.0015539526,0.0037825168],"category_scores_gemma":[0.0027347798,0.0003864027,0.002475126,0.0022252833,0.0004711081,0.0011095343,0.0008263659,0.0031917712,0.0017951569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004215799,0.00008437654,0.00042458274,0.04650142,0.0006090847,0.00012616531,0.000050120812,0.00068315445,0.000879964,0.0015843553,0.09590169,0.85273355],"study_design_scores_gemma":[0.00073209795,0.00032484496,0.004185363,0.097585835,0.003958007,0.0010208184,0.000121698205,0.00046122976,0.00050444616,0.0028876085,0.8881328,0.00008517044],"about_ca_topic_score_codex":0.0042996067,"about_ca_topic_score_gemma":0.008531644,"teacher_disagreement_score":0.0042996067,"about_ca_system_score_codex":0.0015141648,"about_ca_system_score_gemma":0.0031282206,"threshold_uncertainty_score":0.012653768},"labels":[],"label_agreement":null},{"id":"W4390021910","doi":"10.1016/s2352-3026(23)00338-1","title":"Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","year":2023,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"Astex Pharmaceuticals","keywords":"Decitabine; Medicine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Azacitidine; Internal medicine; International Prognostic Scoring System; Adverse effect; Oncology; Pharmacology; Bone marrow","score_opus":0.09378879086140673,"score_gpt":0.4066840908216205,"score_spread":0.31289529996021376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390021910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99176544,0.00243214,0.0007494623,0.00036817585,0.00044192057,0.002130565,0.00069554464,0.00012177789,0.0012949875],"genre_scores_gemma":[0.98717016,0.0027084802,0.001714422,0.0006306375,0.00038443628,0.002328956,0.0007236354,0.000045353576,0.004293736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992204,0.00041903128,0.000037032794,0.000116836265,0.00005636755,0.00015041929],"domain_scores_gemma":[0.99896073,0.00031291455,0.00020894059,0.00012462355,0.000054151486,0.0003385756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015821966,0.001903676,0.0037389956,0.00056620804,0.00044244804,0.0012826865,0.0010531985,0.0017567255,0.0064817164],"category_scores_gemma":[0.0018213912,0.0009719372,0.00200532,0.0006064386,0.0017055552,0.0014008251,0.00049694197,0.0033551925,0.0012522289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9827624,0.00626836,0.00018216108,0.0002524916,0.00041811232,0.000021059082,0.000049741357,0.00020447744,0.0024565563,0.00009651905,0.00026353358,0.00702453],"study_design_scores_gemma":[0.9213977,0.0762592,0.0009425864,0.000016905728,0.00022932542,0.000019042749,0.000022944716,0.00021801212,0.00033008694,0.000116080555,0.0004340614,0.000014138972],"about_ca_topic_score_codex":0.0013519434,"about_ca_topic_score_gemma":0.0027486635,"teacher_disagreement_score":0.0064817164,"about_ca_system_score_codex":0.0009135816,"about_ca_system_score_gemma":0.0010559055,"threshold_uncertainty_score":0.021683455},"labels":[],"label_agreement":null},{"id":"W4391463826","doi":"10.1016/s2352-3026(24)00001-2","title":"Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds de Recherche du Québec - Santé","keywords":"Medicine; Decitabine; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Venetoclax; Regimen; Internal medicine; Oncology; Transplantation; Leukemia; Bone marrow; Pediatrics; Chronic lymphocytic leukemia","score_opus":0.037061835381769936,"score_gpt":0.32741656185620793,"score_spread":0.290354726474438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391463826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57822824,0.358026,0.0029526823,0.026868235,0.0029892188,0.00016565068,0.00067036273,0.00027628517,0.029823331],"genre_scores_gemma":[0.90422523,0.073341146,0.0033456779,0.0039715283,0.0009707651,0.00007300248,0.0004609978,0.00003750685,0.013574131],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999503,0.00001820961,0.000004369781,0.000006116091,0.000008331341,0.000012598749],"domain_scores_gemma":[0.99990594,0.000032261796,0.00001674876,0.000006774491,0.0000071087384,0.000031110103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024531287,0.00015896768,0.00050908467,0.00011681281,0.00013669116,0.0005054761,0.00019906732,0.00035400986,0.0035756207],"category_scores_gemma":[0.0004012671,0.000060598384,0.00028989706,0.00013224862,0.00017506703,0.000398632,0.00020369579,0.001331187,0.00043690606],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0226722,0.0004580308,0.0018254234,0.0006693066,0.00016873423,0.0006241432,0.000058432182,0.0005354192,0.017585494,0.003345263,0.007826763,0.94423074],"study_design_scores_gemma":[0.044944935,0.05863654,0.05979248,0.0018739535,0.002020072,0.010644661,0.0006567589,0.0050028237,0.040839426,0.014398985,0.7610155,0.00017393785],"about_ca_topic_score_codex":0.00056349835,"about_ca_topic_score_gemma":0.002821346,"teacher_disagreement_score":0.0035756207,"about_ca_system_score_codex":0.00028003257,"about_ca_system_score_gemma":0.00028800723,"threshold_uncertainty_score":0.011961639},"labels":[],"label_agreement":null},{"id":"W4391544344","doi":"10.1016/s2352-3026(23)00377-0","title":"Diagnosis and management of pyruvate kinase deficiency: international expert guidelines","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Centre for Social Innovation; University of Toronto; Mount Sinai Hospital","funders":"Agios Pharmaceuticals","keywords":"Medicine; Guideline; Pyruvate kinase deficiency; Expert opinion; Pediatrics; MEDLINE; Inclusion (mineral); Family medicine; Intensive care medicine; Pyruvate kinase; Pathology; Internal medicine","score_opus":0.08962958820728362,"score_gpt":0.3701990562500991,"score_spread":0.28056946804281546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391544344","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011347517,0.86200804,0.011628553,0.09793217,0.009053935,0.0005281879,0.0010867955,0.00049864,0.016128873],"genre_scores_gemma":[0.0154583175,0.8507612,0.05320414,0.049234398,0.015856067,0.0015976289,0.0056418697,0.00018500866,0.008061411],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953962,0.0013502734,0.0013584227,0.0003959954,0.0011808389,0.00031831017],"domain_scores_gemma":[0.9895495,0.003736353,0.0015963824,0.00024127238,0.0039782226,0.0008982897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007612732,0.002605939,0.0048993295,0.0054552634,0.0009787887,0.0033072238,0.0058379094,0.007818933,0.005106539],"category_scores_gemma":[0.016190145,0.00083871075,0.004815999,0.0029162476,0.001424458,0.0024715518,0.0025504844,0.008833207,0.003830358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005036601,0.00030179162,0.001608586,0.010266758,0.00055675954,0.00086031685,0.00014596582,0.0026176074,0.00092770776,0.0037897718,0.3711605,0.6072606],"study_design_scores_gemma":[0.0011710313,0.00035620388,0.009376477,0.07897903,0.001843544,0.0038203092,0.00038078366,0.0025518422,0.0009994482,0.013616712,0.88668627,0.00021847336],"about_ca_topic_score_codex":0.0074264603,"about_ca_topic_score_gemma":0.009010409,"teacher_disagreement_score":0.007818933,"about_ca_system_score_codex":0.003486662,"about_ca_system_score_gemma":0.0062890947,"threshold_uncertainty_score":0.040260494},"labels":[],"label_agreement":null},{"id":"W4392304116","doi":"10.1016/s2352-3026(24)00030-9","title":"Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; Public Health Ontario; University of Toronto","funders":"National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; China-Japan Friendship Hospital; Medical Research Council; Fogarty International Center; Canadian Institutes of Health Research; National Institutes of Health; Public Health England; University of Melbourne; King's College London; Novo Nordisk; National Institute on Aging; National Institute for Health and Care Research; Alnylam Pharmaceuticals; Barts Health NHS Trust; Maze Therapeutics; National Health and Medical Research Council; AstraZeneca; Barts Charity; World Health Organization; Wellcome Trust; Hospital for Sick Children; Broad Institute; GlaxoSmithKline; Bristol-Myers Squibb; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Bill and Melinda Gates Foundation; National Institute for Nutrition and Health; State Government of Victoria; Carolina Population Center, University of North Carolina at Chapel Hill; Pfizer","keywords":"Medicine; Anemia; Pediatrics; Internal medicine","score_opus":0.05589305139803471,"score_gpt":0.3413870395701451,"score_spread":0.2854939881721104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392304116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64440745,0.08347512,0.050460797,0.003816389,0.00044028598,0.0012007754,0.19661574,0.00051079865,0.01907272],"genre_scores_gemma":[0.89960057,0.011286649,0.015920226,0.0007375382,0.0001376355,0.0014790432,0.0702546,0.00010468241,0.0004791979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9726131,0.012561406,0.0057516177,0.0032214813,0.005059906,0.00079247676],"domain_scores_gemma":[0.9181932,0.03452289,0.026847383,0.006190892,0.013432502,0.0008131114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.037189115,0.0010661519,0.0014486127,0.011109602,0.00036112638,0.0019876305,0.0018210983,0.0007669305,0.0013829034],"category_scores_gemma":[0.07058072,0.0005595749,0.003997686,0.017577838,0.0007970732,0.0017142342,0.00353187,0.0012296658,0.00039394043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003611991,0.00002684497,0.9569183,0.0022030033,0.005385607,0.000045348716,0.00085148175,0.0013614877,0.00014798495,0.001269621,0.006232278,0.025196934],"study_design_scores_gemma":[0.0000699608,0.00007248996,0.9815491,0.0019640024,0.0027729236,0.00022919582,0.0005887044,0.0014696671,0.0002671205,0.00079732423,0.010162103,0.000057513073],"about_ca_topic_score_codex":0.019682044,"about_ca_topic_score_gemma":0.011013109,"teacher_disagreement_score":0.037189115,"about_ca_system_score_codex":0.0015185196,"about_ca_system_score_gemma":0.0012609847,"threshold_uncertainty_score":0.19667715},"labels":[],"label_agreement":null},{"id":"W4393238711","doi":"10.1016/s2352-3026(24)00045-0","title":"Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Janssen Research and Development; National Institutes of Health; Incyte; bluebird bio; National Center for Advancing Translational Sciences; Health Resources and Services Administration; Agios Pharmaceuticals; Chiesi Farmaceutici; Bayer Corporation; CSL Behring; Novo Nordisk; Teva Pharmaceutical Industries; United Therapeutics Corporation; Celgene; Bayer HealthCare; Sanofi; Alexion Pharmaceuticals; Penn State College of Medicine; University of Pittsburgh; National Heart, Lung, and Blood Institute; Vifor Pharma; Pfizer","keywords":"Medicine; Riociguat; Placebo; Proteinuria; Internal medicine; Sickle cell anemia; Disease; Clinical trial; Anemia; Gastroenterology; Pulmonary hypertension; Kidney; Pathology","score_opus":0.02517269675344845,"score_gpt":0.2861932875726454,"score_spread":0.26102059081919693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393238711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516425,0.028023317,0.0017041663,0.0023628823,0.0030844344,0.0046473984,0.002316425,0.000560987,0.0056578335],"genre_scores_gemma":[0.9683344,0.011838532,0.0021145109,0.0034204528,0.00110409,0.0043894295,0.0016801213,0.00006707922,0.0070512607],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946755,0.0002473222,0.000027420188,0.0001166851,0.00003303515,0.000108035005],"domain_scores_gemma":[0.9995363,0.00014826735,0.00009484713,0.000034487315,0.000031385694,0.00015475744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012977973,0.002276813,0.00448492,0.000521929,0.00039090915,0.001172603,0.0010240054,0.002503955,0.009314121],"category_scores_gemma":[0.001467817,0.00076147274,0.002261144,0.0004680893,0.001292413,0.0012136399,0.00043599305,0.0035250112,0.0012945561],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98434293,0.0015745278,0.00022776936,0.0012738876,0.0011289485,0.00004570421,0.00003667687,0.00015653297,0.001654691,0.00013692415,0.0010424674,0.008378955],"study_design_scores_gemma":[0.9889368,0.0096266465,0.00049247436,0.00002795005,0.00029902198,0.000014432748,0.000012266473,0.00009186126,0.0000811975,0.000074675474,0.00033450717,0.000008168132],"about_ca_topic_score_codex":0.0014206682,"about_ca_topic_score_gemma":0.0028490885,"teacher_disagreement_score":0.009314121,"about_ca_system_score_codex":0.00062778284,"about_ca_system_score_gemma":0.0006976467,"threshold_uncertainty_score":0.031158864},"labels":[],"label_agreement":null},{"id":"W4393952544","doi":"10.1016/s2352-3026(24)00072-3","title":"Transplant without salvage: cut out the middleman","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myeloid leukaemia; Salvage therapy; Medicine; Refractory (planetary science); Chemotherapy; Transplantation; Hematology; Induction chemotherapy; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Orthodoxy; Stem cell; Intensive care medicine; Haematopoiesis; Biology","score_opus":0.06128884652059418,"score_gpt":0.35350729072832854,"score_spread":0.29221844420773435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393952544","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024936001,0.090993166,0.0025375604,0.8540586,0.03454061,0.000019752524,0.00013812432,0.00013731094,0.0150812315],"genre_scores_gemma":[0.062045984,0.09677618,0.0029097442,0.6936232,0.12893447,0.00007545883,0.00019760235,0.00035823567,0.015079226],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970975,0.0011300818,0.0002495225,0.0003872875,0.000655987,0.0004796796],"domain_scores_gemma":[0.9872155,0.006640615,0.00074804766,0.000792793,0.0012647128,0.0033382704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009686807,0.000568957,0.0016518665,0.0008069782,0.00242112,0.004739139,0.0017881485,0.0080250185,0.017360764],"category_scores_gemma":[0.022666734,0.00039310183,0.001294757,0.00046748266,0.004542751,0.008753051,0.0027767124,0.02206852,0.005680047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059551734,0.00015362109,0.0014684997,0.000587988,0.00014840021,0.001163541,0.0003506936,0.00033407935,0.00041509137,0.046333805,0.71809936,0.23034935],"study_design_scores_gemma":[0.00042242502,0.00046059708,0.002734363,0.004188224,0.00023709616,0.003890224,0.0011014893,0.00063674146,0.00044535694,0.15129581,0.8344541,0.00013357292],"about_ca_topic_score_codex":0.0014388765,"about_ca_topic_score_gemma":0.0034939263,"teacher_disagreement_score":0.017360764,"about_ca_system_score_codex":0.0022936773,"about_ca_system_score_gemma":0.004163821,"threshold_uncertainty_score":0.058077574},"labels":[],"label_agreement":null},{"id":"W4394564034","doi":"10.1016/s2352-3026(24)00067-x","title":"Methodological challenges in the development of endpoints for myelofibrosis clinical trials","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Myeloproliferative neoplasm; Clinical trial; Myeloid; Oncology; Clinical endpoint; Janus kinase 2; Surrogate endpoint; Internal medicine; Myeloid leukemia; Bone marrow","score_opus":0.8278153183857964,"score_gpt":0.584567789265612,"score_spread":0.24324752912018432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394564034","genre_codex":"methods","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007943481,0.07381467,0.7991009,0.05520304,0.01946877,0.026537826,0.0049986183,0.0013367935,0.0115958415],"genre_scores_gemma":[0.18429254,0.011389413,0.66187423,0.031240236,0.011059202,0.0942027,0.0024786077,0.0012821596,0.002180869],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.05911029,0.8459613,0.059987295,0.009280469,0.024636388,0.0010243391],"domain_scores_gemma":[0.042649005,0.8644966,0.021645961,0.04684273,0.022894843,0.0014708125],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.84435153,0.0040417016,0.017447086,0.007548909,0.0038303758,0.023298118,0.012105619,0.0067468877,0.006813518],"category_scores_gemma":[0.9000389,0.0038066942,0.013681292,0.011506858,0.012963741,0.0106677385,0.012025698,0.025696805,0.002377557],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011912216,0.0009767886,0.022741197,0.077146426,0.057221215,0.0006370145,0.0068051293,0.01529257,0.0016717538,0.2673506,0.06493797,0.47330713],"study_design_scores_gemma":[0.010133525,0.0056615323,0.027438527,0.040946234,0.020578958,0.0010640951,0.0019487967,0.035388537,0.003036136,0.6525004,0.20036608,0.0009372886],"about_ca_topic_score_codex":0.0034932867,"about_ca_topic_score_gemma":0.004145273,"teacher_disagreement_score":0.15564847,"about_ca_system_score_codex":0.0073684305,"about_ca_system_score_gemma":0.017053364,"threshold_uncertainty_score":0.19194233},"labels":[],"label_agreement":null},{"id":"W4396517457","doi":"10.1016/s2352-3026(24)00099-1","title":"Diversity, equity, and inclusion in ASH guidelines","year":2024,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Clinical practice guidelines implementation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; University of British Columbia","funders":"","keywords":"Inclusion (mineral); Psychology; Guideline; Autonomy; Scopus; Political science; Public relations; Library science; Social psychology; MEDLINE; Law","score_opus":0.48860161706903926,"score_gpt":0.541388175330978,"score_spread":0.05278655826193879,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396517457","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027867398,0.00022395182,0.00004623107,0.9957337,0.0023099284,0.000004976061,0.000011754889,0.0000028875024,0.0013878709],"genre_scores_gemma":[0.0046476214,0.00019599208,0.00021291139,0.9843812,0.008036077,0.000034719393,0.000010226064,0.000013933984,0.0024673233],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94065386,0.02556684,0.008265471,0.0039543128,0.012726893,0.00883274],"domain_scores_gemma":[0.7815864,0.15844823,0.00937853,0.0041786972,0.016953632,0.029454479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058039162,0.00067284674,0.001848828,0.0013086993,0.016115291,0.015137359,0.004751667,0.14802419,0.010846889],"category_scores_gemma":[0.21889275,0.0016993339,0.001946253,0.0019950895,0.017251449,0.012979541,0.01104783,0.112973616,0.004190199],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056173096,0.00006572087,0.0016170795,0.00009814502,0.00003601746,0.0010390643,0.002420225,0.000094875984,0.00010758376,0.029702693,0.9510584,0.013704057],"study_design_scores_gemma":[0.0003313564,0.00006245693,0.0037534013,0.001431719,0.0000815453,0.0009298895,0.0056539946,0.0007405868,0.0003091336,0.09460962,0.8918738,0.00022251815],"about_ca_topic_score_codex":0.04604965,"about_ca_topic_score_gemma":0.09007757,"teacher_disagreement_score":0.14802419,"about_ca_system_score_codex":0.01416038,"about_ca_system_score_gemma":0.042492658,"threshold_uncertainty_score":0.30694407},"labels":[],"label_agreement":null},{"id":"W4396520704","doi":"10.1016/s2352-3026(24)00078-4","title":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; University of Toronto; University Health Network","funders":"National Heart, Lung, and Blood Institute; Kenya Medical Research Institute; Wellcome Trust; Cincinnati Children’s Research Foundation; Cincinnati Children's Hospital Medical Center; Bristol-Myers Squibb","keywords":"Medicine; Sickle cell anemia; Open label; Pediatrics; Anemia; Clinical trial; Internal medicine; Disease","score_opus":0.036976754108189396,"score_gpt":0.3190857287698329,"score_spread":0.2821089746616435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396520704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865204,0.008629174,0.00047896622,0.00085477147,0.00029593278,0.0009587912,0.0010518472,0.00008494681,0.0011252498],"genre_scores_gemma":[0.9885322,0.004021032,0.0013873169,0.001197595,0.00025363607,0.001881722,0.001128078,0.000029894369,0.0015685571],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992384,0.0004106121,0.00003546858,0.00011294574,0.000050550912,0.00015206165],"domain_scores_gemma":[0.9986601,0.0004470483,0.0003608875,0.00010693885,0.00005945463,0.0003656672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018638977,0.0016077757,0.0028999767,0.0003109637,0.00034930487,0.0011766752,0.00065336487,0.0014399298,0.0038070378],"category_scores_gemma":[0.0026341735,0.0004186947,0.0027454318,0.00038479632,0.0010245489,0.0013646361,0.0004947843,0.003236283,0.0005129349],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93759435,0.0047716787,0.0026994445,0.001490711,0.0038108793,0.00018556099,0.00029615764,0.0013804043,0.0024544818,0.00030997535,0.0020808717,0.042925484],"study_design_scores_gemma":[0.9249005,0.064310685,0.006530617,0.0001587665,0.001318152,0.0001329245,0.00010480493,0.00038823733,0.00032399394,0.00040729548,0.0013950915,0.000028893932],"about_ca_topic_score_codex":0.0014921643,"about_ca_topic_score_gemma":0.0029924363,"teacher_disagreement_score":0.0038070378,"about_ca_system_score_codex":0.0009282123,"about_ca_system_score_gemma":0.0010367379,"threshold_uncertainty_score":0.012735784},"labels":[],"label_agreement":null},{"id":"W4396626940","doi":"10.1016/s2352-3026(24)00081-4","title":"Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of Alberta; Ottawa Allergy Research Corporation; University of Ottawa","funders":"CSL Behring","keywords":"Medicine; Hereditary angioedema; Quality of life (healthcare); Angioedema; Open label; Intensive care medicine; Adverse effect; Term (time); Pediatrics; Internal medicine; Dermatology","score_opus":0.2819201216959628,"score_gpt":0.4705432997549764,"score_spread":0.18862317805901357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396626940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9723672,0.021624587,0.00055892393,0.00081665843,0.0004080367,0.0011266201,0.001347628,0.00010576315,0.0016445855],"genre_scores_gemma":[0.9839443,0.008794589,0.0010260602,0.0012820897,0.00040991668,0.001301726,0.0017405666,0.000032521195,0.0014682118],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990024,0.0005435541,0.000042300573,0.00011867439,0.00009905191,0.00019403044],"domain_scores_gemma":[0.99825364,0.0007486712,0.0003144394,0.00014983644,0.00008831578,0.00044508028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002811039,0.0016684145,0.0033562945,0.00054265157,0.00034375163,0.0012768747,0.0008236667,0.0014940994,0.0048651956],"category_scores_gemma":[0.0023281632,0.0005256051,0.0023473976,0.000565405,0.0012043753,0.0013385995,0.00034864713,0.0032835368,0.0007429984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9521161,0.005880362,0.0012221604,0.0009923007,0.0024731548,0.00010439997,0.000063740634,0.00037458786,0.0044443915,0.00011911996,0.0010838185,0.031125972],"study_design_scores_gemma":[0.9333649,0.05785727,0.0058606304,0.000060120194,0.001353602,0.0000902542,0.000026924878,0.00021766152,0.0003959462,0.00013347283,0.0006162064,0.000023020628],"about_ca_topic_score_codex":0.00082388654,"about_ca_topic_score_gemma":0.001706759,"teacher_disagreement_score":0.0048651956,"about_ca_system_score_codex":0.0007170796,"about_ca_system_score_gemma":0.00086406956,"threshold_uncertainty_score":0.016275704},"labels":[],"label_agreement":null},{"id":"W4399993461","doi":"10.1016/s2352-3026(24)00103-0","title":"The origin of ferritin reference intervals: a systematic review","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; St. Michael's Hospital; University of Toronto","funders":"","keywords":"Ferritin; Computational biology; Biology; Biochemistry","score_opus":0.1398024338734693,"score_gpt":0.42366653195324216,"score_spread":0.28386409807977286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022211127,0.9991855,0.00011188263,0.00012253031,0.00008104995,0.000050775125,0.00014655366,0.0000034098152,0.00007619299],"genre_scores_gemma":[0.010342815,0.9878092,0.00067981886,0.0006597764,0.00010345428,0.00016115124,0.00016624405,0.0000103072425,0.000067284906],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98376656,0.0065016043,0.005540414,0.001526153,0.0022412112,0.00042404802],"domain_scores_gemma":[0.93780756,0.05083896,0.0077314423,0.0007878339,0.0025083506,0.00032580463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020070054,0.0018335452,0.014837327,0.007951268,0.000479358,0.0043657674,0.0030178935,0.0034366697,0.0066162357],"category_scores_gemma":[0.08374077,0.0016371352,0.010278086,0.011249869,0.0012399388,0.0035094167,0.002346415,0.0031352218,0.0005718825],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005340804,0.000012864869,0.0008161087,0.9196464,0.027185243,0.000087281514,0.00017677872,0.0001529933,0.00010506826,0.00056265306,0.0021045792,0.048615858],"study_design_scores_gemma":[0.0012825604,0.00016145222,0.004654132,0.73981136,0.23337145,0.00030184368,0.00027099196,0.00019647786,0.00014851535,0.0012475436,0.018473221,0.000080466045],"about_ca_topic_score_codex":0.008292555,"about_ca_topic_score_gemma":0.020779982,"teacher_disagreement_score":0.020070054,"about_ca_system_score_codex":0.003277302,"about_ca_system_score_gemma":0.008121792,"threshold_uncertainty_score":0.106141925},"labels":[],"label_agreement":null},{"id":"W4399993470","doi":"10.1016/s2352-3026(24)00143-1","title":"Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Novartis; Sierra Oncology; GlaxoSmithKline","keywords":"Medicine; Follicular lymphoma; Radiation therapy; Rituximab; Oncology; Stage (stratigraphy); Lymphoma; Internal medicine; Immunotherapy; CD20; Follicular phase; Cancer","score_opus":0.021878447465958302,"score_gpt":0.28960860053651144,"score_spread":0.26773015307055315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399993470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926426,0.004510901,0.00023179682,0.00053227105,0.00013791467,0.00035912832,0.00034497102,0.000054205946,0.0011862423],"genre_scores_gemma":[0.9942496,0.0016413762,0.000537358,0.0006907665,0.00015072207,0.0005632887,0.0007319395,0.000021142663,0.0014138967],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996152,0.00018615182,0.000011396755,0.000055406355,0.000027303466,0.00010453769],"domain_scores_gemma":[0.9995111,0.00014993563,0.00010938208,0.000053559535,0.000020770169,0.00015530828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014154642,0.00088071666,0.0014684253,0.00023466146,0.0002910111,0.0010742587,0.0007356679,0.0010195461,0.0026431861],"category_scores_gemma":[0.0008956173,0.00028874792,0.0015816462,0.00023918555,0.0008473271,0.0007339284,0.00043058296,0.0027941281,0.0004960846],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8468277,0.013408921,0.0074687204,0.0012442176,0.0024521102,0.00010709518,0.00030018363,0.0022148048,0.007971845,0.00040727635,0.0031607894,0.11443645],"study_design_scores_gemma":[0.7150712,0.24768604,0.02819552,0.00016391445,0.0018088374,0.00019372394,0.00018566362,0.0010000601,0.001349049,0.00062396587,0.0036742943,0.000047708152],"about_ca_topic_score_codex":0.0009666848,"about_ca_topic_score_gemma":0.0024017696,"teacher_disagreement_score":0.0026431861,"about_ca_system_score_codex":0.0009362372,"about_ca_system_score_gemma":0.0007338662,"threshold_uncertainty_score":0.008842349},"labels":[],"label_agreement":null},{"id":"W4400481895","doi":"10.1016/s2352-3026(24)00174-1","title":"Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Ruxolitinib; Interim analysis; Refractory (planetary science); Interim; Graft-versus-host disease; Internal medicine; Disease; Clinical trial; Surgery; Physical therapy","score_opus":0.051263907041721145,"score_gpt":0.34409163184741504,"score_spread":0.2928277248056939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400481895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99193585,0.004316864,0.00052041514,0.00027802706,0.00007943276,0.00037189803,0.0013485096,0.00005987945,0.0010890454],"genre_scores_gemma":[0.9930755,0.001162136,0.0010149402,0.0005092613,0.00007799362,0.0005121971,0.002803547,0.0000228632,0.0008216349],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99824333,0.0009934002,0.000089417445,0.00022459358,0.00015325814,0.00029603802],"domain_scores_gemma":[0.9983766,0.0005504141,0.00050359184,0.00020611438,0.00007161996,0.00029162687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004820796,0.0010935096,0.00237215,0.00022279861,0.0002921492,0.0016703742,0.00069210364,0.0010563155,0.0020719366],"category_scores_gemma":[0.0028306204,0.00036775167,0.0031723406,0.00036455167,0.0006396637,0.0012415692,0.0005199173,0.0018362812,0.0003965752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8813938,0.0028991695,0.017793216,0.0010874115,0.012276002,0.000301527,0.00022790428,0.0044825324,0.0055735814,0.00047047914,0.003234356,0.070259996],"study_design_scores_gemma":[0.63604724,0.22094035,0.11434683,0.0003431909,0.014490175,0.000844225,0.00023308108,0.0036012877,0.0032016274,0.0009604067,0.0048396406,0.00015205175],"about_ca_topic_score_codex":0.0008238535,"about_ca_topic_score_gemma":0.0025350282,"teacher_disagreement_score":0.004820796,"about_ca_system_score_codex":0.0008329406,"about_ca_system_score_gemma":0.0011543416,"threshold_uncertainty_score":0.025495112},"labels":[],"label_agreement":null},{"id":"W4400763660","doi":"10.1016/s2352-3026(24)00185-6","title":"SintraREViewed: practice changing, or validation required?","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Intensive care medicine","score_opus":0.09016371120597517,"score_gpt":0.3947698178445033,"score_spread":0.30460610663852816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400763660","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009500387,0.02660676,0.0092177335,0.90622956,0.030135756,0.00070871186,0.0013494802,0.00053559145,0.015716068],"genre_scores_gemma":[0.2565616,0.03758755,0.0922726,0.5507106,0.042887356,0.0032783756,0.005541537,0.001986737,0.009173634],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.6383455,0.19081606,0.07033931,0.03025357,0.05817461,0.012070958],"domain_scores_gemma":[0.11918898,0.42812407,0.054138515,0.07324342,0.30199417,0.023310987],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.50514495,0.0010421969,0.0030500453,0.006171035,0.0046149795,0.023069719,0.010311341,0.010401387,0.014855629],"category_scores_gemma":[0.7459573,0.0020072104,0.0021249095,0.008569027,0.01333399,0.030890867,0.009741273,0.017436039,0.007700874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009411205,0.00032318302,0.08419509,0.0097906655,0.0007241842,0.00040355828,0.009477053,0.0007810769,0.0011843892,0.045292478,0.465036,0.38185114],"study_design_scores_gemma":[0.0009193361,0.0006108717,0.059400536,0.048434235,0.0009431583,0.001232761,0.019315448,0.003987025,0.0025187468,0.071192235,0.79094803,0.00049767044],"about_ca_topic_score_codex":0.028033493,"about_ca_topic_score_gemma":0.04473803,"teacher_disagreement_score":0.49485505,"about_ca_system_score_codex":0.015106658,"about_ca_system_score_gemma":0.08361438,"threshold_uncertainty_score":0.6102444},"labels":[],"label_agreement":null},{"id":"W4401322439","doi":"10.1016/s2352-3026(24)00223-0","title":"Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List","year":2024,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Canadian Hemophilia Society","funders":"","keywords":"Medicine; Haemophilia; Harm; Do no harm; Intensive care medicine; Family medicine; Environmental health; Pediatrics; Psychiatry; Law","score_opus":0.02926762519966622,"score_gpt":0.3212455867381156,"score_spread":0.29197796153844935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401322439","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00095680787,0.0014478215,0.000079485675,0.97157943,0.010301664,0.000026462536,0.00013011314,0.000025132864,0.015453099],"genre_scores_gemma":[0.004948805,0.0007593851,0.00013662226,0.9579724,0.015106446,0.00005618201,0.000045183268,0.000024597224,0.020950334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959096,0.0011407223,0.00046178667,0.00025876652,0.0011909788,0.0010380889],"domain_scores_gemma":[0.99054796,0.004681277,0.00072776806,0.00023980644,0.0012964067,0.0025067765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00380455,0.0008746173,0.0012595364,0.0007670881,0.006097481,0.0048902854,0.0014059579,0.10529759,0.012271882],"category_scores_gemma":[0.0291178,0.0009440792,0.0017128184,0.0006446025,0.0024710041,0.0042919517,0.0027586466,0.0353505,0.008095407],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013268332,0.000068862835,0.0011483796,0.000068590896,0.000025222644,0.001800832,0.00037016365,0.000054946184,0.00027947625,0.006035404,0.9817664,0.00824903],"study_design_scores_gemma":[0.00024907987,0.00015488673,0.004275361,0.00074771186,0.00007257982,0.002226894,0.001093228,0.00052748184,0.00031686874,0.01684982,0.9733704,0.00011558462],"about_ca_topic_score_codex":0.021036655,"about_ca_topic_score_gemma":0.03370917,"teacher_disagreement_score":0.10529759,"about_ca_system_score_codex":0.0043890746,"about_ca_system_score_gemma":0.009457556,"threshold_uncertainty_score":0.041828394},"labels":[],"label_agreement":null},{"id":"W4401931977","doi":"10.1016/s2352-3026(24)00239-4","title":"Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University Health Network; Mount Sinai Hospital","funders":"University of Toronto","keywords":"Medicine; Predictive value; Value (mathematics); Titration; Obstetrics; Internal medicine; Statistics","score_opus":0.04740498930240186,"score_gpt":0.31936736402540483,"score_spread":0.271962374723003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401931977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013496347,0.9992077,0.00006592678,0.00031355413,0.00009881966,0.0000022537401,0.000010341373,0.000002914621,0.0001635753],"genre_scores_gemma":[0.0026404115,0.99620557,0.00022644237,0.00044031272,0.0003047086,0.000006388943,0.000043476935,0.0000020878165,0.0001305726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993851,0.00021072666,0.000105390915,0.00007632327,0.0001848522,0.000037528796],"domain_scores_gemma":[0.9977048,0.0017116704,0.00033908355,0.000022622336,0.00015776655,0.00006415046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013295264,0.00070158986,0.0023817306,0.0014994651,0.00015229738,0.0010168668,0.0012171575,0.0013679679,0.0021891096],"category_scores_gemma":[0.005131849,0.0002569033,0.0011582137,0.00087892934,0.00044445068,0.0007388607,0.000493873,0.00242772,0.0005677928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000255775,0.0000439523,0.0011418427,0.015193985,0.00036564813,0.00038550422,0.000040413022,0.0004189121,0.00020771963,0.0010590535,0.014533365,0.9663539],"study_design_scores_gemma":[0.0012230548,0.0009972026,0.023144145,0.16045405,0.0063976995,0.015657764,0.0005786113,0.0017225638,0.0010936701,0.011017287,0.7774719,0.00024204052],"about_ca_topic_score_codex":0.0023587986,"about_ca_topic_score_gemma":0.003473111,"teacher_disagreement_score":0.0023817306,"about_ca_system_score_codex":0.0005550705,"about_ca_system_score_gemma":0.0011099925,"threshold_uncertainty_score":0.007323265},"labels":[],"label_agreement":null},{"id":"W4402712904","doi":"10.1016/s2352-3026(24)00274-6","title":"Transplantation and long-term overall survival in acute myeloid leukaemia","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukaemia; Transplantation; Term (time); Oncology; Overall survival; Internal medicine","score_opus":0.03384350003317645,"score_gpt":0.3370490494081314,"score_spread":0.303205549374955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402712904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91048044,0.073730975,0.0002516464,0.0092674745,0.0006357589,0.000012557913,0.0010867709,0.00003188323,0.0045025647],"genre_scores_gemma":[0.9902108,0.0064565623,0.000047474543,0.0011430165,0.0006656197,0.0000067608808,0.000619908,0.0000067737756,0.0008430358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950004,0.00017953101,0.00004255566,0.000052835152,0.00007319223,0.0001519362],"domain_scores_gemma":[0.9965088,0.0009159734,0.0013638809,0.00014456119,0.00015684578,0.00091000256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013828547,0.0001804678,0.00045691634,0.00037395014,0.00032182076,0.0011978882,0.00045790218,0.0011641536,0.0027995743],"category_scores_gemma":[0.004200229,0.0001255199,0.00052873587,0.0010590804,0.0005868202,0.0008883948,0.0007702939,0.002060744,0.00041378645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009873584,0.0004555695,0.8554517,0.00048839103,0.0013272364,0.0006347429,0.00025927,0.0011868769,0.0011738489,0.0018393704,0.0064638583,0.12084557],"study_design_scores_gemma":[0.00023333769,0.0010366187,0.99088836,0.00015678792,0.0005188213,0.0005480493,0.00024072487,0.000366467,0.00012011413,0.0024954688,0.0033713079,0.0000239634],"about_ca_topic_score_codex":0.0015841163,"about_ca_topic_score_gemma":0.0022243718,"teacher_disagreement_score":0.0027995743,"about_ca_system_score_codex":0.0006687377,"about_ca_system_score_gemma":0.000577169,"threshold_uncertainty_score":0.009365499},"labels":[],"label_agreement":null},{"id":"W4403014078","doi":"10.1016/s2352-3026(24)00276-x","title":"Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Canadian Centre for Applied Research in Cancer Control","funders":"National Institutes of Health; National Comprehensive Cancer Network; National Cancer Institute; American Association of Physicists in Medicine","keywords":"Medicine; Clinical trial; Nomenclature; Lymphoma; Medical physics; Intensive care medicine; Internal medicine; Taxonomy (biology)","score_opus":0.2870654028184923,"score_gpt":0.48311623671278964,"score_spread":0.19605083389429734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403014078","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031697631,0.28547,0.09001376,0.48133188,0.058238972,0.028566597,0.010840635,0.002154861,0.04021348],"genre_scores_gemma":[0.026017606,0.111315735,0.48492908,0.2658345,0.01952427,0.06675989,0.010811709,0.00335333,0.011453803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.5712695,0.27401805,0.09692346,0.010769321,0.04133537,0.005684237],"domain_scores_gemma":[0.47311035,0.30978927,0.064895704,0.028577201,0.1041214,0.019506032],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.45826557,0.0042379797,0.019594371,0.011884993,0.0061116577,0.024133183,0.029792633,0.027364634,0.008474162],"category_scores_gemma":[0.49256635,0.0047862963,0.022296537,0.016168164,0.009028005,0.011022934,0.011467197,0.051647827,0.009042228],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063604484,0.0004238496,0.0026172362,0.046590686,0.0059012766,0.00028114254,0.0026203569,0.0030596885,0.0016051837,0.028661832,0.55359155,0.34828687],"study_design_scores_gemma":[0.017125342,0.0010347033,0.0099007115,0.1427096,0.010423046,0.0006175453,0.0013986697,0.003271569,0.0019143876,0.06281532,0.7480599,0.0007291926],"about_ca_topic_score_codex":0.013416207,"about_ca_topic_score_gemma":0.01724508,"teacher_disagreement_score":0.54173446,"about_ca_system_score_codex":0.016145227,"about_ca_system_score_gemma":0.05260966,"threshold_uncertainty_score":0.668055},"labels":[],"label_agreement":null},{"id":"W4403087733","doi":"10.1016/s2352-3026(24)00275-8","title":"The Global Fund should extend its mandate to include universal access to hydroxyurea","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Fogarty International Center; National Heart, Lung, and Blood Institute","keywords":"Medicine; Mandate; Expanded access; Internal medicine","score_opus":0.07488841540356138,"score_gpt":0.380341841491127,"score_spread":0.3054534260875656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403087733","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020589004,0.004187338,0.0018569651,0.90101814,0.04813481,0.0001470586,0.0011703409,0.0006709876,0.040755466],"genre_scores_gemma":[0.016503867,0.002733069,0.004795933,0.9210357,0.013336368,0.0002835707,0.0011168618,0.00021629366,0.039978296],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881259,0.0028077029,0.00078314956,0.0007757437,0.0041742716,0.0033332284],"domain_scores_gemma":[0.9414598,0.016254466,0.004141575,0.0033793913,0.01285818,0.021906687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021287838,0.0011188564,0.0018776415,0.0014121252,0.0019639565,0.0050468002,0.0040515373,0.033598807,0.028442325],"category_scores_gemma":[0.06690988,0.0008017879,0.00319493,0.0011853657,0.0035676823,0.005780381,0.0067056897,0.019208344,0.0069805672],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027657166,0.00024975115,0.0017712195,0.0006254282,0.00013536752,0.00025475427,0.0001978964,0.00036092065,0.00057143124,0.037522975,0.916431,0.041602787],"study_design_scores_gemma":[0.00029689743,0.00017764061,0.005569857,0.00087724935,0.000093259754,0.00026832402,0.00016317521,0.0002599431,0.00041149705,0.011318759,0.98048246,0.000080898615],"about_ca_topic_score_codex":0.023539612,"about_ca_topic_score_gemma":0.024882728,"teacher_disagreement_score":0.033598807,"about_ca_system_score_codex":0.0038744025,"about_ca_system_score_gemma":0.04112006,"threshold_uncertainty_score":0.11258221},"labels":[],"label_agreement":null},{"id":"W4403274656","doi":"10.1016/s2352-3026(24)00251-5","title":"Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"HORIZON EUROPE Framework Programme; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; Agence Nationale de la Recherche","keywords":"Myelodysplastic syndromes; Medicine; Consensus conference; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Bone marrow","score_opus":0.2527579179498377,"score_gpt":0.4168192831024565,"score_spread":0.16406136515261877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403274656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013548046,0.9647204,0.008895534,0.013788761,0.0032745947,0.0009236,0.004568399,0.00016994425,0.0023039465],"genre_scores_gemma":[0.013378587,0.9195443,0.037459392,0.009734173,0.0009877826,0.0011920218,0.016104287,0.00013331055,0.0014662127],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99344665,0.0018079637,0.0020413972,0.00067494274,0.0017529737,0.0002761037],"domain_scores_gemma":[0.98876613,0.004716196,0.0014587372,0.00046276237,0.004229321,0.0003668145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02288882,0.0012645382,0.0066015595,0.0046902783,0.0005400067,0.0032604064,0.00560465,0.0021907787,0.002553979],"category_scores_gemma":[0.023941811,0.000585461,0.006982752,0.004365896,0.00086161995,0.0021988635,0.002224844,0.0042111604,0.0013909858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008531794,0.00011158742,0.001940203,0.07517874,0.004645808,0.00015458507,0.00023327854,0.0021485554,0.00092817546,0.01024312,0.09968288,0.80387986],"study_design_scores_gemma":[0.0017656888,0.0004533142,0.013128275,0.16332266,0.024645891,0.001174838,0.00046511562,0.0025093285,0.0018785374,0.013842679,0.77655655,0.00025707026],"about_ca_topic_score_codex":0.011364103,"about_ca_topic_score_gemma":0.012718815,"teacher_disagreement_score":0.02288882,"about_ca_system_score_codex":0.0046114936,"about_ca_system_score_gemma":0.017353494,"threshold_uncertainty_score":0.121049106},"labels":[],"label_agreement":null},{"id":"W4404095781","doi":"10.1016/s2352-3026(24)00307-7","title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Novo Nordisk","keywords":"Medicine; Haemophilia; Open label; Haemophilia A; Clinical trial; Physical therapy; Pediatrics; Internal medicine","score_opus":0.08556698565095941,"score_gpt":0.3977124130320215,"score_spread":0.3121454273810621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404095781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826841,0.007361068,0.00049468555,0.0008374987,0.00024360191,0.004686967,0.0016051118,0.00006352494,0.0020234415],"genre_scores_gemma":[0.9844221,0.002979217,0.0021826457,0.0014253779,0.00033984697,0.0051766294,0.0016616549,0.000020373325,0.0017921177],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983985,0.0011340086,0.00007890188,0.00017734074,0.00009301144,0.00011825355],"domain_scores_gemma":[0.9981797,0.0005626748,0.0005685696,0.00014103083,0.00013032975,0.00041774067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003546657,0.0012466398,0.0015216933,0.00027445858,0.00040863774,0.00088554417,0.0006348024,0.0015420392,0.004262104],"category_scores_gemma":[0.0025281636,0.00046265515,0.0019532728,0.00035930856,0.0007959058,0.0006614966,0.0005168033,0.0019441545,0.0007013317],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9734666,0.0033843496,0.0035454626,0.0010177643,0.0015761277,0.00009771115,0.00011710777,0.00026527306,0.002307148,0.00015221776,0.0012090879,0.012861207],"study_design_scores_gemma":[0.9464076,0.04776478,0.003568555,0.00006341747,0.0006377321,0.00010754598,0.000033517506,0.00015698968,0.00019153579,0.00012725967,0.00092753116,0.000013347724],"about_ca_topic_score_codex":0.0007423433,"about_ca_topic_score_gemma":0.0016449686,"teacher_disagreement_score":0.004262104,"about_ca_system_score_codex":0.00052426796,"about_ca_system_score_gemma":0.0012015118,"threshold_uncertainty_score":0.018756747},"labels":[],"label_agreement":null},{"id":"W4404170455","doi":"10.1016/s2352-3026(24)00314-4","title":"Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Medicine; Observational study; Retrospective cohort study; Fetus; Cohort study; Haemolytic disease; Cohort; Pediatrics; Obstetrics; Pregnancy; Intensive care medicine; Internal medicine","score_opus":0.030588238713342614,"score_gpt":0.31609669898152226,"score_spread":0.28550846026817966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404170455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983157,0.00044983876,0.00016761599,0.000042233703,0.000012370364,0.000010393384,0.000705686,0.0000032696905,0.00029288363],"genre_scores_gemma":[0.9991358,0.00016801561,0.00011567781,0.000030826344,0.000010161252,0.000012760378,0.00045064665,0.0000041590683,0.00007197458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808735,0.00048905105,0.00021208482,0.0006800339,0.00020963994,0.00032170137],"domain_scores_gemma":[0.9959655,0.00078380655,0.0017584796,0.00071041886,0.00025738546,0.00052436406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014438501,0.0004174425,0.00059023453,0.00066407945,0.00058933016,0.0010759787,0.0008589505,0.0008107361,0.001159477],"category_scores_gemma":[0.0048279595,0.0007025493,0.0008923911,0.0018861899,0.0005322681,0.0008034448,0.00095639046,0.0012335794,0.00018291571],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002044274,0.000035891764,0.99843806,0.000013338428,0.00023203994,0.00010980062,0.0001391696,0.000032153934,0.00021071016,0.000044930646,0.000097366414,0.00044216117],"study_design_scores_gemma":[0.000012439686,0.0000776669,0.9990639,0.000010120552,0.000098480894,0.0002729977,0.0002277195,0.00008640175,0.000027060223,0.000025727126,0.00009102983,0.0000064922424],"about_ca_topic_score_codex":0.012838806,"about_ca_topic_score_gemma":0.010719935,"teacher_disagreement_score":0.012838806,"about_ca_system_score_codex":0.00055349356,"about_ca_system_score_gemma":0.00055767724,"threshold_uncertainty_score":0.025528133},"labels":[],"label_agreement":null},{"id":"W4404942943","doi":"10.1016/s2352-3026(24)00285-0","title":"Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia","year":2024,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Acute lymphocytic leukemia; Disease; Minimal residual disease; Pediatrics; Blinatumomab; Intensive care medicine; Lymphoblastic Leukemia; Oncology; Immunology; Internal medicine; Leukemia","score_opus":0.03919398901172815,"score_gpt":0.3430738836277233,"score_spread":0.3038798946159951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404942943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022710269,0.9987953,0.000039052622,0.00017833947,0.00020343148,0.000004841093,0.000035555244,0.000005735682,0.00051066326],"genre_scores_gemma":[0.0026129088,0.99607265,0.00013006135,0.0005438252,0.00016409667,0.000008922424,0.00009220751,0.000002100945,0.00037321114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985623,0.000036547983,0.000023495273,0.000025793313,0.00003920791,0.000018674096],"domain_scores_gemma":[0.9997687,0.00011596356,0.000061695835,0.000004652431,0.00003011886,0.000018806351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003475207,0.00050654466,0.0014038373,0.00075941434,0.00009808977,0.00053818995,0.00075441104,0.00063915673,0.004855873],"category_scores_gemma":[0.0008045696,0.00017697786,0.0007283766,0.0007424502,0.00015064294,0.00045913295,0.0002793875,0.0013165948,0.0010802267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038412196,0.0000501122,0.00021242969,0.024839561,0.00028937918,0.000100873156,0.000028501952,0.0002691136,0.0005776971,0.0006623766,0.03608677,0.93649894],"study_design_scores_gemma":[0.0013461804,0.0009382903,0.005972073,0.04008354,0.0023785722,0.0018590892,0.00011519077,0.00029289082,0.0005625963,0.0014973631,0.944914,0.000040174116],"about_ca_topic_score_codex":0.0014011433,"about_ca_topic_score_gemma":0.0038019598,"teacher_disagreement_score":0.004855873,"about_ca_system_score_codex":0.00038560346,"about_ca_system_score_gemma":0.0005483091,"threshold_uncertainty_score":0.01624453},"labels":[],"label_agreement":null},{"id":"W4405009230","doi":"10.1016/s2352-3026(24)00319-3","title":"Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Agios Pharmaceuticals","keywords":"Medicine; Placebo; Clinical trial; Internal medicine; Double blind; Physical therapy; Pediatrics; Intensive care medicine; Alternative medicine; Pathology","score_opus":0.023369943051360653,"score_gpt":0.3126086637001989,"score_spread":0.28923872064883827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405009230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96006906,0.03227633,0.00077432377,0.0010503095,0.00078098767,0.0014613958,0.0010283604,0.00021296667,0.0023462723],"genre_scores_gemma":[0.9805729,0.011209583,0.0011455686,0.0015311128,0.00091115315,0.001548789,0.001095966,0.00003894353,0.0019458735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992513,0.00041403156,0.00004660601,0.000118216936,0.00006530695,0.000104623985],"domain_scores_gemma":[0.9988349,0.00047461345,0.0003052318,0.00008808298,0.00006351105,0.00023380849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002007348,0.0015394753,0.0039201207,0.00038179095,0.00040855614,0.001154869,0.00092213094,0.0022732043,0.0049609314],"category_scores_gemma":[0.002479368,0.000612168,0.0023357326,0.00038488052,0.0013053362,0.0013101783,0.00042080984,0.0033894533,0.00081777544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9723159,0.0015890384,0.00054291956,0.001399654,0.0017598943,0.00005783581,0.000041075764,0.00019116957,0.0023828794,0.00009256725,0.0008447041,0.018782409],"study_design_scores_gemma":[0.9507581,0.04381371,0.002751654,0.000087893255,0.0013192826,0.000055635366,0.000019859926,0.00018481702,0.0003624375,0.00011618064,0.0005111775,0.00001930777],"about_ca_topic_score_codex":0.00041781575,"about_ca_topic_score_gemma":0.0008724419,"teacher_disagreement_score":0.0049609314,"about_ca_system_score_codex":0.00047846208,"about_ca_system_score_gemma":0.0005832332,"threshold_uncertainty_score":0.01659596},"labels":[],"label_agreement":null},{"id":"W4406080334","doi":"10.1016/s2352-3026(24)00346-6","title":"Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Chimeric antigen receptor; Food and drug administration; Standard of care; Oncology; Overall survival; Progression-free survival; Immunotherapy; Cancer; Confidence interval; Pharmacology","score_opus":0.06945262945612482,"score_gpt":0.31280173439360864,"score_spread":0.24334910493748382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080334","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.633569,0.039793447,0.0009038647,0.27659026,0.0043035643,0.000058833964,0.0027585865,0.00009534808,0.0419271],"genre_scores_gemma":[0.93893695,0.0049215704,0.00024518458,0.046250436,0.006066089,0.000033102322,0.0010436093,0.000014805783,0.002488268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984699,0.0005188385,0.00017146606,0.00013749622,0.00038297728,0.00031917193],"domain_scores_gemma":[0.99251527,0.003478571,0.0020967086,0.00023856382,0.0006344873,0.0010363283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014895338,0.00016426377,0.00073342293,0.00032164194,0.0005517958,0.0015160152,0.0004950256,0.0029342556,0.0028750845],"category_scores_gemma":[0.008883014,0.000115204275,0.00075439055,0.0011855401,0.0004196493,0.0006697474,0.00046008066,0.0033404452,0.00045544744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009942361,0.0008368475,0.71123064,0.0007556132,0.0011504026,0.025781723,0.0007235585,0.00242926,0.0028148668,0.0031489981,0.08125657,0.15992916],"study_design_scores_gemma":[0.00123128,0.0027953484,0.87182087,0.00055043254,0.0012262494,0.04038063,0.00085283234,0.0026906482,0.0012771172,0.0060115913,0.07099465,0.00016836626],"about_ca_topic_score_codex":0.0022483724,"about_ca_topic_score_gemma":0.003112057,"teacher_disagreement_score":0.0029342556,"about_ca_system_score_codex":0.0020148254,"about_ca_system_score_gemma":0.00075898605,"threshold_uncertainty_score":0.014618695},"labels":[],"label_agreement":null},{"id":"W4406080377","doi":"10.1016/s2352-3026(24)00379-x","title":"Building health advocacy campaigns to engage sexual and gender minority populations with health care","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Food Security and Health in Diverse Populations","field":"Health Professions","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Toronto; University of Ottawa; Stem Cell Network; McGill University","funders":"","keywords":"Medicine; Sexual minority; Health care; Reproductive health; Consumer Advocacy; Nursing; Family medicine; Environmental health; Gerontology; Gender studies; Public relations; Sexual orientation; Population; Political science; Law; Sociology","score_opus":0.2747260672061095,"score_gpt":0.5167277979070518,"score_spread":0.24200173070094233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080377","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028539035,0.005934785,0.0059271096,0.8760462,0.013530232,0.0011879541,0.00015762649,0.0002513537,0.06842579],"genre_scores_gemma":[0.32713208,0.008782469,0.022074303,0.6066574,0.010460074,0.0034070641,0.00029140315,0.00015648366,0.02103875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9845834,0.008113158,0.00041478776,0.00067711854,0.0026402932,0.0035712537],"domain_scores_gemma":[0.897301,0.04816933,0.004732452,0.002096019,0.005679627,0.04202159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033352163,0.0010227199,0.0006967829,0.0022078278,0.009182411,0.0096932035,0.0033284733,0.014170441,0.042292558],"category_scores_gemma":[0.07750449,0.00091142714,0.0013777976,0.00086686155,0.0050095543,0.00920783,0.021869443,0.013331381,0.005298446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031302078,0.0066335327,0.028309623,0.0039973534,0.0005017341,0.0010954501,0.04444532,0.0007042034,0.004246179,0.04110501,0.42118213,0.4474664],"study_design_scores_gemma":[0.0012311402,0.0010952824,0.03077543,0.008466064,0.00041514344,0.0003620956,0.062308706,0.0011857443,0.0020055,0.07002447,0.82195795,0.00017242592],"about_ca_topic_score_codex":0.0063499208,"about_ca_topic_score_gemma":0.013619663,"teacher_disagreement_score":0.042292558,"about_ca_system_score_codex":0.004176241,"about_ca_system_score_gemma":0.043734524,"threshold_uncertainty_score":0.17638522},"labels":[],"label_agreement":null},{"id":"W4406561879","doi":"10.1016/s2352-3026(24)00338-7","title":"Low-dose aspirin versus placebo in postpartum venous thromboembolism: a multi-national, pilot, randomised, placebo-controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McMaster University; Ottawa Hospital; University of British Columbia; University of Ottawa; Lunenfeld-Tanenbaum Research Institute; McGill University; University of Calgary","funders":"Canadian Institutes of Health Research; Eli Lilly Canada; International Society on Thrombosis and Haemostasis; McMaster University; Eli Lilly and Company","keywords":"Medicine; Aspirin; Placebo; Venous thromboembolism; Randomized controlled trial; Internal medicine; Intensive care medicine; Thrombosis; Alternative medicine","score_opus":0.06894980532997748,"score_gpt":0.34984768618087064,"score_spread":0.2808978808508932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406561879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722692,0.01690187,0.0009913228,0.0016776944,0.0015534199,0.0032320707,0.0010529907,0.00013647032,0.0021850439],"genre_scores_gemma":[0.9826461,0.0068130777,0.001557659,0.0012213974,0.00075272954,0.0033368024,0.0006032507,0.000020903051,0.0030481361],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99870574,0.0007539854,0.00012979607,0.00018785757,0.000081180326,0.00014146182],"domain_scores_gemma":[0.99845695,0.0007347562,0.00030336212,0.0001318662,0.00009147511,0.00028152682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019407553,0.0016735323,0.004824799,0.0004960189,0.00054451183,0.0013445005,0.0010832207,0.0029688512,0.0072997636],"category_scores_gemma":[0.003813302,0.0008113215,0.0025054347,0.000583534,0.0014647633,0.0011951723,0.0005973257,0.0028580935,0.00095826766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9911572,0.001397315,0.00018036725,0.0009009448,0.0010987421,0.000029646902,0.000034962417,0.00005417404,0.0007653084,0.00005106634,0.00026490353,0.004065529],"study_design_scores_gemma":[0.9785417,0.019194964,0.0008782969,0.00005354443,0.0008034679,0.000019268127,0.000024557037,0.000088683526,0.00008985203,0.0000809526,0.00021553252,0.0000092455575],"about_ca_topic_score_codex":0.0014410602,"about_ca_topic_score_gemma":0.0025723272,"teacher_disagreement_score":0.0072997636,"about_ca_system_score_codex":0.0008622573,"about_ca_system_score_gemma":0.00091721077,"threshold_uncertainty_score":0.024420083},"labels":[],"label_agreement":null},{"id":"W4407313924","doi":"10.1016/s2352-3026(24)00376-4","title":"Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Acceleron; Bristol-Myers Squibb","keywords":"Medicine; Anemia; Term (time); Blood transfusion; Thalassemia; Pediatrics; Intensive care medicine; Randomized controlled trial; Surgery; Internal medicine","score_opus":0.01966854971311297,"score_gpt":0.29627536648236924,"score_spread":0.27660681676925625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407313924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747917,0.018532183,0.0006096664,0.0014476028,0.00059839373,0.0007036155,0.0010062485,0.000108900385,0.002201628],"genre_scores_gemma":[0.9889142,0.0042742784,0.00074530556,0.0014597699,0.00041056675,0.00069449027,0.0011776281,0.000021738852,0.0023019356],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99942905,0.00028013962,0.00003751441,0.000089134504,0.0000553794,0.00010867098],"domain_scores_gemma":[0.99884355,0.00043959965,0.00027751815,0.00009048176,0.000058521735,0.00029037922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015423996,0.0011923782,0.0023360215,0.00022404629,0.00035826344,0.0014081763,0.0008924523,0.0019210275,0.0053640157],"category_scores_gemma":[0.0018001205,0.0005579787,0.0030205632,0.00032691073,0.001036696,0.0012461992,0.00035260597,0.0044247867,0.0009715168],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96423507,0.0020978218,0.00097541406,0.0010986346,0.0032425732,0.00008674692,0.00007968442,0.00042247953,0.0030515427,0.00014078966,0.0015106326,0.023058502],"study_design_scores_gemma":[0.9423002,0.04924693,0.0049099806,0.000084919615,0.0015014119,0.00011181619,0.000036973986,0.00034730136,0.00035528623,0.00021698803,0.00085774856,0.0000304499],"about_ca_topic_score_codex":0.0009224816,"about_ca_topic_score_gemma":0.0021715125,"teacher_disagreement_score":0.0053640157,"about_ca_system_score_codex":0.00079806347,"about_ca_system_score_gemma":0.00059399597,"threshold_uncertainty_score":0.017944455},"labels":[],"label_agreement":null},{"id":"W4408110711","doi":"10.1016/s2352-3026(25)00002-x","title":"Epistemic limitations of measurable residual disease in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Residual; Minimal residual disease; Intensive care medicine; Disease; Internal medicine; Oncology; Leukemia; Algorithm","score_opus":0.11428568297166725,"score_gpt":0.33325165608240176,"score_spread":0.2189659731107345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110711","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003423677,0.99796605,0.00019225126,0.0011797108,0.00022071521,0.00000101416,0.000008956545,0.0000028376335,0.00039422273],"genre_scores_gemma":[0.002094651,0.9942286,0.0002544766,0.0016720606,0.0014080276,0.000006043602,0.000024358758,0.000003630211,0.00030813995],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987992,0.00053665193,0.000118226795,0.00013703175,0.00033739893,0.00007137673],"domain_scores_gemma":[0.99269474,0.0063082,0.0003421804,0.00011741057,0.00042112498,0.00011625915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047186646,0.00077222165,0.0020583684,0.0014141755,0.00023749055,0.001963536,0.0013442725,0.0022720452,0.0030189352],"category_scores_gemma":[0.008231744,0.00037936305,0.00075098674,0.0012280991,0.002845244,0.002327861,0.0018607812,0.0051699136,0.0010201095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016661106,0.000027749687,0.0003299481,0.012331413,0.00016495369,0.00024842142,0.000089875466,0.00077330053,0.00036875167,0.03656883,0.044572916,0.90435725],"study_design_scores_gemma":[0.000070284346,0.00009551116,0.0014133916,0.012887026,0.00022865334,0.0016523732,0.000118215095,0.00032002197,0.00029520123,0.052591648,0.9302698,0.00005786938],"about_ca_topic_score_codex":0.0012709759,"about_ca_topic_score_gemma":0.00231893,"teacher_disagreement_score":0.0047186646,"about_ca_system_score_codex":0.0017477443,"about_ca_system_score_gemma":0.0019238879,"threshold_uncertainty_score":0.024954975},"labels":[],"label_agreement":null},{"id":"W4408110727","doi":"10.1016/s2352-3026(25)00042-0","title":"Global paediatric haematopoietic stem-cell transplantation training and access: providing strategies to overcome challenges","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Stem cell; Haematopoiesis; Transplantation; Intensive care medicine; Oncology; Internal medicine; Genetics","score_opus":0.0614272692537836,"score_gpt":0.3513424632251694,"score_spread":0.28991519397138577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110727","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022715384,0.01773927,0.0022906733,0.9602156,0.006754861,0.00004612347,0.00035711972,0.0002093185,0.010115497],"genre_scores_gemma":[0.20667866,0.07934972,0.018222356,0.63758934,0.034305118,0.00079389045,0.002173751,0.00044329697,0.020443894],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880448,0.0042377156,0.00065624225,0.0008646894,0.0018064562,0.0043900656],"domain_scores_gemma":[0.94502115,0.016768184,0.004296531,0.0012240232,0.0052540484,0.027436057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02132235,0.0011002581,0.0013902527,0.0015840335,0.0023048643,0.009185245,0.00337429,0.011925344,0.059746232],"category_scores_gemma":[0.041628752,0.0006269914,0.0012571962,0.0016596265,0.0054683955,0.013606871,0.016745558,0.014849524,0.006234168],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017741525,0.00029076514,0.00916641,0.003386026,0.0001176897,0.00068140967,0.002888545,0.0013777153,0.0008202565,0.09387052,0.7002474,0.1869759],"study_design_scores_gemma":[0.00028688027,0.0004221261,0.0217287,0.00810573,0.00011808908,0.0007565168,0.009648064,0.0011245846,0.00045941287,0.07609929,0.88110596,0.0001446503],"about_ca_topic_score_codex":0.017489398,"about_ca_topic_score_gemma":0.024214713,"teacher_disagreement_score":0.059746232,"about_ca_system_score_codex":0.007013087,"about_ca_system_score_gemma":0.05946463,"threshold_uncertainty_score":0.19987106},"labels":[],"label_agreement":null},{"id":"W4408110767","doi":"10.1016/s2352-3026(24)00357-0","title":"Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Adolescent and Pediatric Healthcare","field":"Health Professions","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Ask price; Family medicine; MEDLINE; Intensive care medicine","score_opus":0.12637953908093394,"score_gpt":0.4263011003547665,"score_spread":0.2999215612738325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408110767","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004603237,0.9658237,0.00007194531,0.028129822,0.003332242,0.000025402112,0.00009135325,0.00000882539,0.0020562129],"genre_scores_gemma":[0.005843417,0.949685,0.0004745864,0.03935285,0.0023621146,0.000056516117,0.00017502929,0.0000067279852,0.0020438442],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9981363,0.00095758983,0.00027079883,0.00007798812,0.00039979964,0.00015755987],"domain_scores_gemma":[0.9945463,0.0029512271,0.0009934509,0.000052982698,0.0009145745,0.00054155773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047673564,0.00033347233,0.0014083352,0.0008194833,0.0003729291,0.0016515268,0.00084360206,0.0032795444,0.007051969],"category_scores_gemma":[0.012399073,0.00020161262,0.001012631,0.0010992456,0.00044404628,0.0015121909,0.001052556,0.0032089483,0.0011703974],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035822793,0.00007101743,0.0008773271,0.025945919,0.0005057564,0.00013827364,0.00014917689,0.00008188872,0.00019819199,0.0011739822,0.25248957,0.7180107],"study_design_scores_gemma":[0.0011912762,0.00024075781,0.006504706,0.08775475,0.0010291851,0.00069307414,0.0006171411,0.00009665916,0.00012421099,0.002019198,0.8996739,0.000055172357],"about_ca_topic_score_codex":0.0033016172,"about_ca_topic_score_gemma":0.011772128,"teacher_disagreement_score":0.007051969,"about_ca_system_score_codex":0.0010236806,"about_ca_system_score_gemma":0.005273414,"threshold_uncertainty_score":0.025212526},"labels":[],"label_agreement":null},{"id":"W4409318643","doi":"10.1016/s2352-3026(25)00067-5","title":"Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster Children's Hospital","funders":"Janssen Research and Development; Bayer","keywords":"Medicine; Venous thromboembolism; Anticoagulant therapy; Cohort; Phase (matter); Intensive care medicine; Pediatrics; Internal medicine; Thrombosis","score_opus":0.03844310607800945,"score_gpt":0.37265058045917515,"score_spread":0.3342074743811657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409318643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944507,0.0027231644,0.00020584773,0.00025851856,0.00005321854,0.00011497069,0.0017381965,0.000010515382,0.00044493625],"genre_scores_gemma":[0.99134433,0.0026914205,0.00087756134,0.0004564512,0.00016337239,0.0002870558,0.0034805776,0.000031170952,0.0006680826],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99875414,0.0006280917,0.00007927587,0.0002060266,0.00012489487,0.00020753719],"domain_scores_gemma":[0.9969994,0.0007772935,0.0010601464,0.00048469228,0.00017524148,0.00050326635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023658166,0.0011772375,0.0022749568,0.0002409149,0.00045411827,0.0013333776,0.0006623934,0.0008858002,0.0020684248],"category_scores_gemma":[0.0036400452,0.00045390363,0.0031503174,0.0007226542,0.0007849554,0.00078628835,0.0006075728,0.0022280293,0.00030823372],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47573075,0.0048803654,0.432796,0.0016635134,0.031116929,0.0014832073,0.0008001478,0.0017546945,0.0074111405,0.0011038997,0.008084028,0.033175338],"study_design_scores_gemma":[0.19586045,0.031350736,0.7426657,0.00039044075,0.01773073,0.0017538037,0.00056788424,0.00076080655,0.0011313773,0.00055263034,0.0070762592,0.0001593299],"about_ca_topic_score_codex":0.0034668976,"about_ca_topic_score_gemma":0.0072188517,"teacher_disagreement_score":0.0034668976,"about_ca_system_score_codex":0.0008621805,"about_ca_system_score_gemma":0.0015223136,"threshold_uncertainty_score":0.01251179},"labels":[],"label_agreement":null},{"id":"W4409875243","doi":"10.1016/s2352-3026(25)00109-7","title":"Lessons from EINSTEIN-Jr and next steps for extended-phase anticoagulation in paediatric venous thromboembolism","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Venous thromboembolism; Intensive care medicine; Surgery; Thrombosis","score_opus":0.0626778142135177,"score_gpt":0.35813543995717967,"score_spread":0.29545762574366197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409875243","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002926193,0.0041697617,0.00011286678,0.9863918,0.0076759947,0.0000033163708,0.000015473068,0.000009352403,0.0013288086],"genre_scores_gemma":[0.010338179,0.006361601,0.0006502371,0.89421475,0.08554167,0.000029247483,0.000026123085,0.00004095746,0.0027973058],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99221593,0.0030104618,0.0015212538,0.00070957775,0.0017809207,0.0007618665],"domain_scores_gemma":[0.9680083,0.02038063,0.0017659117,0.0009117601,0.003705404,0.0052280566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009744765,0.00071401853,0.0016799681,0.0008454411,0.0022445717,0.005785263,0.0016714424,0.06118504,0.0062067606],"category_scores_gemma":[0.055949386,0.00076478306,0.0014832154,0.00069806835,0.0056099803,0.008951545,0.0024614295,0.054271605,0.0035292862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109531415,0.00007562336,0.0013849932,0.00017746873,0.00004594472,0.006423702,0.00040799475,0.00030868794,0.0001972139,0.018729398,0.9448578,0.027281733],"study_design_scores_gemma":[0.00043466475,0.00015895539,0.0018493497,0.00172397,0.000067716916,0.008372867,0.0007259421,0.00092357007,0.0002631797,0.04919733,0.9361366,0.0001457839],"about_ca_topic_score_codex":0.006122894,"about_ca_topic_score_gemma":0.0122289825,"teacher_disagreement_score":0.06118504,"about_ca_system_score_codex":0.005870624,"about_ca_system_score_gemma":0.007468024,"threshold_uncertainty_score":0.051535845},"labels":[],"label_agreement":null},{"id":"W4409875303","doi":"10.1016/s2352-3026(25)00038-9","title":"Management of iron deficiency in children, adults, and pregnant individuals: evidence-based and expert consensus recommendations","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; St. Michael's Hospital","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institutes of Health; American College of Physicians","keywords":"Medicine; Iron deficiency; MEDLINE; Pediatrics; Consensus conference; Intensive care medicine; Family medicine; Gerontology; Psychiatry; Anemia; Internal medicine","score_opus":0.06256811193594253,"score_gpt":0.36502193617817963,"score_spread":0.3024538242422371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409875303","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008092894,0.99770135,0.00016015528,0.0013540031,0.00029734767,0.000045495795,0.00011273082,0.000007656613,0.0002402831],"genre_scores_gemma":[0.0009862351,0.9962585,0.001154772,0.0010978926,0.00016380563,0.000064144144,0.00014437569,0.0000027616047,0.00012745909],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99701846,0.00073877437,0.001015993,0.00030637134,0.00076894264,0.00015148586],"domain_scores_gemma":[0.9924442,0.004837711,0.0013384648,0.00008600444,0.0010919493,0.00020165963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007547519,0.0017654846,0.0068457816,0.0037899164,0.00046650242,0.0029594882,0.0043059536,0.0033289208,0.0061542545],"category_scores_gemma":[0.017394042,0.0007063033,0.006904548,0.0033579296,0.00069534377,0.002071835,0.0015347594,0.0032439767,0.0010342101],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004725006,0.00008271306,0.0005599804,0.38207075,0.004741509,0.00017505264,0.00017726631,0.0007951097,0.00029705613,0.0020338797,0.041244723,0.56734943],"study_design_scores_gemma":[0.00092131,0.00020547258,0.0026990424,0.7110811,0.023128932,0.00056212227,0.00029763716,0.0004369633,0.00022050424,0.0038874925,0.2564639,0.000095503696],"about_ca_topic_score_codex":0.010459221,"about_ca_topic_score_gemma":0.020425372,"teacher_disagreement_score":0.010459221,"about_ca_system_score_codex":0.003130044,"about_ca_system_score_gemma":0.008348946,"threshold_uncertainty_score":0.03991556},"labels":[],"label_agreement":null},{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","score_opus":0.09745188310624656,"score_gpt":0.37481295902621686,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036764468,0.9972351,0.00037242667,0.00093655917,0.00017210933,0.000016199005,0.000025186073,0.000007623032,0.00086724554],"genre_scores_gemma":[0.012629687,0.983061,0.0009531847,0.0016233156,0.00078725006,0.00005460189,0.00008019156,0.000010228147,0.00080057606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645114,0.00157334,0.00069962174,0.00021834925,0.0009483719,0.00010914896],"domain_scores_gemma":[0.99258024,0.00474507,0.001421989,0.0001842035,0.00094352395,0.00012496146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008595796,0.00062464975,0.002610556,0.0012864065,0.0001930572,0.0021329285,0.0011783027,0.0012812354,0.0022225229],"category_scores_gemma":[0.0076731546,0.00023515825,0.001421994,0.0013035454,0.0010034064,0.002592752,0.0009537793,0.002790364,0.00056960026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003229744,0.000048892496,0.00033732638,0.026430778,0.00029475996,0.00011227213,0.00015367559,0.0005229376,0.0016154712,0.006237314,0.010051986,0.95387155],"study_design_scores_gemma":[0.00028818136,0.002006077,0.0055674375,0.033944137,0.0014099198,0.0028494243,0.00048241325,0.0006129393,0.0041798614,0.015699508,0.9328183,0.0001418406],"about_ca_topic_score_codex":0.00089369377,"about_ca_topic_score_gemma":0.0013914879,"teacher_disagreement_score":0.008595796,"about_ca_system_score_codex":0.0012618918,"about_ca_system_score_gemma":0.0015385221,"threshold_uncertainty_score":0.04545945},"labels":[],"label_agreement":null},{"id":"W4410800008","doi":"10.1016/s2352-3026(25)00068-7","title":"Machine-learning models to predict iron recovery after blood donation: a model development and external validation study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Lady Davis Institute for Medical Research; National Heart, Lung, and Blood Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; AABB","keywords":"Medicine; Donation; Intensive care medicine; Blood donor; Immunology","score_opus":0.03151211067397029,"score_gpt":0.2796090024901398,"score_spread":0.2480968918161695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97152305,0.0012366744,0.02383608,0.0003802451,0.00013508006,0.00029829785,0.0009223664,0.0003740437,0.0012941642],"genre_scores_gemma":[0.9854718,0.0002617257,0.010052185,0.00012156214,0.000028904835,0.00021874737,0.0026846284,0.00008845968,0.0010719905],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99543554,0.0032932288,0.00026571736,0.00044454663,0.0003404017,0.0002205582],"domain_scores_gemma":[0.9534667,0.037009485,0.0009577421,0.0033999686,0.0047411243,0.0004250524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026749631,0.0018850412,0.0015514208,0.0010403056,0.0008560084,0.001535733,0.0023093226,0.0015908979,0.0014722751],"category_scores_gemma":[0.02611339,0.0007027615,0.002145147,0.00064622425,0.0010101387,0.0014727153,0.0017254133,0.0038228778,0.00094087434],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015320081,0.010629681,0.16791476,0.000697922,0.0043628677,0.0005784892,0.0009879316,0.5596171,0.004131923,0.0017992276,0.012828948,0.22113109],"study_design_scores_gemma":[0.0007638302,0.0025173486,0.018768476,0.00012552855,0.00068546494,0.00015095582,0.00017764056,0.9709583,0.003384426,0.0010996832,0.0013063122,0.000061928455],"about_ca_topic_score_codex":0.008055031,"about_ca_topic_score_gemma":0.0047089783,"teacher_disagreement_score":0.026749631,"about_ca_system_score_codex":0.0013124513,"about_ca_system_score_gemma":0.0018780652,"threshold_uncertainty_score":0.14146721},"labels":[],"label_agreement":null},{"id":"W4410800025","doi":"10.1016/s2352-3026(25)00027-4","title":"Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Hematology; Series (stratigraphy); Internal medicine; Adverse effect; Intensive care medicine","score_opus":0.039359635684619206,"score_gpt":0.31519938223615945,"score_spread":0.27583974655154025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800025","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103690305,0.0073119733,0.00094910176,0.84556323,0.13643943,0.00009849028,0.0012737619,0.0002193027,0.008040962],"genre_scores_gemma":[0.0013400211,0.005255873,0.0011250053,0.82431865,0.15602578,0.00030430712,0.0006805419,0.00027121496,0.010678507],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9676624,0.007846482,0.00654591,0.002525887,0.0134249255,0.0019944708],"domain_scores_gemma":[0.85828567,0.077491425,0.014971257,0.0039564734,0.0309272,0.014368028],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.030920073,0.0021139274,0.003364049,0.0033126934,0.0024945044,0.014474091,0.0058420016,0.0452368,0.018406708],"category_scores_gemma":[0.13927546,0.0014972656,0.0032756487,0.0036933601,0.004122913,0.010595033,0.004015988,0.05299904,0.023747262],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024897034,0.000010249303,0.000083789346,0.00010444444,0.000008178373,0.000041272604,0.000015775717,0.000026162606,0.00004817614,0.0011634269,0.9929114,0.005562264],"study_design_scores_gemma":[0.00015073536,0.000043336127,0.0018600761,0.0015273438,0.00004281487,0.00018962011,0.00007600253,0.00019559434,0.00011373676,0.005069721,0.99065804,0.00007291915],"about_ca_topic_score_codex":0.011101113,"about_ca_topic_score_gemma":0.016871477,"teacher_disagreement_score":0.9690799,"about_ca_system_score_codex":0.008905018,"about_ca_system_score_gemma":0.010341408,"threshold_uncertainty_score":0.16352296},"labels":[],"label_agreement":null},{"id":"W4410800040","doi":"10.1016/s2352-3026(25)00136-x","title":"Optimising communication to patients with venous thromboembolism: development of a provider toolkit","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Healthcare Systems and Technology","field":"Business, Management and Accounting","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; University of Toronto","funders":"Bristol-Myers Squibb","keywords":"Medicine; Venous thromboembolism; Intensive care medicine; MEDLINE; Internal medicine; Thrombosis","score_opus":0.023476279336365907,"score_gpt":0.26827996300928675,"score_spread":0.24480368367292085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410800040","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36933157,0.007440467,0.26252317,0.26184186,0.0031131264,0.009978273,0.001105452,0.005422098,0.07924395],"genre_scores_gemma":[0.50518906,0.006355493,0.46608752,0.009578906,0.000427374,0.0043366035,0.00069851975,0.00040699128,0.0069195023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9795547,0.015629215,0.0011762946,0.0004852711,0.0024151565,0.0007393167],"domain_scores_gemma":[0.92687374,0.04430988,0.004397465,0.004308891,0.00788915,0.012220913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023919638,0.00036679002,0.00039864058,0.0009391203,0.0014925188,0.0033046629,0.0016788968,0.0017872714,0.0072153634],"category_scores_gemma":[0.08709763,0.00044730605,0.0006216381,0.0007180082,0.0010059668,0.004058426,0.008072065,0.0033400138,0.0016805952],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081060507,0.0030028208,0.030103978,0.0023461462,0.0001686282,0.0009082849,0.02308173,0.003732713,0.0023150013,0.011244401,0.06538612,0.85689956],"study_design_scores_gemma":[0.003602609,0.008850813,0.06799231,0.01807172,0.0017873753,0.004958269,0.072064094,0.061425082,0.013882576,0.07589258,0.67057437,0.00089809496],"about_ca_topic_score_codex":0.0040453984,"about_ca_topic_score_gemma":0.007123617,"teacher_disagreement_score":0.023919638,"about_ca_system_score_codex":0.0021074233,"about_ca_system_score_gemma":0.025435463,"threshold_uncertainty_score":0.12650067},"labels":[],"label_agreement":null},{"id":"W4411313705","doi":"10.1016/s2352-3026(25)00144-9","title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"Schleswig-Holstein; Amgen","keywords":"Medicine; Post-hoc analysis; Blinatumomab; Refractory (planetary science); Clinical trial; Internal medicine; Post hoc; Oncology; Pediatrics; Lymphoblastic Leukemia; Leukemia","score_opus":0.015348107925319815,"score_gpt":0.3009847296719843,"score_spread":0.2856366217466645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411313705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98428494,0.010902097,0.0005621445,0.000583767,0.0002399206,0.0008198385,0.0009054681,0.0001316945,0.0015700434],"genre_scores_gemma":[0.988918,0.0047776084,0.0009080088,0.00082787336,0.00016978347,0.0010242945,0.0015536221,0.000033458724,0.0017872576],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994961,0.00028373615,0.000021365822,0.000071799004,0.00003991585,0.00008711375],"domain_scores_gemma":[0.99942005,0.00016787919,0.0001536857,0.000055804943,0.000029683717,0.00017290574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013851356,0.00125564,0.0024883896,0.00034425405,0.00025548632,0.0009379422,0.0006457446,0.00089992466,0.0032578614],"category_scores_gemma":[0.0011721703,0.00039075137,0.001573447,0.00046832714,0.00090849097,0.00079871813,0.00039287572,0.0031420891,0.00082881213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90392953,0.004076521,0.002159409,0.0012812793,0.0022341583,0.00011161026,0.0001196562,0.0011321678,0.007348176,0.00019024676,0.0018770426,0.075540334],"study_design_scores_gemma":[0.9029077,0.08508856,0.006625937,0.00010375982,0.0010545142,0.00017300983,0.000059711732,0.0007763315,0.00092588447,0.00030417356,0.0019598105,0.00002053431],"about_ca_topic_score_codex":0.0007337704,"about_ca_topic_score_gemma":0.0022502302,"teacher_disagreement_score":0.0032578614,"about_ca_system_score_codex":0.0008447796,"about_ca_system_score_gemma":0.0009037835,"threshold_uncertainty_score":0.01089865},"labels":[],"label_agreement":null},{"id":"W4412461070","doi":"10.1016/s2352-3026(25)00163-2","title":"Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Open label; Refractory (planetary science); Surgery; Clinical trial","score_opus":0.04989390241174046,"score_gpt":0.35109203108008247,"score_spread":0.301198128668342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97387606,0.021434259,0.00031040428,0.0008212326,0.00059408654,0.00089670136,0.0009081612,0.000043890206,0.0011153244],"genre_scores_gemma":[0.99050164,0.0045993724,0.0007951259,0.0007612258,0.00046216891,0.0013145478,0.00074789114,0.000011469649,0.0008065624],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99797887,0.0012436699,0.00018239664,0.00027917398,0.00013449251,0.0001815423],"domain_scores_gemma":[0.9973936,0.0010462023,0.0008393446,0.00014025344,0.000113519185,0.00046701106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003023389,0.0014858674,0.0035982379,0.0003440457,0.0004251893,0.0014265975,0.0011804709,0.0020899205,0.004454115],"category_scores_gemma":[0.0035641952,0.000600413,0.0041142195,0.0004864158,0.0013049789,0.0013747829,0.0006518799,0.003644847,0.00055774505],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98221934,0.0015990651,0.0011479884,0.0010621623,0.0037511133,0.000021166348,0.0000433345,0.0002139047,0.0005747377,0.00006589203,0.00040994395,0.008891307],"study_design_scores_gemma":[0.95330983,0.038702533,0.0041239616,0.00011959144,0.0025246898,0.000038154732,0.000045139943,0.00027393058,0.00018336468,0.0001888313,0.00046476224,0.000025232574],"about_ca_topic_score_codex":0.0010772501,"about_ca_topic_score_gemma":0.0018896961,"teacher_disagreement_score":0.004454115,"about_ca_system_score_codex":0.0011677125,"about_ca_system_score_gemma":0.0008778985,"threshold_uncertainty_score":0.015989363},"labels":[],"label_agreement":null},{"id":"W4413707382","doi":"10.1016/s2352-3026(25)00146-2","title":"Getting back on track to meet global anaemia reduction targets: a Lancet Haematology Commission","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Iron Metabolism and Disorders","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Public Health Ontario; University of Toronto","funders":"University of California, Davis; Instituto Tecnológico y de Estudios Superiores de Monterrey; University of South Carolina; World Health Organization; World Bank Group; National Institute for Nutrition and Health; Bill and Melinda Gates Foundation","keywords":"Medicine; Hematology; Reduction (mathematics); Track (disk drive); Commission; Internal medicine; Fast track; Intensive care medicine; Surgery; Computer science","score_opus":0.05768926400618695,"score_gpt":0.3826757696689444,"score_spread":0.32498650566275744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413707382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000102451886,0.89554656,0.00016246527,0.072589904,0.028363334,0.000034635646,0.00017563268,0.000056366243,0.002968677],"genre_scores_gemma":[0.0031560336,0.8665283,0.0008795714,0.10929923,0.013572327,0.00010242682,0.00033287753,0.00004349973,0.0060857497],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967709,0.0008143055,0.00030701238,0.00023550141,0.0012384958,0.000633638],"domain_scores_gemma":[0.99079484,0.0037546426,0.0009457354,0.00018924124,0.0021660035,0.0021495614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008684253,0.0017420622,0.0036215703,0.002029425,0.000967584,0.004797764,0.0021486168,0.010486488,0.0142597435],"category_scores_gemma":[0.013226505,0.0007463006,0.0018580457,0.0023656096,0.0013876818,0.00521918,0.0035463974,0.012724672,0.005769788],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020896255,0.00006781737,0.00008573574,0.011943483,0.00019142046,0.00013348386,0.00013292453,0.00017888009,0.00026304103,0.0074554984,0.6857964,0.29354233],"study_design_scores_gemma":[0.00018552649,0.000075434145,0.0004594615,0.0115521,0.00015343723,0.000109729655,0.00010444487,0.000051271178,0.00004398168,0.0036035203,0.9836368,0.000024234823],"about_ca_topic_score_codex":0.00812966,"about_ca_topic_score_gemma":0.01884952,"teacher_disagreement_score":0.0142597435,"about_ca_system_score_codex":0.0050243572,"about_ca_system_score_gemma":0.022049855,"threshold_uncertainty_score":0.047703624},"labels":[],"label_agreement":null},{"id":"W4414300162","doi":"10.1016/s2352-3026(25)00204-2","title":"Sustainable anticoagulation for climate resilient care","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Climate Change and Health Impacts","field":"Environmental Science","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"Multidisciplinary approach; Sustainability; Stakeholder engagement; Procurement; Portfolio; Stewardship (theology); Health care; Scarcity; General partnership; Consumables","score_opus":0.10087812522687645,"score_gpt":0.41177500734611683,"score_spread":0.3108968821192404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414300162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025456398,0.9955955,0.00007638373,0.0022323516,0.00096820976,0.0000042047527,0.000026450834,0.000010511846,0.0010609237],"genre_scores_gemma":[0.00058749365,0.9958651,0.00014311558,0.0017853954,0.0010438391,0.000010093114,0.000035737903,0.0000032044982,0.00052598794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992424,0.0002028935,0.00012840303,0.000081268656,0.000266222,0.00007882043],"domain_scores_gemma":[0.99781334,0.0013993643,0.0003386408,0.000044692213,0.00026936125,0.00013456232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023659472,0.0010396086,0.0023723554,0.0022166176,0.00040449845,0.0020804696,0.0011675451,0.0028398335,0.015469485],"category_scores_gemma":[0.004985909,0.00029847224,0.0010451593,0.002311356,0.00084433577,0.001934948,0.0016105252,0.0040792557,0.0031411361],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083037514,0.000034366683,0.00011255803,0.026372446,0.00023530403,0.0001125752,0.00004070525,0.00032774938,0.000214716,0.00884653,0.114740446,0.8488795],"study_design_scores_gemma":[0.00011119386,0.00006362834,0.00058602286,0.029145723,0.0003843521,0.00033210195,0.00008385584,0.00013473268,0.000085826,0.009087149,0.9599646,0.000020898467],"about_ca_topic_score_codex":0.0033420618,"about_ca_topic_score_gemma":0.007948459,"teacher_disagreement_score":0.015469485,"about_ca_system_score_codex":0.0018095545,"about_ca_system_score_gemma":0.004043115,"threshold_uncertainty_score":0.0517506},"labels":[],"label_agreement":null},{"id":"W4414984131","doi":"10.1016/s2352-3026(25)00254-6","title":"Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Celgene; AbbVie; Bristol-Myers Squibb","keywords":"Venetoclax; Myeloid leukaemia; Refractory (planetary science); Myelodysplastic syndromes; Myeloid leukemia; Myeloid; Clinical trial","score_opus":0.03281879553664856,"score_gpt":0.3313487312351916,"score_spread":0.298529935698543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414984131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734621,0.017676407,0.00047691358,0.001263667,0.00065002294,0.00064316904,0.0013613,0.00014932317,0.004317304],"genre_scores_gemma":[0.98061395,0.007619161,0.0011920873,0.0017007377,0.0003002032,0.0006603982,0.0021503614,0.000029917384,0.005733162],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997906,0.00010794993,0.0000070964447,0.000035948644,0.00001392972,0.00004446938],"domain_scores_gemma":[0.99975544,0.000065545915,0.000044312153,0.000017287693,0.0000116004985,0.00010585977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090026006,0.00084673427,0.0014149185,0.00018082143,0.00015890553,0.00082945405,0.00054276333,0.00072353525,0.0045760055],"category_scores_gemma":[0.0007065541,0.00023536326,0.001002034,0.00022137185,0.00047132326,0.0006490168,0.0002559991,0.002439919,0.00069502543],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76621383,0.007067209,0.0038384213,0.0026533455,0.0033999423,0.00027775456,0.00022067342,0.0039848983,0.010277948,0.0013371329,0.012070494,0.18865833],"study_design_scores_gemma":[0.90923977,0.07149802,0.0070426962,0.0001711234,0.0009916674,0.00035516242,0.000098193144,0.001479521,0.0010065369,0.0009440662,0.007139726,0.000033564247],"about_ca_topic_score_codex":0.00051425025,"about_ca_topic_score_gemma":0.0025566916,"teacher_disagreement_score":0.0045760055,"about_ca_system_score_codex":0.00054931187,"about_ca_system_score_gemma":0.00049246696,"threshold_uncertainty_score":0.015308261},"labels":[],"label_agreement":null},{"id":"W4415900074","doi":"10.1016/s2352-3026(25)00264-9","title":"Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Phase (matter); Clinical trial; Phases of clinical research; MEDLINE","score_opus":0.05743628741329941,"score_gpt":0.4161781471176606,"score_spread":0.3587418597043612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913049,0.004967713,0.00054784137,0.0003433739,0.00019651414,0.00095670787,0.0004561406,0.00006795798,0.0011589255],"genre_scores_gemma":[0.9906495,0.003310162,0.0010683963,0.0008453645,0.00024508615,0.0008992081,0.00073247956,0.000018318216,0.0022315038],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99957675,0.00022149732,0.000021331141,0.000063644045,0.000034562105,0.00008219634],"domain_scores_gemma":[0.99939144,0.00019903074,0.00010664642,0.00004568631,0.000024784933,0.00023236785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016264329,0.001066856,0.002023057,0.00033055333,0.00026051758,0.0009567665,0.0005778623,0.0013626984,0.004621522],"category_scores_gemma":[0.0009898833,0.00047799211,0.0017855419,0.0002922988,0.00090621813,0.0010404459,0.00033402024,0.0021576313,0.0006050135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9653817,0.004605505,0.00077463244,0.0005453519,0.0012369062,0.00007456234,0.00007986025,0.00036799215,0.005062899,0.00012740995,0.0005477534,0.021195332],"study_design_scores_gemma":[0.9364705,0.05915357,0.0026076501,0.000032972508,0.0004079088,0.000058633843,0.000026710026,0.0002523062,0.000346461,0.00011599308,0.0005135799,0.000013795889],"about_ca_topic_score_codex":0.0010424188,"about_ca_topic_score_gemma":0.0018594584,"teacher_disagreement_score":0.004621522,"about_ca_system_score_codex":0.00054257066,"about_ca_system_score_gemma":0.00062179595,"threshold_uncertainty_score":0.015460551},"labels":[],"label_agreement":null},{"id":"W4415900075","doi":"10.1016/s2352-3026(25)00262-5","title":"Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Third Health Programme; Ministero dell'Università e della Ricerca; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Università degli Studi di Milano; Swedish Orphan Biovitrum; Ministero della Salute; CSL Behring; Dipartimenti di Eccellenza; Sanofi; European Commission; Pfizer","keywords":"Von Willebrand factor; Von Willebrand disease; Coagulation; Disease; Thrombosis; Population; Hemostasis; Coagulopathy","score_opus":0.05715202487120226,"score_gpt":0.3800579027299175,"score_spread":0.3229058778587153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900075","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030705243,0.9993212,0.00003140736,0.00027012255,0.00015174164,0.000001297749,0.000008630469,0.000002160191,0.00018266132],"genre_scores_gemma":[0.00021859218,0.99914217,0.00006518558,0.00019745917,0.00019281478,0.0000024535036,0.00001293175,4.820034e-7,0.00016777171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971014,0.000061376086,0.000038114806,0.000039977207,0.000120311546,0.000029999135],"domain_scores_gemma":[0.9991548,0.0004815351,0.00011914671,0.000016703409,0.00016521796,0.000062698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011610166,0.0008957351,0.0023419857,0.0017517504,0.00025483046,0.0015528772,0.0010361534,0.0016986034,0.003935254],"category_scores_gemma":[0.0017940968,0.0002529578,0.0006108156,0.0024303624,0.0006116419,0.0015204599,0.0009896726,0.0026082788,0.0017842957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016443979,0.00004734547,0.00018718123,0.021242736,0.00018619222,0.00016784834,0.00006633212,0.0002721653,0.0007293573,0.005066095,0.044649426,0.9272209],"study_design_scores_gemma":[0.00007339942,0.00010732307,0.0014077496,0.010700385,0.00034671547,0.0009941593,0.00011507806,0.00010727855,0.0001592829,0.0052334326,0.9807225,0.000032683838],"about_ca_topic_score_codex":0.0014940902,"about_ca_topic_score_gemma":0.0031158407,"teacher_disagreement_score":0.003935254,"about_ca_system_score_codex":0.0007466606,"about_ca_system_score_gemma":0.0015810482,"threshold_uncertainty_score":0.013164699},"labels":[],"label_agreement":null},{"id":"W4415900082","doi":"10.1016/s2352-3026(25)00287-x","title":"Perspectives of potential haematopoietic stem-cell donors on education TikToks","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Social Media in Health Education","field":"Social Sciences","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; University of Toronto","funders":"","keywords":"Haematopoiesis; Social media; Public health; Affect (linguistics); Commercialization; Health care","score_opus":0.04806970459555981,"score_gpt":0.3879551075529508,"score_spread":0.339885402957391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900082","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08429938,0.005977636,0.00055087137,0.8396018,0.007093239,0.000057591336,0.0001789395,0.000022209813,0.062218282],"genre_scores_gemma":[0.7144594,0.010990978,0.00096558494,0.1839953,0.003379933,0.00013671027,0.00014997726,0.000035986955,0.085886165],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"qualitative","domain_scores_codex":[0.99520797,0.0021939941,0.00009630553,0.00020641094,0.00046920415,0.0018260317],"domain_scores_gemma":[0.98675066,0.003796222,0.00049449655,0.0001565216,0.0010261472,0.0077759037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007444376,0.00029355695,0.00033727405,0.00049771945,0.005283985,0.008968473,0.0010685332,0.007727344,0.046818603],"category_scores_gemma":[0.008859581,0.00016225221,0.00046411768,0.0005497283,0.0033110047,0.004333793,0.007891634,0.007875779,0.0031436905],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013353532,0.0020363745,0.03286951,0.0013557896,0.000055658504,0.007479428,0.05664709,0.00045551895,0.003762622,0.31036264,0.287074,0.29656598],"study_design_scores_gemma":[0.0004083985,0.00066966267,0.008675552,0.0021819957,0.000059564354,0.0018137817,0.1907755,0.00044943532,0.0017558394,0.05793939,0.7351732,0.00009779594],"about_ca_topic_score_codex":0.0030046513,"about_ca_topic_score_gemma":0.007546799,"teacher_disagreement_score":0.046818603,"about_ca_system_score_codex":0.003002704,"about_ca_system_score_gemma":0.012596093,"threshold_uncertainty_score":0.15662384},"labels":[],"label_agreement":null},{"id":"W4415900084","doi":"10.1016/s2352-3026(25)00256-x","title":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Dexamethasone; Multiple myeloma; Refractory (planetary science); Randomized controlled trial; Phases of clinical research","score_opus":0.047484709287832494,"score_gpt":0.3549491914005954,"score_spread":0.3074644821127629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415900084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806866,0.013931547,0.00035185908,0.00077338866,0.0006192268,0.0013910583,0.00095583434,0.00005054032,0.001239922],"genre_scores_gemma":[0.9900855,0.003519996,0.0008979491,0.0007740576,0.0004991433,0.002214955,0.00082105456,0.0000117273785,0.001175613],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99852544,0.000852226,0.00012450074,0.00024465396,0.00010166581,0.0001515913],"domain_scores_gemma":[0.9981006,0.00066199974,0.0006040924,0.00011259614,0.00009128015,0.0004295596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024731043,0.0018298938,0.003736897,0.00037522282,0.00048910594,0.0014126243,0.0012882021,0.0023011423,0.0059167],"category_scores_gemma":[0.0028826953,0.0007328256,0.0037067563,0.00045093842,0.0012784312,0.0014970226,0.0006635044,0.0039278013,0.00070722605],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98620087,0.0019933463,0.0008740746,0.0007534584,0.0023457832,0.000020511723,0.000037172726,0.00019745553,0.0005612095,0.00006216242,0.00035873795,0.006595248],"study_design_scores_gemma":[0.95508295,0.039582636,0.00278866,0.000076677876,0.0014385578,0.000030122625,0.000033285578,0.00026033793,0.00014657436,0.00015821164,0.00038128952,0.000020851368],"about_ca_topic_score_codex":0.0009592944,"about_ca_topic_score_gemma":0.0016072004,"teacher_disagreement_score":0.0059167,"about_ca_system_score_codex":0.0011162971,"about_ca_system_score_gemma":0.00082766183,"threshold_uncertainty_score":0.019793391},"labels":[],"label_agreement":null},{"id":"W4417231207","doi":"10.1016/s2352-3026(25)00291-1","title":"Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Venous thromboembolism; Major bleeding; Pulmonary embolism; MEDLINE; Clinical trial; Thrombosis","score_opus":0.0258051171126176,"score_gpt":0.3478896615024365,"score_spread":0.32208454438981887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417231207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918115,0.004603268,0.00062637375,0.00045033367,0.00053700607,0.0005325354,0.0005723006,0.00004999169,0.000816649],"genre_scores_gemma":[0.99577135,0.00092795945,0.00071628887,0.00030974948,0.0004451328,0.0004917723,0.00049791764,0.000020068366,0.0008196925],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9947508,0.0038204999,0.00030089356,0.0005672155,0.00019804893,0.000362648],"domain_scores_gemma":[0.98836714,0.007955325,0.0015056137,0.0011103159,0.00031477225,0.0007467187],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054359585,0.0022743996,0.0050003384,0.00031546308,0.00051018206,0.002499785,0.0012059417,0.0020141697,0.0062951287],"category_scores_gemma":[0.012303214,0.0008775878,0.0073311226,0.00045892384,0.001720073,0.0018884202,0.00097481534,0.0043712677,0.0005746528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9862918,0.0005114248,0.001800763,0.0005103276,0.0066845836,0.00004041607,0.000048918424,0.0002666993,0.00044435874,0.00010419184,0.00025451585,0.0030419743],"study_design_scores_gemma":[0.922366,0.04105162,0.014923536,0.00012617327,0.018322906,0.00009580867,0.00008776466,0.0014475329,0.0003693917,0.0006216059,0.00051533035,0.00007238931],"about_ca_topic_score_codex":0.0010725944,"about_ca_topic_score_gemma":0.0017746431,"teacher_disagreement_score":0.0062951287,"about_ca_system_score_codex":0.00091553875,"about_ca_system_score_gemma":0.0010534342,"threshold_uncertainty_score":0.028748453},"labels":[],"label_agreement":null},{"id":"W7116844175","doi":"10.1016/s2352-3026(25)00318-7","title":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"Fonds de recherche du Québec","keywords":"Bispecific antibody; Chimeric antigen receptor; Sequence (biology); Antibody; Antigen; Antibody therapy; Immunotherapy","score_opus":0.10609664797253764,"score_gpt":0.39051698920371775,"score_spread":0.2844203412311801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844175","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014699521,0.98266673,0.00065145426,0.0002485633,0.000251077,0.00019544242,0.0009114771,0.00003584731,0.00033999144],"genre_scores_gemma":[0.5720494,0.41972497,0.0024045308,0.0026210262,0.00041242654,0.00070021104,0.0011809195,0.00007555156,0.0008309234],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99422365,0.0026220656,0.001420262,0.00094360876,0.0004849124,0.00030562383],"domain_scores_gemma":[0.98996884,0.0066645388,0.0023099496,0.00040497305,0.00045124057,0.00020033898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007088534,0.0020337494,0.014494021,0.002637992,0.00042860498,0.0025077334,0.0020161893,0.0023357691,0.005092558],"category_scores_gemma":[0.014510438,0.0011899899,0.02894769,0.0044316924,0.00082447665,0.0017176078,0.0015481706,0.0019722981,0.0004666472],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044314833,0.000026347308,0.005979177,0.17273223,0.8080128,0.000112367095,0.000073219504,0.00041304508,0.00035945114,0.000119183744,0.00071714824,0.007023584],"study_design_scores_gemma":[0.0012939924,0.00019334332,0.003380505,0.005272731,0.9884558,0.000057215766,0.000037577232,0.00010697073,0.00005569631,0.00012278883,0.0010053279,0.000018086015],"about_ca_topic_score_codex":0.0053531765,"about_ca_topic_score_gemma":0.016139086,"teacher_disagreement_score":0.014494021,"about_ca_system_score_codex":0.0018329595,"about_ca_system_score_gemma":0.0020461008,"threshold_uncertainty_score":0.037488163},"labels":[],"label_agreement":null}]}